FORM 10-K
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(MARK ONE)
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the Fiscal Year Ended September 30, 2009
OR
|
|
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the Transition Period from
to
Commission file number: 000-30326
FIRST PHYSICIANS CAPITAL GROUP, INC.
(Exact name of Registrant as Specified in its Charter)
|
|
|
DELAWARE
(State or Other Jurisdiction
of Incorporation or Organization)
|
|
77-0557617
(I.R.S. Employer
Identification No.)
|
|
|
|
433 North Camden Drive #810
Beverly Hills, California
|
|
90210
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(310) 860-2501
SECURITIES REGISTERED PURSUANT TO SECTION 12 (b) OF THE ACT:
NONE
SECURITIES REGISTERED PURSUANT TO SECTION 12 (g) OF THE ACT:
COMMON STOCK, PAR VALUE $0.01 PER SHARE
Indicate by check mark whether the registrant is a well-known seasoned issuer, as defined in Rule
405 of the Securities Act.
o
Yes
þ
No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or
Section 15(d) of the Act.
o
Yes
þ
No
Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section
13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days.
þ
Yes
o
No
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months
(or such shorter period that the registrant was required to submit and post such files).
o
Yes
þ
No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§
229.405 of this chapter) is not contained herein, and will not be contained, to the best of
registrants knowledge, in definitive proxy or information statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K.
o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated
filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
(Check one):
|
|
|
|
|
|
|
Large accelerated filer
o
|
|
Accelerated filer
o
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
þ
|
|
|
|
|
(Do not check if a smaller reporting company)
|
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act).
o
Yes
þ
No
The aggregate market value of common stock of the registrant held by non-affiliates of the
registrant on March 31, 2009 was $5,161,465, computed upon the basis of the closing price on that
date.
|
|
|
Number of shares of common stock outstanding as of January 7, 2010
|
|
14,807,851
|
FIRST PHYSICIANS CAPITAL GROUP, INC.
FORM 10-K ANNUAL REPORT
FOR THE PERIOD ENDED SEPTEMBER 30, 2009
TABLE OF CONTENTS
i
SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS
The discussion in this Form 10-K (this
Form 10-K
) for the fiscal year ended
September 30, 2009 (the
Fiscal Year Ended September 30, 2009
) contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the
Securities Act
), Section 21E of the Securities Exchange Act of 1934, as amended (the
Exchange Act
), and, if applicable, the Private Securities Litigation Reform Act of 1995,
including, among others, (i) prospective business opportunities and (ii) our potential strategies
for redirecting and financing our business. Forward-looking statements are statements other than
historical information or statements of current condition. Some forward-looking statements may be
identified by use of terms such as believes, anticipates, intends or expects. These
forward-looking statements relate to our plans, objectives and expectations. Although we believe
that our expectations with respect to the forward-looking statements are based upon reasonable
assumptions within the bounds of our knowledge of our business and operations, in light of the
risks and uncertainties inherent in all future projections, the inclusion of forward-looking
statements in this report should not be regarded as a representation by us or any other person that
our objectives or plans will be achieved. Readers should carefully review the risk factors
described in this document as well as in our other documents that we file from time to time with
the Securities and Exchange Commission (
SEC
), including our Quarterly Reports on Form
10-Q and Current Reports on Form 8-K.
We undertake no obligation to release publicly the results of any future revisions we may make
to forward-looking statements to reflect events or circumstances after the date of this report or
to reflect the occurrence of unanticipated events.
PART I
References to we, us, our, TIGroup, FPCG or the Company refers to First Physicians
Capital Group, Inc. (f/k/a Tri-Isthmus Group, Inc.) and its subsidiaries. We maintain our executive
offices at 433 North Camden Drive, #810, Beverly Hills, California 90210. Our telephone number is
+1 (310) 860-2501, and our website is at
www.firstphysicianscapitalgroup.com
.
We invest in and provide financial and managerial services to healthcare facilities in
non-urban markets. We promote quality medical care by offering improved access and breadth of
services. We unlock the value of our investments by developing strong, long-term and mutually
beneficial relationships with our physicians and the communities they serve.
In November 2007, our Board of Directors approved a change to our fiscal year end from January
31 to September 30. In view of this change, we filed a Transition Report on Form 10-KT for the
eight-month period ended September 30, 2007 (the
Transition Period Ended September 30,
2007
) on January 15, 2008. A Form 10-KT/A amendment to that report was filed on February 11,
2008. Since that time, we filed a Form 10-K for the fiscal year ended September 30, 2008 (the
Fiscal Year Ended September 30, 2008
) on January 12, 2009. This Form 10-K report covers
the twelve-month period ended September 30, 2009 and the twelve-month period ended September 30,
2008, with additional information on other fiscal years, as required by SEC rules and regulations.
Information in this Form 10-K is current as of January 7, 2010 unless otherwise specified.
COMPANY BACKGROUND
We were originally incorporated in Nevada in October 1980 and re-incorporated in Delaware in
November 2000. From 2001 to November 2004, we provided Fortune 500 and Global 500 companies with
customizable and comprehensive business process outsourcing (
BPO
) solutions into and
across the Asia-Pacific region. In November 2004, our active business operations ceased with the
sale of our BPO operations in Asia.
1
On December 16, 2005, at our Annual Meeting of Stockholders, our stockholders voted to amend
our Certificate of Incorporation to change our legal name from Vsource, Inc. to Tri-Isthmus
Group, Inc.
(
TIGroup
) and to reduce the number of authorized shares of our common stock, par
value $0.01 per share (the
Common Stock
), from 500,000,000 shares to 100,000,000 shares,
as described in our Definitive Proxy Statement filed with the SEC on November 28, 2005. The
reduction of the number of authorized shares of our Common Stock did not affect the number of
shares of Common Stock issued and outstanding.
During the Fiscal Year Ended January 31, 2007 (the
Fiscal Year Ended January 31,
2007
), we resumed active operations following the acquisition of two ambulatory surgical
centers located in Southern California. On December 2, 2005, through newly created indirect
subsidiaries, we entered into two separate purchase agreements to acquire from Surgical Ventures,
Inc., a California corporation, a controlling interest in two separate outpatient surgical centers
in San Diego, California, Point Loma Surgical Center, L.P. and Outpatient Surgery of Del Mar, L.P.
and we completed these acquisitions on November 16, 2006. On February 9, 2007, we converted these
limited partnerships into Outpatient Surgery of Point Loma, L.L.C. (
Point Loma
) and
Outpatient Surgery of Del Mar, L.L.C. (
Del Mar
, and, together with Point Loma, the
San Diego ambulatory surgical centers
), respectively. In June 2007, we consolidated the
operations of the San Diego ambulatory surgical centers at the Del Mar facility.
On October 29, 2007, we acquired 51% of the issued and outstanding membership units of Rural
Hospital Acquisition, LLC, an Oklahoma limited liability company (
RHA
). Based in
Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an
ancillary support services unit, all focused on the delivery of healthcare services to rural
communities in Oklahoma. On May 1, 2008, RHA Anadarko, LLC, a wholly owned subsidiary of RHA,
purchased 100% of the issued and outstanding membership interests of Southern Plains Medical Center
(
SPMC
). Founded in 1915, SPMC is one of the oldest continuously operating
multi-specialty physician practices in the United States. Located in Chickasha, Oklahoma, SPMCs
15 physicians and other licensed healthcare providers deliver primary and specialty care in the
following areas: family medicine; pediatrics; internal medicine; acute care; occ/med; general
surgery; gynecology; ophthalmology; orthopedic surgery; radiology; oncology; cardiology and
urology. Ancillary services provided onsite include imaging (computer-assisted tomography
(
CT
), magnetic resonance imaging (
MRI
), mammography, x-ray, EKG, vascular and
ultra-sound bone densitometry) and laboratory services. SPMC also provides urgent care services
outside of normal business hours seven days a week through its Quick Care department. Beginning
November 18, 2008, RHA began operating under the trade name Southern Plains Medical Group. On
December 11, 2008, we acquired the remaining 49% of the issued and outstanding membership units of
RHA, making RHA an indirect wholly-owned subsidiary of ours.
On December 12, 2008, we and certain of our subsidiaries entered into three loan agreements,
effective November 6, 2008, with two Oklahoma-based lenders, Canadian State Bank and Valliance
Bank, resulting in an aggregate debt financing of $8.4 million. We obtained the financing to
purchase the building and real property of the Stroud Regional Medical Center Hospital and clinics,
refinance existing loans totaling $4.6 million, upgrade facilities at the Johnston Memorial
Hospital and improve the consolidated balance sheet and maintain general working capital. The
loans are evidenced by promissory notes issued by RHA Anadarko, LLC, RHA Stroud, LLC and RHA
Tishomingo, LLC, two of which mature on November 6, 2028 and one of which matures on November 6,
2024.
On May 1, 2009, we purchased The Chandler Clinic (
TCC
), a family medical practice
located in Chandler, Oklahoma. TCC is located within the service area of the Stroud Regional
Medical Center.
On September 29, 2009, at our Annual Meeting of Stockholders, our stockholders voted to amend
our Certificate of Incorporation to change our legal name from Tri-Isthmus Group, Inc. to First
Physicians Capital Group, Inc. to reflect our focus on the healthcare industry. We became First
Physicians Capital Group, Inc. on September 29, 2009.
CURRENT OPERATIONS
Following the sale of our BPO operations in November 2004, we reduced our headcount
significantly to a two-person staff when David Hirschhorn and Todd Parker joined us as our Co-Chief
Executive Officers in July 2005. Our new management initiated a growth strategy defined by
acquisitions. Our management team and Board of Directors have been and are currently comprised of
a group of individuals with complementary talents across a broad range of disciplines, including
mergers and acquisitions, finance and operations.
2
During the Fiscal Years Ended January 31, 2006 and January 31, 2007, our management team
focused our acquisition strategy on the healthcare industry.
In December 2006, we resumed active operations following the acquisition of the San Diego
ambulatory surgical centers.
In 2007, we refined our acquisition strategy to focus on the delivery of financial and
managerial services to healthcare facilities in non-urban markets.
In September 2007, David Hirschhorn became our sole Chief Executive Officer upon Todd Parkers
resignation. Dennis M. Smith, formerly a director and senior consultant to us, re-joined us as our
Chief Financial Officer. On October 9, 2008, Mr. Smiths employment agreement with us was
terminated. Effective January 26, 2009, Mr. Smith ceased to be our Chief Financial Officer. Upon
the termination of his employment agreement, Mr. Smith had certain contractual rights, pursuant to
which we continued to pay Mr. Smith until April 9, 2009. Mr. Smith was offered a severance package
to continue his pay beyond April 9, 2009 in recognition for past services rendered, and Mr. Smith
accepted the severance package which entitled him to severance payments which began May 10, 2009
and lasted until October 20, 2009. Mr. Smith had and has no disagreements with us on any matter
related to our operations, policies or practices. On March 3, 2009, Mr. Smith resigned as a member
of our Board of Directors.
In November 2008, we appointed Thomas Rice as President of RHA. Mr. Rice has over 37 years
experience in the administration and operation of healthcare facilities, including key senior
management positions with major Oklahoma-based healthcare services companies. Also in November
2008, we announced the addition of Donald C. Parkerson as Chief Financial Officer of RHA, a
position he held until June 2009 when he ceased acting as the CFO of RHA. On January 30, 2009, Mr.
Parkerson was also appointed as our Chief Financial Officer. Mr. Parkerson has served in financial
leadership positions with companies in healthcare businesses during his more than 30-year career.
In November 2008, we hired Richard Rentsch as Vice President of Finance of RHA, and currently he
serves as the Chief Accounting Officer of RHA. Mr. Rentsch is an experienced financial leader with
more than 25 years of healthcare experience.
Our support staff at RHAs hospitals and Del Mar consists of registered nurses, operating room
technicians, an administrator who supervises the day-to-day activities of the surgery center and a
small number of office staff. Each operating unit also has appointed a medical director, who is
responsible for and supervises the quality of medical care provided at the center. Use of our
surgery centers is limited to licensed physicians. With the acquisition of SPMC in May 2008, we
added 15 physicians and other healthcare providers to our team at RHA as employees. Our business
depends upon the efforts and success of these physicians and non-employee physicians who provide
medical services at our facilities. Our business could be adversely affected by the loss of our
relationship with, or a reduction in use of our facilities by, a key physician or group of
physicians.
As discussed above, in December 2008, RHA became an indirect wholly-owned subsidiary of ours
with the acquisition by RHA of the interests not already held by us.
Strategy
Our initial strategy was to identify and invest in platform companies in the business
services and healthcare industries that provided essential core offerings, which could be expanded
over time. As we focused our efforts in the healthcare industry, two particular segments,
ambulatory surgical centers and rural hospitals, stood out in terms of fundamentally-favorable
economics, positive regulatory trends, inherent cost advantages, improving demographics and, for
non-urban healthcare opportunities, a large, under-served market. We determined that the top-down
trends and attractive cash flows of ambulatory surgical centers made this an area of particular
interest. Less well-known, however, is the non-urban sector, which has suffered from a long-term
lack of access to capital despite providing care to more than 50 million people in the United
States. We determined that focusing on rural healthcare would represent a significant long-term
opportunity for us. We believe that we have identified a differentiated approach based on the
recognition that the physician is at the center of the healthcare industry. Our operating
philosophy is tied to a belief that the provision of flexible financial solutions to rural
hospitals and
ambulatory surgical centers through the alignment of our interests with those of the
physicians will result in a strong, predictable cash flow stream with excellent risk-adjusted
returns.
3
On October 29, 2007, we acquired 51% of the issued and outstanding membership units of RHA.
Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic
and an ancillary support services unit, all focused on the delivery of healthcare services to rural
communities in Oklahoma. Together, the acquisition of RHA and the subsequent acquisition of SPMC
by RHA are referred to herein collectively as the
RHA Acquisition
, and the three RHA
hospitals, the medical clinic, ancillary support services units and SPMC are referred to herein
collectively as the
RHA Healthcare Operations
. On May 1, 2008, RHA purchased 100% of the
issued and outstanding membership interests of SPMC. Beginning November 18, 2008, RHA began
operating under the trade name Southern Plains Medical Group. On December 11, 2008, through one
of our wholly-owned subsidiaries, we acquired the remaining 49% of the issued and outstanding
membership units of RHA, making RHA an indirect wholly-owned subsidiary. We believe that these
transactions are consistent with our current operating strategy.
Our portfolio is expected to consist of (i) majority interests in healthcare platforms or
facilities, such as RHA, the San Diego ambulatory surgical center and SPMC and (ii) equity positions
in a diversified portfolio of minority interests in ambulatory surgical centers with a history of
positive cash flows. In addition, we expect to selectively invest in business solutions providing
financial and processing services to healthcare providers and physicians and in support of new
treatment solutions.
In line with our strategy, we re-branded our activities. The operations in non-urban markets
previously known as RHA were re-branded Southern Plains Medical Group to leverage the old and
well-established recognition that SPMC has in the regional markets. In addition, effective
September 29, 2009, we changed our name to First Physicians Capital Group, Inc. to reflect our
focus on the healthcare industry.
FUNDING
We have sustained operating losses since our inception and had an accumulated deficit of
approximately $86.0 million as of September 30, 2009, which has been funded primarily through the
issuance of preferred stock, the issuance of promissory notes and cash generated from operations.
As of September 30, 2009 we had current liabilities of $12.5 million and current assets of
$10.6 million. Significant events relating to funding of operations in the twelve-month period
ended September 30, 2009 include:
|
|
|
In February 2009 we received $1,500,000 in connection with the issuance of two
promissory notes under the Bridge Financing (as defined in Item 7, Funding, in this
Form 10-K)
|
|
|
|
In March 2009 we received $500,000 in connection with the issuance of nine
promissory notes under the Bridge Financing.
|
|
|
|
In April 2009 we received $200,000 in connection with the issuance of three
promissory notes under the Bridge Financing.
|
|
|
|
In April and May 2009 we received $202,500 in connection with the exercise of
then-outstanding warrants to purchase 405,000 shares of our Common Stock.
|
|
|
|
In June 2009 we received $350,000 in connection with the subscription of 350 shares
of our Series 6-A Convertible Preferred Stock, par value $0.01 per share (the
6-A
Preferred
) and warrants to purchase our Common Stock.
|
Upon completion of the RHA Acquisition in October 2007, RHA assumed a bank obligation in the
amount of $4.4 million (the
RHA Loan
). With the completion of the SPMC acquisition by
RHA in May 2008, we acquired SPMC bank obligations in the amount of $4.5 million. In December
2008, subsidiaries of RHA obtained three loans totaling an aggregate of $8.4 million, the proceeds
of which were used for (i) the purchase of the real property and assets of the hospital operated by
RHA in Stroud, Oklahoma for a consideration of $3.2 million pursuant to an existing option
agreement; (ii) the repayment of the RHA Loan and (iii) the financing of capital expenditures, fees
associated with the financings and working capital requirements (the
2008 Loans
). The
2008
Loans carry amortization schedules of 16-years to 20-years and are guaranteed up to 80% by the
U.S. Department of Agriculture Rural Development 80% Business & Industry Loan Guarantee program
(
USDA
). The completion of the 2008 Loans had the effect of reducing our current
liabilities by $4.6 million.
4
Our management believes that we have adequate funding from the RHA Healthcare Operations and
Del Mar, cash and cash equivalents, the 2008 Loans and the Bridge Financing for us to continue in
operation for at least 12 months from the balance sheet date. Therefore, we have prepared our
financial statements on a going concern basis.
Our investment and acquisition targets will continue to derive their working capital from
their respective operations or financing efforts. We will assist our subsidiaries in expanding
their access to working capital as appropriate.
INTELLECTUAL PROPERTY
We formerly operated under the trademarks Tri-Isthmus Group and TIGroup. In line with our
strategy, we re-branded our activities. The operations in non-urban markets currently known as RHA
were re-branded Southern Plains Medical Group to leverage the old and well-established
recognition that SPMC has in the regional markets in which we operate. In addition, effective
September 29, 2009, we changed our name to First Physicians Capital Group, Inc. to reflect our
focus on the healthcare industry.
We do not currently have any patents, trademarks, licenses, franchises, concessions, royalty
agreements or labor contracts, other than those that are incidental and customary to our business,
such as licenses to use software applications.
EMPLOYEES
We have five employees at the parent company level as of January 7, 2010, including David
Hirschhorn, our chairman and Chief Executive Officer, Donald C. Parkerson, our Chief Financial
Officer, a director of corporate development, a corporate controller and an administrative
secretary. We consider our relations with employees to be good. None of our employees are
represented by a labor union or work under any collective bargaining agreement.
As
of January 7, 2010, RHA and Del Mar employed 388 and 31 personnel, respectively. We
consider relations with employees at each of RHA and Del Mar to be good. None of these employees
are represented by a labor union or work under any collective bargaining agreement.
GOVERNMENT REGULATIONS
The United States healthcare industry is subject to extensive regulation by a number of
governmental entities at the federal, state and local level. Government regulation affects our
business activities by controlling our growth, requiring licensure and certification for our
facilities, regulating the use of our properties and controlling reimbursement to us for the
services we provide.
State Licensing and CONs
State licensing of ambulatory surgical centers, rural hospitals and surgical hospitals is
generally a prerequisite to the operation of each center and to participation in federally-funded
programs, such as Medicare and Medicaid. Once a facility becomes licensed and operational, it must
continue to comply with federal, state and local licensing and certification requirements, as well
as local building and safety codes. In addition, every state imposes licensing requirements on
individual physicians and facilities, as well as services operated and owned by physicians.
Physician practices are also subject to federal, state and local laws dealing with issues such as
occupational safety, employment, medical leave, insurance regulations, civil rights and
discrimination and medical waste and other environmental issues.
5
Certificate of Need (
CON
) statutes and regulations control the development of
ambulatory surgical centers in certain states. CON statutes and regulations generally provide
that, prior to the expansion of existing centers, the construction of new centers, the acquisition
of major items of equipment or the introduction of certain new services, approval must be obtained
from the designated state health planning agency. In giving approval, a designated state health
planning agency must determine that a need exists for expanded or additional facilities or
services. We do not operate in any CON states currently, but we may do so in the future.
Corporate Practice of Medicine
The laws of certain states in which we operate or may operate in the future do not permit
business corporations to practice medicine, exercise control over physicians who practice medicine
or engage in various business practices, such as fee-splitting with physicians. The interpretation
and enforcement of these laws vary significantly from state to state. We are not required to
obtain a license to practice medicine in any jurisdiction in which we currently own and operate
ambulatory surgical centers, rural hospitals or surgical hospitals because these entities are not
engaged in the practice of medicine as defined by state laws. The physicians who perform
procedures at the ambulatory surgical centers, rural hospitals and surgical hospitals are
individually licensed to practice medicine. In some instances, the physicians and physician group
practices are not affiliated with us other than through the physicians ownership in the limited
partnerships and limited liability companies that own the surgery centers and through the service
agreements we have with some physicians. The laws in most states regarding the corporate practice
of medicine have been subjected to limited judicial and regulatory interpretation. We cannot
provide assurances that our activities, if challenged, will be found to be in compliance with these
laws.
Certification
We depend on third-party programs, including governmental and private health insurance
programs, to reimburse us for services rendered to patients in our facilities. In order to receive
Medicare reimbursement, each facility must meet the applicable conditions of participation set
forth by the United States Department of Health and Human Services, or DHS, relating to the type of
facility, the services it provides, its equipment, personnel and standard of medical care, as well
as compliance with state and local laws and regulations, all of which are subject to change from
time to time. Ambulatory surgical centers and hospitals undergo periodic on-site Medicare
certification surveys. Each of our existing facilities is certified as a Medicare provider.
Although we intend for our facilities to participate in Medicare and other government reimbursement
programs, there can be no assurance that these centers will continue to qualify for participation.
Medicare-Medicaid Fraud and Abuse Provisions
Section 1128B(b) of the Social Security Act (the
Federal Anti-Kickback Statute
)
prohibits the knowing or willful offering, payment, solicitation or receipt or remuneration,
directly or indirectly, overtly or covertly, in cash or in kind, for: (1) the referral of patients
or arranging for the referral of patients to receive services for which payment may be made in
whole or in part under a federal or state healthcare program; or (2) the purchase, lease, order or
arranging for the purchase, lease or order of any good, facility, service or item for which payment
may be made under a federal or state healthcare program. The Federal Anti-Kickback Statute is very
broad in scope and many of its provisions have not been uniformly or definitively interpreted by
case law or regulations. Violations may result in criminal penalties or fines of up to $25,000,
imprisonment for up to five years, or both. Violations of the Federal Anti-Kickback Statute may
also result in substantial civil penalties, including penalties of up to $50,000 for each
violation, plus three times the amount claimed and exclusion from participation in the Medicare and
Medicaid programs. Exclusion from these programs would result in significant reductions in revenue
and would have a material adverse effect on our business.
As authorized by Congress, the Office of the Inspector General (
OIG
) promulgated
safe harbor regulations that outline categories of activities protected from prosecution under the
Federal Anti-Kickback Statute. These safe harbors cover, among other things, investment interests,
personal services and management contracts and employment arrangements. Although conduct or
business arrangements that do not fall within a safe harbor are not unlawful
per se
, noncompliant
conduct or business arrangements risk increased scrutiny by governmental enforcement authorities.
6
In addition to the Federal Anti-Kickback Statute, the Health Insurance Portability and
Accountability Act of 1996, or
HIPAA,
provides for criminal penalties for healthcare
fraud offenses that apply to all health benefit programs, including the payment of inducements to
Medicare and Medicaid beneficiaries in order to influence those beneficiaries to order or receive
services from a particular provider or practitioner. Federal enforcement officials have numerous
enforcement mechanisms to combat fraud and abuse, including the Medicare Integrity Program and an
incentive program under which individuals can receive up to $1,000 for providing information on
Medicare fraud and abuse that leads to the recovery of at least $100 of Medicare funds. In
addition, federal enforcement officials have the ability to exclude from Medicare and Medicaid any
investors, officers and managing employees associated with business entities that have committed
healthcare fraud.
Evolving interpretations of current, or the adoption of new, federal or state laws or
regulations could affect many of our arrangements. Law enforcement authorities, including the OIG,
the courts and Congress, are increasing their scrutiny of arrangements between healthcare providers
and potential referral sources to ensure that the arrangements are not designed as a mechanism to
exchange remuneration for patient care referrals and opportunities. Investigators also have
demonstrated a willingness to look behind the formalities of a business transaction to determine
the underlying purposes of payments between healthcare providers and potential referral sources.
Prohibition on Physician Ownership of Healthcare Facilities and Certain Self-Referrals
Section 1877(a) of the Social Security Act sets forth the federal physician self-referral law,
commonly referred to as the Stark Law, which prohibits a physician from making a referral for a
designated health service to an entity if the physician or a member of the physicians immediate
family has a financial relationship with the entity, subject to certain exceptions. Sanctions for
violating the Stark Law include civil money penalties of up to $15,000 per prohibited service
provided and exclusion from the federal healthcare programs. The Stark Law applies to referrals
involving the following services under the definition of designated health services: clinical
laboratory services; physical therapy services; occupational therapy services; radiology and
imaging services; radiation therapy services and supplies; durable medical equipment and supplies;
parenteral and enteral nutrients, equipment and supplies; prosthetics, orthotics and prosthetic
devices and supplies; home health services; outpatient prescription drugs and inpatient and
outpatient hospital services.
The Center for Medicare and Medicaid Services (
CMS
) issued two phases of final
regulations implementing the Stark Law, which became effective on January 4, 2002 and July 26,
2004, respectively. Most recently, on September 5, 2007, CMS issued the third phase of final
regulations which became effective on December 4, 2007. While these regulations help clarify the
requirements of the exceptions to the Stark Law, it is unclear how the government will interpret
the exceptions for enforcement purposes.
Nevertheless, under these regulations, services that would otherwise constitute a designated
health service, but that are paid by Medicare as a part of the surgery center payment rate, are not
a designated health service for purposes of the Stark Law. In addition, the Stark Law contains an
exception covering implants, prosthetics, implanted prosthetic devices and implanted durable
medical equipment provided in a surgery center setting under certain circumstances. Therefore, we
believe the Stark Law does not prohibit physician ownership or investment interests in our surgery
centers to which they refer patients.
With regard to the rural hospitals and the surgical hospitals, the Stark Law regulations
include exceptions for investments in rural providers and hospital ownership. We believe the
investment structure of each of our rural hospitals and surgical hospitals complies with either the
rural provider or hospital ownership exception.
The rural provider exception under the Stark Law reads as follows:
The following ownership or investment interests in the following entities do not constitute a
financial relationship: (1) A rural provider, in the case of DHS furnished in a rural area by the
provider. A rural provider is an entity that furnishes substantially all (not less than 75
percent) of the DHS that it furnishes to residents of a rural area and, for the 18-month period
beginning on December 8, 2003 (or such other period as Congress may specify), is not a specialty
hospital. A rural area for purposes of this paragraph (c)(1) is an area that is not an urban area
as defined in Sec. 412.62(f)(1)(ii) of this chapter.
7
The hospital ownership exception under the Stark Law reads as follows:
The following ownership or investment interests in the following entities do not constitute a
financial relationship: A hospital that is located outside of Puerto Rico, in the case of DHS
furnished by such a hospital, if:
(i) the referring physician is authorized to perform services at the hospital;
(ii) effective for the 18-month period beginning on December 8, 2003 (or such other period as
Congress may specify), the hospital is not a specialty hospital; and
(iii) the ownership or investment interest is in the entire hospital and not merely in a
distinct part or department of the hospital.
In 2003, Congress passed legislation modifying the hospital ownership exception to the Stark
Law by creating an 18-month moratorium on allowing physician ownership of new specialty hospitals.
While the moratorium technically expired in 2005, the DHS suspended the processing of new provider
enrollment applications for specialty hospitals, effectively extending the moratorium. On August
28, 2006, CMS issued its final report to Congress (the
Final Report
) addressing the
specialty hospital moratorium as required by the Deficit Reduction Act of 2005. In the Final
Report, CMS declined to extend the suspension of processing new provider enrollment applications
for specialty hospitals. CMS also declined to recommend an amendment to the whole hospital
exception to exclude physician investments in specialty hospitals. Nevertheless, future regulatory
changes may prohibit physicians from investing in specialty hospitals. The Stark Law defines a
specialty hospital as a hospital that primarily or exclusively treats cardiac, orthopedic or
surgical conditions or any other specialized category of patients or cases designated by
regulation. According to this definition, we believe that none of our facilities is a specialty
hospital, and therefore, the moratorium does not apply to our facilities. There can be no
assurance, however, that the federal government will not amend the definition of specialty
hospital to include the any of our facilities.
Furthermore, on July 12, 2007, CMS published proposed updates to the Medicare Physician Fee
Schedule for 2008, which included a number of significant proposed revisions to the Stark Law.
While none of the proposed revisions are directly relevant for purposes of this disclosure,
investors should be aware that CMS may propose changes to the Stark Law in the future that may
significantly impact our investment structures and our relationships with referring physicians.
We also have various compensation arrangements, including personal service arrangements and
management arrangements with physicians, that we have structured to comply with applicable Stark
Law exceptions.
The Federal False Claims Act and Similar Federal and State Laws
The False Claims Act (the
FCA
) prohibits any person from knowingly presenting or
causing to be presented a false or fraudulent claim, record or statement to obtain payment from the
government or decrease any payments owed to the government. Governmental enforcement agencies or
courts may impose fines up to three times the actual damages sustained by the government, plus
mandatory civil penalties of between $5,500 and $11,000 for each separate false claim.
Criminal false claims provisions apply to (1) false claims or statements made knowingly or
willfully to obtain benefits under Medicare or Medicaid or feign compliance with certification
requirements, or (2) failure to refund, knowingly and with fraudulent intent, Medicare and Medicaid
funds not properly paid. Governmental enforcement agencies or courts may impose up to five years
in prison, $25,000 in fines for each offense, or both.
8
FCA claims may be brought by governmental enforcement authorities or by individuals on the
governments behalf under the FCAs
qui tam
, or whistleblower, provisions. Whistleblower
provisions allow private individuals to bring actions on behalf of the government alleging that the
defendant defrauded the federal government. Additionally, HIPAA established (1) civil liability
for upcoding and billing medically unnecessary
items and services, and (2) federal criminal sanctions for healthcare fraud against a private,
nongovernmental healthcare benefit program. Although we have implemented policies and procedures
to avoid violations of these laws, there can be no assurance that the conduct will not be reviewed
and challenged by whistleblowers or governmental enforcement authorities. Any adverse
determination could subject us to criminal and civil liability.
A number of states have adopted their own false claims provisions as well as their own
qui tam
provisions whereby a private party may file a civil lawsuit in state court. We are currently not
aware of any actions against us under any such state laws.
Healthcare Industry Investigations
Both federal and state government agencies have heightened and coordinated civil and criminal
enforcement efforts as part of numerous ongoing investigations of healthcare companies, as well as
their executives and managers. These investigations relate to a wide variety of topics, including
referral and billing practices.
From time to time, the OIG and the United States Department of Justice (the
DOJ
)
have established national enforcement initiatives that focus on specific billing practices or other
suspected areas of abuse. Some of our activities could become the subject of governmental
investigations or inquiries. For example, we have significant Medicare billings and we have joint
venture arrangements involving physician investors. In addition, our executives and managers, many
of whom have worked at other healthcare companies that are or may become the subject of federal and
state investigations and private litigation could be included in governmental investigations or
named as defendants in private litigation. We are not aware of any governmental investigations
involving any of our facilities, our executives or our managers. A future adverse investigation of
us, our executives or our managers could result in significant expense to us, as well as adverse
publicity.
Privacy Requirements and Administrative Simplification
Federal and state governmental enforcement authorities extensively regulate the
confidentiality of patient health information. HIPAA privacy regulations regulate the use and
disclosure of patient health information, whether communicated electronically, on paper or orally.
The regulations also provide patients with significant rights related to understanding and
controlling how their health information is used or disclosed. HIPAA security regulations require
healthcare providers to implement administrative, physical and technical safeguards to protect the
security of patient health information that is maintained or transmitted electronically. Further,
as required by HIPAA, DHS has adopted regulations establishing electronic data transmission
standards that all healthcare providers must use when submitting or receiving certain healthcare
transactions electronically.
The penalty for failure to comply with HIPAA privacy and security standards is a fine of up to
$100 for each violation, with a maximum penalty of $25,000 imposed for all violations of an
identical requirement during a calendar year. Additionally, any person or entity who violates
HIPAA privacy or security regulations may be fined up to $250,000, imprisoned for not more than 10
years or both. We believe we comply in all material respects with all applicable federal and state
laws, rules and regulations governing the privacy and security of patient health information.
Because of the complexity of these regulations, however, there can be no assurance that our privacy
and security practices will not be reviewed and found not to be in compliance with these standards.
An adverse determination by governmental enforcement authorities could materially and adversely
affect our business.
In addition, our facilities will continue to remain subject to any state laws that are more
restrictive than the HIPAA privacy and security regulations. These statutes vary by state and
could impose additional penalties.
Environmental Regulation
Our operations generate medical waste that must be disposed of in compliance with federal,
state and local environmental laws, rules and regulations. Our operations are also subject to
compliance with various other environmental laws, rules and regulations. Such compliance costs are
not significant, and we do not anticipate that they will be significant in the future.
9
Medicare and Medicaid Regulatory and Audit Impacts
Medicare and state Medicaid programs are subject to regulatory changes, administrative
rulings, interpretations and determinations, post-payment audits, requirements for utilization
review and new governmental funding restrictions, all of which could materially increase or
decrease program payments, impact cost of providing services and affect the timing of payments to
our hospitals. The final determination of amounts received under the Medicare and Medicaid
programs often takes many years because of audits by the programs representatives, providers
rights of appeal and the application of numerous technical reimbursement provisions. Until final
adjustments are made, certain issues remain unresolved and established allowances may be higher or
lower than what is ultimately required.
The Medicare program utilizes a system of contracted carriers and fiscal intermediaries across
the country to process claims and conduct post-payment audits. Per the Medicare Prescription Drug,
Improvement and Modernization Act of 2003 (the
2003 Act
), CMS is reforming the carrier
and fiscal intermediary functions. As part of such reform, CMS is competitively bidding the
carrier and fiscal intermediary functions to Medicare Administrative Contractors. These changes
could affect claims processing, auditing and cash flow to Medicare providers.
COMPETITORS
In our current markets, we compete with other healthcare providers, including major acute
care, surgical, specialty and rural hospitals and other surgery centers. We compete with other
providers for patients, physicians and for contracts with insurers or managed care payors. There
are several publicly-held companies, or divisions of large publicly-held companies, that acquire
and develop freestanding multi-specialty surgery centers. Some of these competitors have greater
resources than we do. The principal competitive factors that affect our ability and the ability of
our competitors to acquire surgery centers and private surgical, rural and specialty hospitals are
price, experience, reputation and access to capital. The principal competitive factors that affect
our surgery centers are location and the quality of medical care provided by our physician-partners
and other physicians who use our facilities.
ANY INVESTMENT IN OUR COMMON STOCK INVOLVES A HIGH DEGREE OF RISK. YOU SHOULD CAREFULLY CONSIDER
THE FOLLOWING RISK FACTORS IN ADDITION TO THE OTHER INFORMATION CONTAINED IN THIS REPORT.
Risks Related to Our Business
We are subject to uncertainties regarding healthcare reform.
Both houses of the United States Congress are working on healthcare reform legislation. Among
the proposals that have been introduced are price controls on hospitals, insurance market reforms
to increase the availability of group health insurance to small businesses, requirements that all
businesses offer health insurance coverage to their employees and the creation of government health
insurance plans that would cover all citizens and increase payments by beneficiaries. Similar
legislation may be considered by states or other regulators. We cannot predict whether any
healthcare reform proposals will be adopted. If adopted, such reforms could harm our business. It
is possible that these reforms may be interpreted and applied in a manner that is inconsistent with
our business practices. If so, in addition to the possibility of fines, this could result in an
order requiring that we change our business practices, which could have an adverse effect on our
business. Complying with these various reforms could cause us to incur substantial costs or
require us to change our business practices in a manner adverse to our business.
10
We have a need for ongoing financing.
We will need additional capital to continue to maintain and expand our operations and will
endeavor to raise funds through the sale of equity shares and other types of securities and
revenues from operations. There can be no assurance that we will generate revenues from operations
or obtain sufficient capital on acceptable terms, if at all. Failure to obtain such capital or
generate such operating revenues would have an adverse impact on our financial position and results
of operations and ability to continue as a going concern. Our operating capital and capital
expenditure requirements during the fiscal year ending September 30, 2010 and thereafter will vary
based on a number of factors, including the level of sales and marketing activities for our
services and products. There can be no assurance that additional private or public financings,
including debt or equity financing, will be available as needed, or, if available, on terms
favorable to us. Any additional equity financing may be dilutive to stockholders and such
additional equity securities may have rights, preferences or privileges that are senior to those of
our existing Common Stock. Furthermore, debt financing, if available, will require payment of
interest and may involve restrictive covenants that could impose limitations on our operating
flexibility. Our failure to successfully obtain additional future funding may jeopardize our
ability to continue our business and operations. If we raise additional funds by issuing equity
securities, existing stockholders may experience a dilution in their ownership. In addition, as a
condition to giving additional funds to us, future investors may demand, and may be granted, rights
superior to those of existing stockholders.
The recent disruption in the overall economy and the financial markets may adversely impact our
business.
Many industries, including businesses providing healthcare solutions outside of traditional
hospital settings, have been affected by current economic factors, including the deterioration of
national, regional and local economic conditions, declines in employment levels and shifts in
consumer spending patterns. The recent disruptions in the overall economy and volatility in the
financial markets have reduced, and may continue to reduce, consumer confidence in the economy,
negatively affecting consumer spending, which could be harmful to our financial position.
Disruptions in the overall economy may also lead to a lower collection rate on billings as
consumers or businesses are unable to pay their bills in a timely fashion. Decreased cash flow
generated from our businesses may adversely affect our financial position and our ability to fund
our operations. In addition, macroeconomic disruptions, as well as the restructuring of various
commercial and investment banking organizations, could adversely affect our ability to access the
credit markets. The disruption in the credit markets may also adversely affect the availability of
financing for our acquisition of interests in ambulatory surgical centers, rural hospitals,
surgical hospitals and other healthcare delivery platforms. There can be no assurance that
government responses to the disruptions in the financial markets will restore consumer confidence,
stabilize the markets or increase liquidity and the availability of credit.
We are dependent for our success on a few key executive officers. Were we to lose one or more of
these key executive officers, we would be forced to expend significant time and money in the
pursuit of a replacement, which would result in both a delay in the implementation of our business
plan and the diversion of working capital.
Our success depends to a critical extent on the continued efforts and services of our Chief
Executive Officer, David Hirschhorn, our Chief Financial Officer, Donald C. Parkerson and the
President and Chief Operating Officer of RHA, Thomas Rice. Were we to lose one or more of these
key executive officers, we would be forced to expend significant time and money in the pursuit of a
replacement or replacements, which would result in both a delay in the implementation of our
business plan and the diversion of limited working capital. We can give you no assurance that we
can find satisfactory replacements for these key executive officers at all, or on terms that are
not unduly expensive or burdensome to us. Although Mr. Hirschhorn and Mr. Rice have signed
employment agreements with us, their agreements do not preclude them from leaving us, nor can we
assure you that the noncompetition provisions contained in their employment agreements would be
enforceable in any such event.
11
If we are unable to acquire and develop additional healthcare facilities on favorable terms, we may
be unable to execute our acquisition and development strategy, which could limit our future growth.
Part of our strategy to increase our revenues and earnings is through the continuing
acquisition of interests in rural hospitals, physician practices, ambulatory surgical centers,
surgical hospitals and other healthcare delivery
platforms operating in partnership with physicians ambulatory surgical centers. Our efforts
to execute our acquisition and development strategy may be affected by our ability to identify
suitable candidates and negotiate and close acquisition and development transactions. We are
currently evaluating potential acquisitions and development projects and expect to continue to
evaluate acquisitions and development projects in the foreseeable future. The businesses we
acquire may experience losses in their early months of operation, or may never become profitable.
We may not be successful in acquiring additional companies or achieving satisfactory operating
results at acquired or newly developed facilities. Further, the companies or assets we acquire in
the future may not ultimately produce returns that justify our related investment. If we are
unable to execute our acquisition and development strategy, our ability to increase revenues and
earnings through future growth would be impaired.
We have incurred significant losses and may incur losses in the future.
We have sustained operating losses since inception and had an accumulated deficit of
approximately $85.8 million as of September 30, 2009. This deficit has been funded primarily
through sales of equity, the issuance of promissory notes and cash generated from operations. Our
management intends to continue in the pursuit of a growth strategy defined by acquisitions. We
anticipate that our operating expenses will increase in the foreseeable future as we increase our
acquisition activities, and continue to develop our technology, products and services. We will
need to generate significant revenues to achieve profitability, and we cannot assure you that we
will ever realize revenues at such levels. If we do achieve profitability in any period, we may
not be able to sustain or increase our profitability on a quarterly or annual basis.
If we incur material liabilities as a result of acquiring companies, hospitals or ambulatory
surgical centers, our operating results could be adversely affected.
Although we conduct extensive due diligence prior to the acquisition of companies, hospitals,
ambulatory surgical centers, physician practices and other healthcare businesses, and seek
indemnification from prospective sellers covering unknown or contingent liabilities, we may acquire
companies that have material liabilities for failure to comply with healthcare laws and regulations
or other past activities. Although we maintain professional and general liability insurance, we do
not currently maintain insurance specifically covering any unknown or contingent liabilities that
may have occurred prior to any acquisition. If we incur these liabilities and are not adequately
indemnified or insured for them, our operating results and financial condition could be adversely
affected.
If we are unable to manage growth, we may be unable to achieve our growth strategy.
We expect to continue to expand our operations in the future. To accommodate our past and
anticipated future growth, and to compete effectively, we will need to continue to implement and
improve our management, operational and financial information systems and to expand, train, manage
and motivate our workforce. Our personnel, systems, procedures or controls may not be adequate to
support our operations in the future. Further, focusing our financial resources and management
attention on the expansion of our operations may negatively impact our financial results. Any
failure to implement and improve our management, operational and financial information systems, or
to expand, train, manage or motivate our workforce, could reduce or prevent our growth.
If we are unable to grow revenues at our existing facilities, our operating margins and
profitability could be adversely affected.
Our growth strategy includes increasing our revenues and earnings by increasing the number of
procedures performed at our facilities. Because we expect the amount of the payments we receive
from third-party payors to remain fairly consistent, our operating margins will be adversely
affected if we do not increase the revenues and procedure volume of our facilities to offset
increases in our operating costs. We seek to increase procedure volume and revenues at our
surgical facilities by increasing the number of physicians performing procedures at our centers,
obtaining new or more favorable managed care contracts, improving patient flow at our centers,
promoting screening programs, increasing patient and physician awareness of our facilities and
achieving operating efficiencies. We can give you no assurances that we will be successful at
increasing or maintaining revenues and operating margins at our facilities.
12
Appropriate acquisitions or investment opportunities may not be available.
As noted above, we may use a portion of our cash resources to pursue acquisition
opportunities. If we decide to seek such opportunities, our future results will be dependent on
our ability to identify, attract and complete desirable acquisition opportunities, which may take
considerable time. In addition, our cash position, $2.3 million at September 30, 2009, may limit
the scale and therefore the number of opportunities available. Our future results will be
dependent on the performance of the acquired businesses, if any. We may not be successful in
identifying, attracting or acquiring desirable acquisition candidates, or in realizing profits from
any acquisitions.
With the completion of the acquisition of the San Diego ambulatory surgical centers, our
strategy evolved during the Fiscal Year Ended January 31, 2007 from a focus on investment in
platform strategies in the business services and healthcare industries to a concentration on
healthcare and ancillary services, targeting companies valued at $3 million to $50 million. In
particular, we are actively seeking to build our portfolio of interests in healthcare services
operations, including ambulatory surgical centers, rural hospitals, surgical hospitals and other
healthcare delivery platforms operating in partnership with physicians. Our strategy is predicated
on managements belief that the provision of flexible financial solutions to ambulatory surgical
centers, specialty hospitals and other healthcare platforms aligns our interests with those of
physician-partners, providing the basis for interdependent relationships that will establish sound
operating partnerships and deliver solid risk adjusted returns. Our portfolio is expected to
consist of (i) majority interests in healthcare platforms or facilities, such as RHA and the San Diego ambulatory surgical center and (ii) equity positions in a diversified portfolio of minority
interests in ambulatory surgical centers with a history of positive cash flows. In addition, we
will selectively invest in business solutions providing financial and processing services to
healthcare providers and physicians and in support of new treatment solutions.
We will have sole and absolute discretion in identifying and selecting acquisition and
investment opportunities and in structuring, negotiating and undertaking transactions with our
target companies. We may acquire, invest or be sold (in whole or in part) at any time, as our
Board of Directors and management determine is appropriate. Our stockholders generally will not be
able to evaluate the merits of the acquisition, investment or sale (partial or otherwise) before we
take any of these actions. In addition, in making decisions to complete acquisitions, investments
or a sale, we will rely, in part, on financial projections developed by our management and
financial advisors and the management of potential target companies. These projections will be
based on assumptions and subjective judgments. The actual results of these transactions may differ
significantly from these projections.
A significant portion of our revenues are produced by a small number of our facilities, which are
concentrated in Oklahoma and California.
A significant portion of our revenues are produced by a small number of our facilities based
in Oklahoma and California. Our future patient volumes, net revenues and profitability in this
market could be unfavorably impacted as a result of increased competitor capacity and expansion of
services. A continuation of increased provider competition in this market, as well as potential
future capacity added by us and others, could result in additional erosion of the patient volumes,
net revenues and financial operating results of our facilities in this market.
The significant portion of our revenues derived from these facilities makes us particularly
sensitive to regulatory, economic, environmental and competition changes in Oklahoma and
California. Any material change in the current payment programs or regulatory, economic,
environmental or competitive conditions in these states could have a disproportionate effect on our
overall business results.
We depend on our relationships with the physicians who use our facilities. Our ability to provide
medical services at our facilities would be impaired and our revenues reduced if we were unable to
maintain these relationships.
Our business depends upon the efforts and success of the physicians who provide medical and
surgical services at our facilities and the strength of our relationships with these physicians.
Our revenues would be reduced if we lost our relationship with one or more key physicians or group
of physicians or if such physicians or groups reduce their use of our facilities. In addition, any
failure of these physicians to maintain the quality of medical care provided or to otherwise adhere
to professional guidelines at our surgical facilities, or any damage to the reputation
of a key physician or group of physicians could damage our reputation, subject us to liability
and significantly reduce our revenues.
13
Continued growth in the number of uninsured and underinsured patients or further deterioration in
the collectability of the accounts of such patients could harm our results of operations.
The principal collection risks for our accounts receivable relate to uninsured patient
accounts and patient accounts for which the primary insurance carrier has paid the amounts required
by the applicable agreement but patient responsibility amounts (e.g., deductibles, co-payments and
other amounts not covered by insurance) remain outstanding. If we continue to experience
significant increases in uninsured and underinsured patients and/or uncollectible accounts
receivable, our results of operations could be harmed.
We may incur liabilities not covered by our insurance or which exceed our insurance limits.
In the ordinary course of business, our subsidiary hospitals are subject to medical
malpractice lawsuits, product liability lawsuits and other legal actions. Some of these actions
may involve large claims, as well as significant defense costs. We self-insure a substantial
portion of our liability risks for property and other typical insurance coverage with commercial
carriers, subject to self-insurance retention levels, but we do not have any coverage for
malpractice liability. We believe that, based on our past experience and actuarial estimates, our
insurance coverage and our self-insurance reserves are sufficient to cover claims arising from the
operations of our subsidiary hospitals. However, if payments for claims and related expenses
exceed our estimates or if payments are required to be made by us that are not covered by
insurance, our business could be harmed and our results of operations could be adversely impacted.
We believe that our insurance is adequate in amount and coverage. However, in the future, insurance
may not be available at reasonable prices or we may have to increase our levels of self-insurance.
Because we have facilities in Oklahoma and California, we may incur liabilities or have operational
difficulties as a result of damage from tornados, mudslides, earthquakes and wildfires, as well as
damage from other natural disasters.
We own and operate hospitals in Oklahoma. Oklahoma has one of the highest rates of tornado
activity in the United States. Potential tornado damage and disruption to our hospitals, as well
as employees homes, local businesses, local infrastructure (such as roads and bridges leading to
our hospitals) and physicians offices could be extensive. If we experience damage as a result of
tornados or other natural disasters in the vicinity of any of our Oklahoma facilities, the results
of operations could be harmed due to financial losses to repair or rebuild our facilities or
disruption to our customers or employees that could negatively impact our operations.
We also own and operate facilities in California. Mudslides, earthquakes, wildfires and other
natural disasters occur frequently in California. Potential damage and disruption in our
facilities, local businesses, local infrastructure (such as roads and bridges leading to our
hospitals) or employees homes located in California as a result of mudslides, earthquakes,
wildfires or other natural disasters could be substantial. If we experience mudslides,
earthquakes, wildfires or other natural disasters in the vicinity of any of our California
facilities, our reputation and results of operations could be harmed due to financial losses to
repair or rebuild our facilities or disruption to our customers or employees that could hurt our
ability to effectively provide our services.
Risks Related to Our Industry/General Market Conditions
Current and future disruptions in the banking industries may limit our access to our funds or cause
us to lose funds, which could negatively impact our business.
We are affected by certain economic factors that are beyond our control, including changes in
the overall banking environment. Due to the current economic climate, some banks may fail. The
rate of bank failures has increased significantly in recent periods. A large percentage of our
cash is held in banks, not all of our cash is insured by the FDIC against an event of bank failure
and it would be impractically burdensome to rearrange our banking relationships to ensure a 100%
insurance coverage rate on our deposits. Should a bank at which we have a
deposit fail, we could lose all funds that are not insured or face significant delays in
recovering funds if any recovery of our uninsured amounts is possible at all. The loss of our
cash, or the ability to access our cash, could have a material adverse affect on our business and
could possibly cause us to file for bankruptcy or be forced to dissolve.
14
We depend on payments from third-party payors, including government healthcare programs. If these
payments are reduced, our revenue will decrease.
We are dependent upon private and governmental third-party sources of payment for the services
provided to patients in our facilities. The amount of payment a facility receives for its services
may be adversely affected by market and cost factors as well as other factors over which we have no
control, including Medicare and Medicaid regulations and the cost containment and utilization
decisions of third-party payors. Fixed fee schedules, capitation payment arrangements, exclusion
from participation in or inability to reach agreement with managed care programs or other factors
affecting payments for healthcare services over which we have no control could also cause a
reduction in our revenues.
If federal or state healthcare programs or managed care companies reduce the payments we receive as
reimbursement for services we provide, our net operating revenues may decline.
In recent years, federal and state governments made significant changes in the Medicare and
Medicaid programs, including the 2003 Act. Some of these changes could decrease the amount of
money we receive for our services relating to these programs
.
In recent years, Congress and some
state legislatures have introduced an increasing number of other proposals to make major changes in
the healthcare system including an increased emphasis on the linkage between quality of care
criteria and payment levels such as the submission of patient quality data to the Secretary of
Health and Human Services. Federal funding for existing programs may not be approved in the
future. Future federal and state legislation may further reduce the payments we receive for our
services. In addition, insurance and managed care companies and other third parties from whom we
receive payment for our services increasingly are attempting to control healthcare costs by
requiring that hospitals discount payments for their services in exchange for exclusive or
preferred participation in their benefit plans. We believe that this trend may continue and may
reduce the payments we receive for our services, which will lead to a decrease in our revenues
without a corresponding reduction in our costs.
Providers in the hospital industry have been the subject of federal and state investigations and we
could become subject to such investigations in the future.
For the past several years, significant media and public attention has been focused on the
hospital industry due to ongoing investigations related to referrals, cost reporting and billing
practices, laboratory and home healthcare services and physician ownership of joint ventures
involving hospitals. Both federal and state government agencies have previously announced
heightened and coordinated civil and criminal enforcement efforts. Moreover, the OIG and the DOJ
have, from time to time, established enforcement initiatives that focus on specific areas of
suspected fraud and abuse. Recent initiatives included a focus on hospital billing practices.
In March 2005, CMS implemented a three-year pilot recovery audit contractor program, commonly
known as RAC, covering providers in certain states where we operate hospitals. RAC auditors are
independent contractors hired by CMS. Among other things, the auditors have been focusing on
clinical documentation supporting billings under the Medicare program. If an auditor concludes
that such documentation does not support the providers Medicare billings, CMS will revise the
amount due to the provider, compare such amount to what was previously paid and withhold the
difference from a current remittance. The affected facility can appeal the auditors decision
through an administrative process. At the conclusion of the pilot demonstration program, a
permanent program may be implemented that will include hospital providers throughout the country.
We closely monitor our billing and other hospital practices to maintain compliance with
prevailing industry interpretations of applicable laws and regulations, and we believe that our
practices are consistent with those in our industry. However, government investigations could be
initiated that are inconsistent with industry practices and prevailing interpretations of existing
laws and regulations. In public statements, government authorities have taken positions on issues
for which little official interpretation had been previously available. Some of those positions
appear to be inconsistent with practices that have been common within our industry and, in some
cases, they have
not yet been challenged. Moreover, some government investigations that were previously
conducted under the civil provisions of federal law are now being conducted as criminal
investigations under fraud and abuse laws.
15
We cannot predict whether we will be the subject of future governmental investigations or
inquiries. Any determination that we have violated applicable laws or regulations or even a public
announcement that we are being investigated for possible violations could harm our business by the
issuance of injunctions requiring that we change our practices, loss of confidence by customers and
damage to our reputation, fines and other losses. Becoming subject to such investigations could
cause us to incur substantial costs or require us to change our business practices in a manner
adverse to our business.
If we fail to comply with other applicable laws and regulations, we could suffer penalties or be
required to make significant changes to our operations.
We are subject to many laws and regulations at the federal, state and local government levels
in the jurisdictions in which we operate. These laws and regulations require that our healthcare
facilities meet various licensing, certification and other requirements, including those relating
to:
|
|
|
physician ownership of our facilities;
|
|
|
|
|
the adequacy of medical care, equipment, personnel, operating policies and procedures;
|
|
|
|
|
building and safety codes;
|
|
|
|
|
licensure, certification and accreditation;
|
|
|
|
|
billing for services;
|
|
|
|
|
maintenance and protection of records; and
|
|
|
|
|
environmental protection.
|
We believe that we are in material compliance with applicable laws and regulations. However,
if we fail or have failed to comply with applicable laws and regulations, we could suffer civil or
criminal penalties, including the loss of our licenses to operate and our ability to participate in
Medicare, Medicaid and other government-sponsored healthcare programs. New interpretations or
enforcement of existing or new laws and regulations could subject our current practices to
allegations of impropriety or illegality, or could require us to make changes in our facilities,
equipment, personnel, services, capital expenditure programs and operating expenses. Current or
future legislative initiatives or government regulation may have a material adverse effect on our
operations or reduce the demand for our services.
In pursuing our growth strategy, we may expand our presence into new geographic markets. In
entering a new geographic market, we will be required to comply with laws and regulations of
jurisdictions that may differ from those applicable to our current operations. If we are unable to
comply with these legal requirements in a cost-effective manner, we may be unable to enter new
geographic markets.
We are subject to anti-kickback and self-referral laws and regulations that provide for
criminal and civil penalties if they are violated.
The healthcare industry is subject to many laws and regulations designed to deter and prevent
practices deemed by the government to be fraudulent or abusive. Unless an exception applies, Stark
Law prohibits physicians from referring Medicare or Medicaid patients to providers of enumerated
designated health services with whom the physician or a member of the physicians immediate
family has an ownership interest or compensation arrangement. Such referrals are deemed to be
self-referrals due to the physicians financial relationship with the entity providing the
designated health services. Moreover, many states have adopted or are considering similar
legislative proposals, some of which extend beyond the scope of the Stark Law to prohibit the
payment or receipt of remuneration for the prohibited referral of patients for designated
healthcare services and physician self-referrals, regardless of the source of the payment for the
patients care.
16
We review our operations from time to time and believe that we are either exempted from or in
compliance with the Stark Law and similar state statutes. We are currently working to implement a
more systematic review process, which will ensure ongoing compliance. When evaluating strategic
joint ventures or other collaborative relationships with physicians, we consider the scope and
effect of these statutes and seek to structure the arrangements in full compliance with their
provisions. Nevertheless, if it is determined that certain of our practices or operations violate
the Stark Law or similar statutes, we could become subject to civil and criminal penalties,
including exclusion from the Medicare and/or Medicaid programs. The imposition of any such
penalties could harm our business.
We could fail to comply with the federal Emergency Medical Treatment and Active Labor Act, or
EMTALA, which could subject us to civil monetary penalties or cause us to be excluded from
participation in the Medicare program.
Our hospital facilities are subject to EMTALA, which requires every hospital participating in
the Medicare program to conduct a medical screening examination of each person presented for
treatment at its emergency room. If a patient is suffering from an emergency medical condition,
the hospital must either stabilize that condition or make an appropriate transfer of the patient to
a facility that can handle the condition, regardless of the individuals ability to pay for care.
EMTALA imposes severe penalties if a hospital fails to screen, appropriately stabilize or transfer
a patient, or if a hospital delays service while first inquiring about the patients ability to
pay. Such penalties include, but are not limited to, civil monetary penalties and exclusion from
participation in the Medicare program. In addition to civil monetary penalties, an aggrieved
patient, a patients family or a medical facility that ultimately suffers a financial loss as a
direct result of a transferring hospitals EMTALA violation can commence a civil suit under EMTALA.
Although we believe that our facilities comply with EMTALA, there can be no assurances that claims
will not be brought against us and, if successfully asserted against one or more of our hospitals,
such claims could adversely affect our business and results of operations.
Our hospitals face competition for medical support staff, including nurses, pharmacists, medical
technicians and other personnel, which may increase our labor costs and adversely affect our
business.
We are highly dependent on our experienced medical support personnel, including nurses,
pharmacists and lab technicians, seasoned local hospital management and other medical personnel.
We compete with other healthcare providers to recruit and ultimately retain these healthcare
professionals. On a national level, a shortage of nurses and other medical support personnel has
become a significant operating issue for a number of healthcare providers. In the future, this
shortage may require us to enhance wages and benefits to recruit and retain such personnel or
require us to hire expensive temporary and per diem personnel. Additionally, to the extent that a
significant portion of our employee base unionizes, or attempts to unionize, our labor costs could
increase. If our wages and related expenses increase, we may not be able to raise our
reimbursement rates correspondingly. Our failure to recruit and retain qualified hospital
management, nurses and other medical support personnel or modulate our labor costs could adversely
affect our results of operations and harm our business.
If we do not continually enhance our hospitals with the most recent technological advances in
diagnostic and surgical equipment, our ability to maintain and expand our markets will be adversely
affected.
There are ongoing technological advances regarding CT scanners, MRI equipment, positron
emission tomography (
PET
) scanners and other similar equipment. In order to effectively
compete, we must continually assess our equipment needs and upgrade when significant technological
advances occur. If our hospitals do not stay abreast of the technological advances in the
healthcare industry, patients may seek treatment from other providers and physicians may refer
their patients to alternate sources.
If we are unable to effectively compete for patients, local residents could use other hospitals.
The hospital industry is highly competitive. In addition to the competition we face for
acquisitions and physicians, we must also compete with other hospitals and healthcare providers for
patients. The competition among hospitals and other healthcare providers for patients has
intensified in recent years. Our hospitals are located in non-urban service areas. However, our
hospitals face competition from hospitals outside of their primary service area, including
hospitals in urban areas that provide more complex services. Patients in our primary service areas
may travel to these other hospitals for a variety of reasons. These reasons include physician
referrals or the need for services we do not offer. Patients who seek services from these other
hospitals may subsequently shift their preferences to those hospitals for the services we provide.
17
Some of our hospitals operate in primary service areas where they compete with other
hospitals. Some of these competing hospitals use equipment and services more specialized than
those available at our hospitals. In addition, some competing hospitals are owned by tax-supported
governmental agencies or not-for-profit entities supported by endowments and charitable
contributions. These hospitals can make capital expenditures without paying sales, property and
income taxes. We also face competition from other specialized care providers, including outpatient
surgery, orthopedic, oncology and diagnostic centers.
We expect that these competitive trends will continue. Our inability to compete effectively
with other hospitals and other healthcare providers could cause local residents to use other
hospitals.
Risks Related to Our Common Stock
We have broad discretion in using our cash resources and may not use them in a manner that our
stockholders would prefer.
We have broad discretion in how we use our limited cash resources. In general, our
stockholders will not have the opportunity to evaluate the economic, financial or other information
on which we base our decisions on how to use our cash resources. The choices of our Board of
Directors and management on how to apply the funds could have a material adverse effect on our
financial condition.
We may finance acquisitions by issuing additional capital stock or incurring substantial debt, both
of which could have negative consequences.
As noted, we may use a portion of our resources to pursue acquisition opportunities and the
timing, size and success of our acquisition efforts and any associated capital commitments cannot
be readily predicted. We may raise additional funds to complete such acquisitions. Generally, our
Board of Directors has the power to issue new equity (to the extent of authorized shares) without
stockholder approval. If additional funds are raised through the issuance of equity securities,
the percentage ownership of our then-current stockholders would be diluted, our earnings and book
value per share could be diluted and, if such equity securities take the form of preferred stock,
the holders of such preferred stock may have the rights, preferences or privileges senior to those
of holders of Common Stock. If we are able to raise additional funds through the incurrence of
debt, and we do so, we would likely become subject to restrictive financial covenants and other
risks associated with the incurrence of debt.
The market for our Common Stock may be illiquid.
The 90-day average daily trading volume of our registered Common Stock in the over-the-counter
markets derived from historical data reported by finance.google.com as of January 7, 2010 was
approximately 297 shares and we have had some days with no trading. There can be no assurance that
trading volumes will increase to a consistently higher level or that holders of the shares will be
able to sell their shares in a timely manner or at all.
Our common stock is not listed on a national securities exchange.
Our Common Stock is currently traded on the Over The Counter Bulletin Board, commonly referred
to as the OTCBB, and we do not currently meet the listing requirements for the NASDAQ Global
Market or any other national securities exchange in the United States. The fact that our Common
Stock is not listed for trading in such markets may have an effect on the perception of us among
potential investors or acquirers and may adversely affect the liquidity of our shares and therefore
can have an effect on our ability to complete such transactions or raise additional funds.
18
The following principal facilities are leased by us and are material to our operations:
|
|
|
|
|
|
|
|
|
|
|
|
|
Facility
|
|
Address
|
|
Lease Term
|
|
Monthly Rent
|
|
|
Area (sq. ft.)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outpatient Surgery
|
|
12264 El Camino Real, Suite 55
|
|
Lease expires
|
|
$
|
20,169.07
|
|
|
|
6,684
|
|
Center
|
|
San Diego, California 92130
|
|
1/1/2016; one,
|
|
|
|
|
|
|
|
|
|
|
|
|
seven year option
|
|
|
|
|
|
|
|
|
|
|
|
|
to extend
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RHA Home Office
|
|
3555 N.W. 58
th
Street, Suite 700
|
|
Lease expires
|
|
$
|
13,429.50
|
|
|
|
10,232
|
|
|
|
Oklahoma City, Oklahoma 73112
|
|
11/30/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Chandler Clinic
|
|
114 North Highway 18
|
|
Lease expires
|
|
$
|
7,417.50
|
|
|
|
4,470
|
|
|
|
Chandler, Oklahoma 74834
|
|
4/30/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Office Sublease
|
|
433 N. Camden, Suite 810
|
|
Lease expires
|
|
$
|
4,800.00
|
|
|
|
1183.5
|
|
from HSP, Inc.
|
|
Beverly Hills, California 90210
|
|
11/1/2012
|
|
|
|
|
|
|
|
|
RHA operates three hospitals and one clinic in Oklahoma. The following properties are owned
by RHA and are material to our operations as of September 30, 2009:
|
|
|
|
|
|
|
Facility
|
|
Address
|
|
Area (sq. ft.)
|
|
|
|
|
|
|
|
|
Hospital and Medical Office Buildings
|
|
1002 E. Central Boulevard
|
|
|
57,887
|
|
|
|
Anadarko, Oklahoma 73005
|
|
|
|
|
|
|
|
|
|
|
|
Hospital and Medical Office Building
|
|
1101 S. Byrd
|
|
|
37,393
|
|
|
|
Tishomingo, Oklahoma 73460
|
|
|
|
|
|
|
|
|
|
|
|
Physician Clinic
|
|
2222 W. Iowa Avenue
|
|
|
65,800
|
|
|
|
Chickasha, OK 73018
|
|
|
|
|
|
|
|
|
|
|
|
Hospital and Clinic
|
|
2308 Highway 66 West
|
|
|
33,333
|
|
|
|
Stroud, Oklahoma 74079
|
|
|
|
|
|
|
|
Item 3.
|
|
LEGAL PROCEEDINGS
|
None.
19
|
|
|
Item 4.
|
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
|
On September 29, 2009, we held an Annual Meeting of Stockholders for the submission of the
following matters to a vote of security holders: 1) to elect five (5) directors to serve until the
2010 Annual Meeting of Stockholders or until their successors have been duly elected and qualified;
2) to amend our Certificate of Incorporation to change our name from Tri-Isthmus Group, Inc. to
First Physicians Capital Group, Inc.; 3) to ratify the appointment of Whitley Penn LLP, as our
independent accountants for the Fiscal Year Ended September 30, 2009 and 4) to transact any other
business properly brought before the meeting or any adjournments or postponements thereof. Mr.
Houlihan was elected, and Messrs. Hirschhorn, Sells, Parker, and Schwartz were each
re-elected, to serve on the Board of Directors. The amendment of our Certificate of
Incorporation to change our name to First Physicians Capital Group, Inc. was approved. The
appointment of Whitley Penn LLP as our independent accountants for the Fiscal Year Ended September
30, 2009 was ratified. No other business was transacted at the meeting, nor any adjournments or
postponements thereof.
The voting tabulation with respect to the re-election of the Board of Directors is as follows:
1) Mr. Hirschhorn received 29,416,912 votes in favor of, and 175,114 votes withheld from, his
re-election; 2) Mr. Sells received 29,425,509 votes in favor of, and 166,517 votes withheld from,
his re-election, 3) Mr. Parker received 29,120,224 votes in favor of, and 471,802 votes withheld
from, his re-election; 4) Mr. Schwartz received 29,105,298 votes in favor of, and 486,728 votes
withheld from, his re-election and 5) Mr. Houlihan received 29,425,509 votes in favor of, and
166,517 votes withheld from, his election. There were zero broker non-votes with respect to the
re-election of any of the directors.
The amendment of our Certificate of Incorporation to change our name from Tri-Isthmus Group,
Inc. to First Physicians Capital Group, Inc. received 29,578,571 votes in favor of such amendment,
12,040 votes against such amendment and 1,415 abstentions with respect to such amendment. There
were zero broker non-votes with respect to such amendment.
The ratification of Whitley Penn LLP as our independent accountants for the Fiscal Year Ended
September 30, 2009 received 28,943,550 votes in favor of such ratification, 647,053 votes against
such ratification and 1,423 abstentions with respect to such ratification. There were zero broker
non-votes with respect to such ratification.
PART II
|
|
|
Item 5.
|
|
MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER REPURCHASES
OF EQUITY SECURITIES
|
PERFORMANCE GRAPH
The following graph reflects the cumulative stockholder return (change in stock price plus
reinvested dividends) of a $100 investment in our Common Stock for the five-year period from
January 31, 2003 through September 30, 2009, in comparison with the NASDAQ Market Index, our prior
self-determined industry peer group index and our current self-determined industry peer group
index
1
. Although our Common Stock stopped trading on the NASDAQ National Market on
December 21, 2001, and now trades in the over-the-counter market, we have compared the cumulative
total stockholder return of our Common Stock with the NASDAQ Market Index because we believe this
provides stockholders with a broad index comparison. The comparisons are not intended to forecast
or be indicative of the possible future performance of our Common Stock.
|
|
|
1
|
|
Our current self-determined peer group is
made up of AmSurg Corp., Community Health Systems, Inc., Health Management
Associates, Inc., Novamed, Inc., and Universal Health Services, Inc. Our prior
self-determined peer group index is made up of Community Health Systems, Inc.,
Health Management Associates, Inc., and Lifepoint Hospitals, Inc.
|
20
COMPARISON OF 5-YEAR CUMULATIVE TOTAL RETURN
AMONG FIRST PHYSICIANS CAPITAL GROUP, INC. PEER GROUP AND
NASDAQ COMPOSITE INDEX
ASSUMES DIVIDEND REINVESTED
FISCAL YEAR ENDING SEPT. 30, 2009
ASSUMES $100 INVESTED ON JAN 31, 2003
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Fiscal Year Ended
|
|
1/31/2003
|
|
|
1/31/2004
|
|
|
1/31/2005
|
|
|
1/31/2006
|
|
|
9/30/2007
|
|
|
9/30/2008
|
|
|
9/30/2009
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company/Index/Market
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Physicians Capital
Group, Inc.
|
|
$
|
100.00
|
|
|
$
|
32.00
|
|
|
$
|
8.57
|
|
|
$
|
51.43
|
|
|
$
|
20.57
|
|
|
$
|
20.57
|
|
|
$
|
34.29
|
|
Peer Group Index
|
|
$
|
100.00
|
|
|
$
|
175.49
|
|
|
$
|
232.48
|
|
|
$
|
239.60
|
|
|
$
|
177.72
|
|
|
$
|
183.86
|
|
|
$
|
181.35
|
|
Old Peer Group Index
|
|
$
|
100.00
|
|
|
$
|
138.40
|
|
|
$
|
139.56
|
|
|
$
|
141.62
|
|
|
$
|
106.51
|
|
|
$
|
100.54
|
|
|
$
|
104.54
|
|
NASDAQ Market Index
|
|
$
|
100.00
|
|
|
$
|
156.26
|
|
|
$
|
157.97
|
|
|
$
|
171.29
|
|
|
$
|
210.49
|
|
|
$
|
147.43
|
|
|
$
|
160.68
|
|
Our current self-determined peer group is made up of AmSurg Corp., Community Health
Systems, Inc., Health Management Associates, Inc., Novamed, Inc. and Universal Health Services,
Inc. Our prior self-determined peer group index is made of Community Health Systems, Inc., Health
Management Associates, Inc. and Lifepoint Hospitals, Inc.
21
MARKET INFORMATION
Our Common Stock is traded in the over-the-counter market under the symbol FPCG.OB. The
following table presents, for the periods indicated, the high and low bid prices per share of our
Common Stock. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or
commissions and may not represent actual transactions.
|
|
|
|
|
|
|
|
|
The Fiscal Year Ended September 30, 2009
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
0.75
|
|
|
$
|
0.15
|
|
Second Quarter
|
|
|
1.00
|
|
|
|
0.30
|
|
Third Quarter
|
|
|
0.70
|
|
|
|
0.50
|
|
Fourth Quarter
|
|
|
0.80
|
|
|
|
0.36
|
|
|
|
|
|
|
|
|
|
|
The Fiscal Year Ended September 30, 2008
|
|
High
|
|
|
Low
|
|
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
0.37
|
|
|
$
|
0.26
|
|
Second Quarter
|
|
|
0.51
|
|
|
|
0.29
|
|
Third Quarter
|
|
|
0.89
|
|
|
|
0.35
|
|
Fourth Quarter
|
|
|
0.75
|
|
|
|
0.31
|
|
STOCKHOLDERS
As of January 7, 2010, and to the best of our records, there were approximately 2,685
stockholders of record of our Common Stock.
DIVIDENDS
We have never declared or paid cash dividends on our Common Stock or preferred stock. Holders
of our Series 1-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared
by the Board of Directors, of $0.20 per share annually. Holders of our Series 2-A Convertible
Preferred Stock are entitled to non-cumulative dividends, if declared by the Board of Directors, in
an amount equal to 8% of the price originally paid to us for each share of Series 2-A Convertible
Preferred Stock. Holders of our Series 5-A Convertible Preferred Stock, par value $0.01 per share
(the
5-A Preferred
) are entitled to non-cumulative dividends, if declared by the Board of
Directors, of $40 per share annually. Holders of our 6-A Preferred are entitled to non-cumulative
dividends, if declared by the Board of Directors and
pari passu
with 5-A Preferred, of $40 per
share annually. No dividend may be declared and paid upon shares of our Common Stock in any fiscal
year unless dividends on all such preferred stock have been paid or declared and set aside for
payment to holders of our preferred stock for such fiscal year. We currently intend to retain all
future earnings to finance future growth and therefore do not anticipate declaring or paying any
cash dividends in the foreseeable future.
EQUITY COMPENSATION PLAN INFORMATION
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of securities
|
|
|
|
|
|
|
|
|
|
|
|
remaining available for
|
|
|
|
Number of securities
|
|
|
|
|
|
|
future issuance under
|
|
|
|
to be issued upon
|
|
|
Weighted-average
|
|
|
equity compensation
|
|
|
|
exercise of
|
|
|
exercise price of
|
|
|
plans (excluding
|
|
|
|
outstanding options,
|
|
|
outstanding options,
|
|
|
securities reflected in
|
|
|
|
warrants and rights at
|
|
|
warrants and rights
|
|
|
column (a)) at
|
|
|
|
Sep. 30, 2009
|
|
|
at Sep. 30, 2009
|
|
|
Sep. 30, 2009
|
|
Plan category
|
|
(a)
|
|
|
(b)
|
|
|
(c)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity compensation plans
approved by security
holders(2)(5)(6)(7)(8)(9)
|
|
|
8,355,983
|
|
|
$
|
0.61191
|
|
|
|
9,682,601
|
|
Equity compensation plans
not approved by security
holders(1)(3)(4)
|
|
|
1,420,206
|
|
|
$
|
0.7773
|
|
|
|
12,579
|
|
Total
|
|
|
9,776,189
|
|
|
$
|
0.6359
|
|
|
|
9,695,180
|
|
|
|
|
(1)
|
|
In July 2000, our Board of Directors approved a stock option plan (the
2000
Plan
). Our stockholders have not approved this plan. The 2000 Plan authorizes the grant
of incentive stock options and non-statutory stock options covering an aggregate of 39,750
shares of Common Stock, as adjusted for our November 2002 reverse stock split (subject to
limitations of applicable laws, and adjustment in the event of
stock dividends, stock splits, reverse stock splits and certain other corporate events).
The 2000 Plan expires on July 6, 2010, unless it is terminated earlier or suspended by the
Board. The 2000 Plan is not subject to any provisions of the Employee Retirement Income
Security Act of 1974. As of September 30, 2009, options to purchase an aggregate of 27,171
shares of Common Stock are classified as outstanding under the 2000 Plan, with a weighted
average exercise price of $15.25. We do not intend to issue any further options under the
2000 Plan or warrants to purchase stock to additional individuals or vendors as compensation
for services rendered.
|
22
|
|
|
(2)
|
|
In 2001, at our 2001 Annual Meeting, our stockholders approved two equity compensation plans:
(a) our 2001 Stock Options/Stock Issuance Plan (the
2001 Plan
) and (b) our Employee
Stock Purchase Plan (
ESPP
). The maximum number of shares of Common Stock that may
be issued under the 2001 Plan cannot exceed 20% of the total shares of Common Stock
outstanding at the time the calculation is made (including, on an as-converted basis, all
convertible preferred stock, convertible debt securities, warrants, options and other
convertible securities that are exercisable), but in no event will the maximum number of
shares of Common Stock which may be issued under the 2001 Plan as incentive stock options
exceed 20,000,000. The weighted average exercise price under the 2001 Plan shall be fixed by
the Plan Administrator (as that term is defined in the 2001 Plan) and, in the case of an
incentive option, shall be limited by the following: 1) the exercise price per share shall not
be less than 100% of the fair market value (as that term is defined in the 2001 Plan) per
share of our Common Stock on the date of option grant and 2) in the event that the optionee is
a 10% stockholder, then the exercise price per share shall not be less than 110% of the fair
market value per share of Common Stock on the date of option grant. We have granted various
incentive stock options as well as non-qualified stock options to key executives, management
and other employees at exercise prices equal to or below the market price at the date of
grant. As of September 30, 2009, based on the 20% calculation, the maximum number of shares
issuable under the 2001 Plan was 17,756,180, and as of September 30, 2009, 9,682,601 shares
remain available for issuance. The maximum number of shares of Common Stock that may be
purchased under our ESPP is 350,000, with a weighted average exercise price of $1.48. As of
September 30, 2009, we have discontinued offering the ESPP, no shares have been issued
subsequent to the original issuance, and we currently have no intention to issue additional
shares under the ESPP. Since its inception, a total of 22,940 shares of Common Stock have
been purchased pursuant to the ESPP.
|
|
(3)
|
|
On November 20, 2001, our Board of Directors approved a grant of options to purchase a total
of 3,750 shares (adjusted for reverse split) of our Common Stock at an exercise price of $2.00
per share to Robert N. Schwartz, one of the members of our Board of Directors.
|
|
(4)
|
|
On August 2, 2005, our Board of Directors approved the issuance of warrants to purchase an
aggregate of 727,500 shares of our Common Stock at an exercise price of $0.35 per share to the
seven initial members of our Advisory Board, as compensation for participation on our Advisory
Board. The shares underlying these warrants became fully vested in August 2007. In August
2008, three of the initial Advisory Board members exercised their warrants in full and a total
of 302,500 shares of Common Stock were issued. The other four initial Advisory Board members,
holding an aggregate of 425,000 shares of Common Stock, allowed their warrants to expire
unexercised. In December 2006, our Board of Directors approved the issuance of a warrant to
purchase 50,000 shares of our Common Stock at an exercise price of $0.45 per share to Steven
Spector, upon his addition as a member to the Advisory Board. The shares underlying the
warrant issued to Mr. Spector became fully vested on December 12, 2008. The warrant issued to
Mr. Spector expired unexercised on December 12, 2008. On September 11, 2007, our Board of
Directors approved the issuance of warrants to purchase an aggregate of 350,000 shares of our
Common Stock at an exercise price of $0.45 per share to six new members of our Advisory Board.
The shares underlying these warrants became fully vested on September 13, 2009 and expired on
September 13, 2009. On February 15, 2008, our Board of Directors approved the issuance of a
warrant dated October 30, 2007, to purchase a total of 714,285 shares of our Common Stock at
an exercise price of $0.45 per share to Brian Potiker, in consideration for his continued
service as a member of our Advisory Board. The shares underlying the warrant issued to Mr.
Potiker became fully vested on October 30, 2008, and the warrant was exercised on October 30,
2009. During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 125,000
shares of our Common Stock to individuals for participation on our Advisory Board. These
warrants were issued at an exercise price of $0.625. One-third of the shares underlying the
warrants vested
immediately, one-third vest on March 16, 2010 and one-third vest on March 16, 2011. These
warrants expire on March 16, 2012. As of September 30, 2009, all of these warrants remain
outstanding. During the Fiscal Year Ended September 30, 2009, we issued warrants to
purchase 150,000 shares of our Common Stock to a member of the newly-created Medical
Advisory Board. These warrants were issued an exercise price of $0.625. One-third of the
shares underlying the warrants vested immediately upon issuance on June 10, 2009, and the
remaining two-thirds vest on June 10, 2010. These warrants expire on June 10, 2012. As of
September 30, 2009, all of these warrants remain outstanding.
|
23
|
|
|
(5)
|
|
On November 17, 2005, our Board of Directors approved the grants of options to acquire an
aggregate of 360,000 shares of our Common Stock at an exercise price of $0.40 per share to two
independent directors. The shares underlying these options vested in quarterly increments
over three years, beginning on the effective issuance date of August 1, 2005.
|
|
(6)
|
|
On July 1, 2008, our Compensation Committee approved the issuance of options to purchase
6,250,000 shares of our Common Stock to David Hirschhorn pursuant to the 2001 Plan. These
options are exercisable for a period of seven years at an exercise price of $0.625 per share.
Mr. Hirschhorns shares vest according to the following schedule: 1,250,000 shares vested on
July 1, 2009; 1,250,000 shares vest on July 1, 2010; 1,250,000 shares vest on July 1, 2011;
1,250,000 shares vest on July 1, 2012 and the last 1,250,000 vest on July 1, 2013.
|
|
(7)
|
|
On November 10, 2008, in connection with Thomas Rices employment agreement, we entered into
an Option Grant Agreement under which we granted Mr. Rice an incentive stock option to
purchase up to 500,000 shares of Common Stock at an exercise price of $0.625 per share. Mr.
Rices shares vest according to the following schedule: 125,000 shares vested immediately on
November 10, 2008; 125,000 shares vested on November 10, 2009 and the remaining 250,000 shares
vest on November 10, 2010. The option expires on November 15, 2015.
|
|
(8)
|
|
On April 22, 2009, pursuant to the terms of our 2001 Plan, we granted incentive stock options
(the
2009 Employee Options
) to 126 of our subsidiaries employees (the
2009
Employee Optionees
) to purchase an aggregate of 1,319,390 shares of Common Stock in
variable individual amounts. Pursuant to the terms of the Option Grant Agreements, and
subject to the terms of the 2001 Plan, the shares of Common Stock subject to the 2009 Employee
Options (the
2009 Employee Option Shares
) vest according to the following schedule:
(1) one-quarter vested immediately upon the date of issuance; (2) an additional one-quarter of
the 2009 Employee Option Shares vest upon the passing of the one year anniversary of the date
of issuance and (3) the remaining one-half of the 2009 Employee Option Shares vest upon the
second anniversary of the date of issuance. The 2009 Employee Options were issued at an
exercise price of $0.625 per share and are exercisable by the 2009 Employee Optionees with
respect to all or any of the vested Shares until April 22, 2016, subject to the terms and
conditions of the 2001 Plan and the related Option Grant Agreements. As of September 30,
2009, 161,003 of these options have been forfeited due to employee terminations.
|
|
(9)
|
|
On May 27, 2009, in connection with the employment of David Jamin as the administrator of RHA
Stroud, LLC, we entered into an Option Grant Agreement, under which we granted to Mr. Jamin an
incentive stock option to purchase up to 20,000 shares of Common Stock, at an exercise price
of $0.625 per share, which option shall expire on May 27, 2016. Mr. Jamins option to
purchase Common Stock shall vest incrementally on the following vesting schedule: (1) 6,667
shares vest on May 27, 2010; (2) 6,667 shares vest on May 27, 2011; and (3) 6,666 shares
shall vest on May 27, 2012.
|
SALES OF UNREGISTERED EQUITY SECURITIES
During the Transition Period Ended September 30, 2007, we sold and issued an aggregate of
1,175 shares of 5-A Preferred and warrants to purchase an aggregate of 705,000 shares of Common
Stock, pursuant to Series 5-A Preferred Stock and Warrant Purchase Agreements to various investors
through private placements. Each investor represented to us in writing that it was an accredited
investor, as that term is defined in Rule 501 of Regulation D promulgated under the Securities
Act.
24
On May 15, 2008, we sold and issued 25 shares of 5-A Preferred to an investor, pursuant to a
Series 5-A Preferred Stock and Warrant Purchase Agreement. Such investor represented to us in
writing that he was an accredited investor, as that term is defined in Rule 501 of Regulation D
promulgated under the Securities Act. In connection with this issuance, we also issued warrants to
purchase 15,000 shares of our Common Stock to an investor, pursuant to the same Series 5-A
Preferred Stock and Warrant Purchase Agreement. These warrants are exercisable for a period of 2
years at an exercise price of $0.50 per share. Such investor represented to us in writing that he
was an accredited investor, as that term is defined in Rule 501 of Regulation D promulgated under
the Securities Act.
In May 2009, we accepted warrant exercises in the amount of 60,000 shares of Common Stock for
an aggregate amount of $30,000 from one investor, who represented to us in writing that he is an
accredited investor, as that term is defined in Rule 501(a) of Regulation D promulgated under the
Securities Act. The shares were issued pursuant to the exercise of warrants originally issued on
March 23, 2007, in connection with a private placement of our 5-A Preferred to various investors.
In September 2009, we accepted warrant exercises in the amount of 60,000 shares of Common
Stock for an aggregate amount of $30,000 from two investors, each of whom represented to us in
writing that he is an accredited investor, as that term is defined in Rule 501(a) of Regulation D
promulgated under the Securities Act. The shares were issued pursuant to the exercise of warrants
originally issued on August 10, 2007 and March 8, 2007 in connection with a private placement of
our 5-A Preferred to various investors.
|
|
|
Item 6.
|
|
SELECTED CONSOLIDATED FINANCIAL DATA
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Transition
|
|
|
Fiscal
|
|
|
|
Year
|
|
|
Period
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
Jan. 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2007
|
|
|
2006
|
|
|
2005
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue
|
|
$
|
39,090
|
|
|
$
|
29,641
|
|
|
$
|
2,452
|
|
|
$
|
702
|
|
|
$
|
|
|
|
$
|
254
|
|
Operating expenses
|
|
|
46,631
|
|
|
|
34,689
|
|
|
|
4,444
|
|
|
|
2,453
|
|
|
|
2,175
|
|
|
|
2,503
|
|
Net income/(loss) before
minority interest
|
|
|
(9,874
|
)
|
|
|
(5,601
|
)
|
|
|
(1,990
|
)
|
|
|
(1,748
|
)
|
|
|
(2,170
|
)
|
|
|
(2,252
|
)
|
Minority interest
|
|
|
(177
|
)
|
|
|
1,368
|
|
|
|
93
|
|
|
|
168
|
|
|
|
|
|
|
|
|
|
Net profit/(loss) per
share allocable to common
stockholders
|
|
|
(10,368
|
)
|
|
|
(7,111
|
)
|
|
|
(1,897
|
)
|
|
|
(1,580
|
)
|
|
|
(2,170
|
)
|
|
|
(2,252
|
)
|
- Basic
|
|
$
|
(0.94
|
)
|
|
$
|
(0.86
|
)
|
|
$
|
(0.50
|
)
|
|
$
|
(0.43
|
)
|
|
$
|
(0.91
|
)
|
|
$
|
9.77
|
|
- Diluted
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
$
|
9.53
|
|
Cash and cash equivalents
|
|
|
2,324
|
|
|
|
2,970
|
|
|
|
733
|
|
|
|
286
|
|
|
|
1,289
|
|
|
|
1,064
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivables
|
|
|
4,891
|
|
|
|
6,289
|
|
|
|
1,418
|
|
|
|
1,403
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
|
17,033
|
|
|
|
12,277
|
|
|
|
1,163
|
|
|
|
1,115
|
|
|
|
1
|
|
|
|
40
|
|
Goodwill
|
|
|
759
|
|
|
|
759
|
|
|
|
759
|
|
|
|
987
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
|
29,491
|
|
|
|
26,498
|
|
|
|
4,504
|
|
|
|
4,571
|
|
|
|
1,579
|
|
|
|
2,714
|
|
Current liabilities
|
|
|
12,450
|
|
|
|
9,803
|
|
|
|
1,624
|
|
|
|
839
|
|
|
|
552
|
|
|
|
779
|
|
Long term liabilities
|
|
|
12,441
|
|
|
|
1,091
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Minority interest
|
|
|
1,083
|
|
|
|
967
|
|
|
|
920
|
|
|
|
1,285
|
|
|
|
|
|
|
|
|
|
Non-redeemable preferred
stock
|
|
|
191
|
|
|
|
191
|
|
|
|
191
|
|
|
|
191
|
|
|
|
191
|
|
|
|
191
|
|
Redeemable preferred stock
|
|
|
12,282
|
|
|
|
14,432
|
|
|
|
5,019
|
|
|
|
4,050
|
|
|
|
1,307
|
|
|
|
|
|
Stockholders equity/
(deficit)
|
|
|
(8,956
|
)
|
|
|
(4,350
|
)
|
|
|
(3,250
|
)
|
|
|
(1,603
|
)
|
|
|
(280
|
)
|
|
|
1,744
|
|
25
|
|
|
Item 7.
|
|
MANAGEMENTS DISCUSSION & ANALYSIS OF RESULTS OF OPERATIONS
|
The following discussion and analysis of our financial condition and results of operations
should be read in conjunction with our financial statements and the related notes thereto appearing
elsewhere in this Form 10-K.
FORWARD LOOKING STATEMENTS
The information set forth in this Item 7. Managements Discussion and Analysis of Financial
Condition and Results of Operations contains certain forward-looking statements. Please refer to
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS at the beginning of this Form 10-K for more
information about forward-looking statements.
We undertake no obligation to release publicly the results of any future revisions we may make
to forward-looking statements to reflect events or circumstances after the date of this report or
to reflect the occurrence of unanticipated events.
OVERVIEW
From 2001 to November 2004, we provided Fortune 500 and Global 500 companies with BPO
solutions into and across the Asia-Pacific region. In November 2004, our active business
operations ceased with the sale of our BPO operations in Asia.
On December 2, 2005, we resumed active operations through newly created indirect subsidiaries,
and we entered into two separate purchase agreements to acquire from Surgical Ventures, Inc., a
California corporation, a controlling interest in Del Mar and Point Loma, two separate outpatient
surgical centers in the San Diego ambulatory surgical centers. In June 2007, we consolidated the
operations of the San Diego ambulatory surgical centers at the Del Mar facility.
On October 29, 2007, we acquired 51% of the issued and outstanding membership units of RHA.
Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic
and an ancillary support services units all focused the delivery of healthcare services to rural
communities in Oklahoma. On May 1, 2008, RHA completed a material acquisition with the purchase of
SPMC, a multi-specialty physician practice, also located in Oklahoma. Beginning November 18, 2008,
RHA began operating under the trade name Southern Plains Medical Group. On December 11, 2008,
through a wholly-owned subsidiary, we acquired the remaining 49% of the issued and outstanding
membership units of RHA, thus making RHA an indirect wholly-owned subsidiary of ours.
CHANGE IN THE FISCAL YEAR END
In November 2007, our Board of Directors approved a change to our fiscal year end from January
31 to September 30. In view of this change, this report includes the twelve-month periods ended
September 30, 2009 and 2008, the eight-month Transition Period Ended September 30, 2007 and the
twelve-month periods ended January 31, 2007, 2006 and 2005. References to 2007 refer to the
Transition Period Ended September 30, 2007 unless otherwise specified. Throughout Managements
Discussion and Analysis in this Item 7, data for all periods are derived from our audited
consolidated financial statements.
FUNDING
We have sustained operating losses since our inception and had an accumulated deficit of
approximately $86.0 million as of September 30, 2009, which has been funded primarily through the
issuance of preferred stock, the issuance of promissory notes and cash generated from operations.
With the completion of the acquisition of the San Diego ambulatory surgical centers in November
2006 and the acquisition of RHA in October 2007, we resumed active business operations.
As of September 30, 2009 we had current liabilities of $12.5 million and current assets of
$10.6 million.
26
In December 2008, subsidiaries of RHA completed the 2008 Loans. The completion of the 2008
Loans, which carry amortization schedules of 16 years to 20 years and are guaranteed up to 80% by
the USDA, had the effect of reducing our current liabilities by $4.6 million.
In 2009, we completed a bridge financing transaction (the
Bridge Financing
) for $2.2
million, which was consummated in three separate closings. The notes are due and payable as
follows: $1.5 million was due on November 6, 2009, $0.5 million was due on December 3, 2009, $0.1
million was due on December 31, 2009 and $50,000 are due on
January 14, 2010. On the due dates of
the $1.5 million due on November 6, 2009, the $0.5 million due on December 3, 2009 and the $0.1
million due on December 31, 2009, we exercised our right to extend the due dates to February 6,
2010, March 3, 2010 and March 31, 2010, respectively.
Our management believes that we have adequate funding from the RHA Healthcare Operations and
Del Mar, cash and cash equivalents, the 2008 Loans and the Bridge Financing for us to continue in
operation for at least 12 months from the balance sheet date. Therefore, we have prepared our
financial statements on a going concern basis.
CRITICAL ACCOUNTING POLICIES
We prepare our consolidated financial statements in conformity with accounting principles
generally accepted in the United States of America. As such, we are required to make certain
estimates, judgments and assumptions that we believe are reasonable based upon the information
available. These estimates and assumptions affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during
the periods presented. The significant accounting policies which we believe are the most critical
to aid in fully understanding and evaluating our reported financial results include the following:
Principles of Consolidation and Basis of Presentation
The consolidated financial statements include our accounts and the accounts of our
subsidiaries. All significant intercompany balances and transactions have been eliminated.
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting
principles generally accepted in the United States requires our management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Our actual results could differ from
estimates and assumptions made.
Reclassifications
Certain reclassifications and format changes have been made to the prior period amounts in
order to conform to the current period presentation.
Cash and Cash Equivalents
Cash consists of cash on hand and amounts deposited with high quality financial institutions.
Amounts on deposit at times exceeds the FDIC insurance limits. Cash equivalents are highly liquid
instruments including cash in money market current accounts that are interest-bearing, capital
guaranteed and without any withdrawal restrictions.
Restricted cash consists of funds on deposit with a bank held as security for debt relating to
the SPMC acquisition.
27
Accounts Receivable
Accounts receivable are reported at estimated net realizable amounts from services rendered
from federal and state agencies (under the Medicare and Medicaid programs), managed care health
plans, commercial insurance companies, workers compensation, employers and patients. A significant
portion of our revenues are concentrated with federal and state agencies.
Additions to the allowance for doubtful accounts are made by means of the line item Provision
for Doubtful Accounts in our financial statements. We write off uncollectible accounts against the
allowance for doubtful accounts after exhausting collection efforts and adding subsequent
recoveries. Net accounts receivable include only those amounts we estimate we will collect.
We perform an analysis of our historical cash collection patterns and consider the impact of
any known material events in determining the allowance for doubtful accounts. In performing our
analysis, we considered the impact of any adverse changes in general economic conditions, business
office operations, payor mix, or trends in federal or state governmental healthcare coverage.
Property and Equipment
Property and equipment are stated at cost. Depreciation for property and equipment is
provided using the straight-line method over the estimated useful lives of the respective assets as
follows:
|
|
|
|
|
Computer hardware
|
|
|
2 to 5 years
|
|
Computer software
|
|
|
3 to 5 years
|
|
Office equipment, furniture and fixtures
|
|
5 years
|
|
Medical equipment
|
|
|
5 to 7 years
|
|
Buildings
|
|
|
30 to 40 years
|
|
Leasehold improvements
|
|
15 years
|
|
Depreciation for leasehold improvements is provided using the straight-line method over the
shorter of the estimated useful lives of the respective assets or the remaining lease term.
Impairment of Goodwill and Long-lived Assets
We review long-lived assets, certain identifiable intangible assets and goodwill related to
these assets for impairment. For assets to be held and used, including acquired intangibles, we
initiate a review whenever events or changes in circumstances indicate that the carrying value of a
long-lived asset may not be recoverable and annually for goodwill and other intangible assets not
subject to amortization. Recoverability of an asset is measured by comparison of its carrying
value to the future undiscounted cash flows that the asset is expected to generate. Any impairment
to be recognized is measured by the amount by which the carrying value exceeds the projected
discounted future operating cash flows. Assets to be disposed of and for which management has
committed a plan to dispose of the assets, whether through sale or abandonment, are reported at the
lower of carrying value or fair value less costs to sell.
In the Fiscal Year Ended September 30, 2009, we determined that an impairment to the goodwill
previously recorded upon the acquisition of RHA had occurred. An impairment charge of $209,000 was
recorded. In the Fiscal Year Ended September 30, 2008, we recorded an impairment of $308,000 with
respect to fixed assets at Point Loma arising from the termination of activities at this facility
as part of our review of long-lived assets, certain identifiable intangible assets and goodwill.
Revenue Recognition
We recognize revenue when persuasive evidence of an arrangement exists, delivery or
performance has occurred, the sales price is fixed or determinable and collectibility is probable
or reasonably assured.
28
Income Taxes
The asset and liability approach is used to account for income taxes by recognizing deferred
tax assets and liabilities for the expected future tax consequences of temporary differences
between the carrying amounts and the tax bases of assets and liabilities. We record a valuation
allowance to reduce the deferred tax assets to the amount that is more likely than not to be
realized.
Accounting for Uncertainty in Income Taxes
Financial Accounting Standards Board (
FASB
) Accounting Standards Codification
(
ASC
) 740 creates a single model to address accounting for uncertainty in tax positions
by prescribing a minimum recognition threshold a tax position is required to meet before being
recognized in the financial statements. FASB ASC 740 also provides guidance on derecognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and
transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated
financial statements.
Functional Currency
Our functional currency is United States dollars.
Other Comprehensive Income (Loss)
Other comprehensive income (loss) refers to revenues, expenses, gains and losses that under
generally accepted accounting principles in the United States are included in comprehensive income
(loss) but are excluded from net income (loss), as these amounts are recorded directly as an
adjustment to stockholders equity, net of tax. Our other comprehensive income (loss) is composed
of unrealized gains and losses on foreign currency translation adjustments.
Stock-Based Compensation
Effective February 1, 2006, we adopted the fair value recognition provisions of FASB ASC 718,
Accounting for Compensation Arrangements, using the modified prospective application method. Our
stock option plans are described in Note 15 to our financial statements contained in Item 8 of this
Form 10-K.
Earnings Per Share
Basic earnings/(loss) per share is computed by dividing net income/(loss) by the weighted
average shares of Common Stock outstanding during the year. Diluted earnings per share is computed
by dividing net income by the weighted average shares of Common Stock and potential common shares
outstanding during the year. Potential common shares outstanding consist of dilutive shares
issuable upon the conversion of our preferred stock to Common Stock as computed using the
if-converted method and the exercise of outstanding options and warrants to purchase Common Stock,
computed using the treasury stock method.
Recent Accounting Pronouncements
In September 2006, the FASB issued authoritative guidance on Fair Value Measurements. The
new guidance sets forth the standards for using fair value to measure assets and liabilities. It
addresses the requests from investors for expanded disclosure about the extent to which companies
measure assets and liabilities at fair value, the information used to measure fair value and the
effect of fair value measurements on earnings. The new standard applies whenever other standards
require (or permit) assets or liabilities to be measured at fair value and does not expand the use
of fair value in any new circumstances. The standard is effective for financial statements issued
for fiscal years beginning after November 15, 2007 and was adopted by us in the first quarter of
fiscal year 2009. Adoption of the new standard did not have a material impact on our financial
condition or results of operations.
29
In February 2007, the FASB issued new standards regarding The Fair Value Option for Financial
Assets and Financial Liabilities Including an amendment of the previous standards relative to the
Fair Value Option for Financial Assets and Financial Liabilities. This statement permits entities
to choose to measure many financial instruments and certain other items at fair value. The
objective is to improve financial reporting by providing entities with the opportunity to mitigate
volatility in reported earnings caused by measuring related assets and liabilities differently
without having to apply complex hedge accounting provisions. This statement is effective as of the
beginning of an entitys first fiscal year that begins after November 15, 2007. Adoption of this
pronouncement is optional and management has elected not to adopt this standard.
In December 2007, the FASB issued guidance on Noncontrolling Interests in Consolidated
Financial Statementsan amendment of ARB No. 51. This guidance requires companies with
noncontrolling interests to disclose such interests clearly as a portion of equity but separate
from the parents equity. The noncontrolling interests portion of net income must also be clearly
presented on the income statement. This is effective for financial statements issued for fiscal
years beginning after December 15, 2008 and will be adopted by us in the first quarter of fiscal
year 2010. We do not expect that the adoption of the new rules will have a material impact on our
financial condition or results of operation.
In December 2007, the FASB issued updated guidance on business combinations. This guidance
applies the acquisition method of accounting for business combinations where the acquirer gains a
controlling interest, regardless of whether consideration was exchanged. The updated guidance
requires the acquirer to fair value the assets and liabilities of the acquiree and record goodwill
on bargain purchases and is effective for financial statements issued for fiscal years beginning
after December 15, 2008 and will be adopted by us in the first quarter of fiscal year 2010. We do
not expect that the adoption will have a material impact on our financial condition or results of
operation.
In June 2009, the FASB established the FASB ASC as the single authoritative source for GAAP.
The ASC was effective for financial statements that cover interim and annual reports ended after
September 15, 2009. While not intended to change GAAP, the ASC significantly changed the way in
which the accounting literature is organized. Because the ASC completely replaced existing
standards, it affected the way GAAP is referenced by companies in their financial statements and
accounting policies. Our adoption and use of the ASC beginning with the Fiscal Year Ended September
30, 2009 did not have an impact on our financial position, results of operations or cash flows.
Fair Value of Financial Instruments
Carrying amounts of certain of our financial instruments, including cash equivalents, accounts
receivable and accounts payable approximate fair value due to their short maturities. Carrying
value of notes payable and long-term debt approximate fair values as they bear market rates of
interest. None of our financial instruments are held for trading purposes.
30
RESULTS OF OPERATIONS (All amounts in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
Transition
|
|
|
Fiscal
|
|
|
|
Year
|
|
|
Year
|
|
|
Period
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
Jan. 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from services
|
|
$
|
39,090
|
|
|
$
|
29,641
|
|
|
$
|
2,452
|
|
|
$
|
702
|
|
Selling, general and administrative
expenses and provision for doubtful
accounts
|
|
|
44,075
|
|
|
|
33,336
|
|
|
|
3,966
|
|
|
|
2,255
|
|
Amortization of stock-based compensation
|
|
|
1,245
|
|
|
|
339
|
|
|
|
250
|
|
|
|
198
|
|
Impairment of long-lived assets and goodwill
|
|
|
209
|
|
|
|
308
|
|
|
|
228
|
|
|
|
|
|
Depreciation and amortization
|
|
|
1,102
|
|
|
|
706
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
46,631
|
|
|
|
34,689
|
|
|
|
4,444
|
|
|
|
2,453
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(7,541
|
)
|
|
|
(5,048
|
)
|
|
|
(1,992
|
)
|
|
|
(1,751
|
)
|
Other income (expense)
|
|
|
(281
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
42
|
|
|
|
320
|
|
|
|
2
|
|
|
|
3
|
|
Interest expense
|
|
|
(2,094
|
)
|
|
|
(873
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss from operations before taxation
and non-cash beneficial conversion feature
|
|
|
(9,874
|
)
|
|
|
(5,601
|
)
|
|
|
(1,990
|
)
|
|
|
(1,748
|
)
|
Minority interest
|
|
|
(177
|
)
|
|
|
1,368
|
|
|
|
93
|
|
|
|
168
|
|
Taxation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss before non-cash beneficial
conversion feature
|
|
|
(10,051
|
)
|
|
|
(4,233
|
)
|
|
|
(1,897
|
)
|
|
|
(1,580
|
)
|
Non-cash beneficial conversion feature
preferred dividend
|
|
|
(317
|
)
|
|
|
(2,878
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss allocable to common stockholders
|
|
$
|
(10,368
|
)
|
|
$
|
(7,111
|
)
|
|
$
|
(1,897
|
)
|
|
$
|
(1,580
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
MANAGEMENTS DISCUSSION & ANALYSIS OF RESULTS OF OPERATIONS FISCAL YEAR ENDED SEPTEMBER 30, 2009
COMPARED TO YEAR ENDED SEPTEMBER 30, 2008, EIGHT-MONTH TRANSITION PERIOD ENDED SEPTEMBER 30, 2007
AND YEAR ENDED JANUARY 31, 2007
Revenue
Revenue of $39.1 million was generated in the Fiscal Year Ended September 30, 2009 compared
with $29.6 million in the Fiscal Year Ended September 30, 2008, $2.5 million in the Transition
Period Ended September 30, 2007 and $0.7 million in the Fiscal Year Ended January 31, 2007.
Revenue in the Fiscal Year Ended September 30, 2009 increased 32.1%, primarily due to increased
revenues generated by SPMC. Revenue in the Fiscal Year Ended September 30, 2008 reflects only five
months of operations for SPMC. The increase in the Fiscal Year Ended September 30, 2008 over the
Transition Period Ended September 30, 2007 was primarily due to revenues derived from the San Diego
ambulatory surgical center and the delivery of healthcare services at the RHA Healthcare Operation
commencing with the RHA Acquisition in October 2007. Revenues in Fiscal Year Ended January 31,
2007 reflect only two months of operations for the San Diego ambulatory surgical centers during the
period.
Selling, General and Administrative Expenses and Provision for Doubtful Accounts
Selling, general and administrative expenses, including provision for doubtful accounts,
consisted primarily of employee-related costs that are not directly related to providing goods or
services, such as salaries and benefits of administrative and support personnel, rental, insurance
premiums and costs relating to certain other outside services, including services delivered by the
San Diego ambulatory surgical centers.
Selling, general and administrative expenses and provision for doubtful accounts totaled $44.1
million in the Fiscal Year Ended September 30, 2009 and $33.3 million in the Fiscal Year Ended
September 30, 2008, for an increase of 32.4%. The increase, which was commensurate with the
increase in revenue, is due to the operations of SPMC. Selling, general and administrative
expenses for the Transition Period Ended September 30, 2007 were $4.0 million. The expenses for
the Fiscal Year Ended September 30, 2008 reflect the increased costs associated with operating the
RHA Healthcare Operations and a full year of operating costs of the San Diego ambulatory surgical
centers, while the Transition Period Ended September 30, 2007 only includes corporate expenditures
and two months of operating costs for the San Diego ambulatory surgical centers. Selling, general
and administrative expenses totaled $2.3 million in the Fiscal Year Ended January 31, 2007.
31
Amortization of Stock-Based Compensation
Significant
components of amortization of stock-based compensation are as follows:
On August 18, 2005, in connection with its approval of employment agreements for each of David
Hirschhorn and Todd Parker, our then-Co-Chairmen of the Board and then-Co-Chief Executive Officers,
our Board of Directors approved the issuance of an aggregate of 1,600,000 shares of restricted
Common Stock to Messrs. Hirschhorn and Parker, with Mr. Hirschhorn to receive 1,250,000 shares and
Mr. Parker to receive 350,000 shares. The compensation expense for these shares was recorded as
deferred compensation expense and amortized over the three-year term of the employment agreements.
These shares were issued to Messrs. Hirschhorn and Parker in November 2005. The amortization
recognized is $51,000, $71,000, $27,000 and $0 in Fiscal Year Ended September 30, 2008, the
Transition Period Ended September 30, 2007, the Fiscal Year Ended January 31, 2007 and the Fiscal
Year Ended January 31, 2006 (the
Fiscal Year Ended January 31, 2006
), respectively.
Pursuant to Mr. Parkers resignation as Co-Chief Executive Officer and Co-Chief Financial Officer
in September 2007, the number of shares held by Mr. Parker originally received pursuant to the
August 18, 2005 agreement have been reduced from 350,000 to 301,389.
On August 2, 2005, we issued warrants to purchase 727,500 shares of our Common Stock to seven
individuals for participation on our Advisory Board. All warrants were issued with Black-Scholes
assumptions of 99% volatility, $0.35 share price, risk-free interest rates of 4.1% and exercise
price of $0.35. The warrants had a calculated value of $161,001, recognized over the two-year
vesting period. For the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended September 30,
2008, the Transition Period Ended September 30, 2007, the Fiscal Year Ended January 31, 2007 and
the Fiscal Year Ended January 31, 2006, we recorded charges of $0, $0, $27,000, $54,000 and
$80,000, respectively, in respect of the amortization of these warrants.
On November 17, 2005, our Board of Directors approved the grants of options to acquire an
aggregate of 360,000 shares of our Common Stock at an exercise price of $0.40 per share to two
independent directors. These options vest in quarterly increments over three years, beginning on
the effective issuance date of August 1, 2005, and were issued with Black-Scholes assumptions of
99% volatility, $0.37 share price, risk-free interest rates of 4.1% and exercise price of $0.40.
The effective date of the issuance was August 1, 2005. The options had a calculated value of
$82,223, recognized over the vesting period. For the Fiscal Year Ended September 30, 2009, the
Fiscal Year Ended September 30, 2008, the Transition Period Ended September 30, 2007, the Fiscal
Year Ended January 31, 2007 and the Fiscal Year Ended January 31, 2006, the amortization recognized
was $0, $23,000, $18,000, $27,000 and $14,000, respectively.
In December 2006, we issued a warrant to purchase 50,000 shares of our Common Stock to an
individual for participation on our Advisory Board. The warrant was issued with Black-Scholes
assumptions of 212% volatility, $0.42 share price, risk-free interest rates of 4.5% and exercise
price of $0.45. The warrants had a calculated value of $20,000, recognized over the two-year
vesting period. For the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended September 30,
2008, the Transition Period Ended September 30, 2007, the Fiscal Year Ended January 31, 2007 and
the Fiscal Year Ended January 31, 2006, we recorded charges of $1,000, $7,000, $6,000, $2,000 and
$0, respectively, in respect of the amortization of the warrant.
On December 12, 2006, our Board of Directors approved the grant of an option to acquire an
aggregate of 120,000 shares of our Common Stock at an exercise price of $0.42 per share to Dennis
M. Smith. The shares underlying this option vest in quarterly increments over three years. The
option was granted with Black-Scholes assumptions of 212% volatility, $0.42 share price, risk-free
interest rates of 4.5% and exercise price of $0.45. The option had a calculated value of $47,162,
recognized over the vesting period. For the Fiscal Year Ended September 30, 2009, the Fiscal Year
Ended September 30, 2008, the Transition Period Ended September 30, 2007, the Fiscal Year Ended
January 31, 2007 and the Fiscal Year Ended January 31, 2006, the amortization recognized was
$4,000, $16,000, $10,000, $3,000 and $0, respectively.
On July 16, 2007, we issued a warrant to purchase 50,000 shares of our Common Stock to a
company for services rendered. The warrant was issued with Black-Scholes assumptions of 212%
volatility, $0.32 share price, risk-free interest rates of 4.5% and exercise price of $0.45. For
the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended September 30, 2008 and the
Transition Period Ended September 30, 2007, we recorded charges of $6,000, $9,000 and $1,000,
respectively, in respect of the amortization of the warrant.
32
On September 13, 2007, we issued warrants to purchase an aggregate of 350,000 shares of our
Common Stock to four individuals for participation on our Advisory Board. The warrants were issued
with Black-Scholes assumptions of 52% volatility, $0.26 share price, risk-free interest rates of
3.1% and exercise price of $0.45. For the Fiscal Year Ended September 30, 2009, the Fiscal Year
Ended September 30, 2008 and the Transition Period Ended September 30, 2007, we recorded charges of
$6,000, $6,000 and $0, respectively, in respect of the amortization of the warrants.
On October 10, 2007, subsequent to the completion of the Transition Period Ended September 30,
2007, our Board of Directors approved the grant of an option pursuant to the 2001 Plan to acquire
an aggregate of 600,000 shares of our Common Stock at an exercise price of $0.3125 to Dennis M.
Smith, following his appointment as our Chief Financial Officer. Mr. Smiths shares vested
according to the following schedule: 150,000 shares vested upon the grant of the option and 150,000
shares vested on October 10, 2008. Mr. Smiths employment was terminated on January 26, 2009 and
all options under this grant were forfeited. For the Fiscal Years Ended September 30, 2009 and
2008, the amortization recognized was $3,000 and $38,000, respectively.
On July 1, 2008, our Compensation Committee approved the issuance of options to purchase
6,250,000 shares of our Common Stock pursuant to the 2001 Plan to David Hirschhorn. These options
are exercisable for a period of seven years at an exercise price of $0.625 per share. Mr.
Hirschhorns shares vest according to the following schedule: 1,250,000 shares vested on July 1,
2009; 1,250,000 shares vest on July 1, 2010; 1,250,000 shares vest on July 1, 2011; 1,250,000
shares vest on July 1, 2012 and the last 1,250,000 vest on July 1, 2013. For the Fiscal Year Ended
September 30, 2009 and the Fiscal Year Ended September 30, 2008, the amortization recognized was
$741,000 and $185,000, respectively.
On November 10, 2008, in connection with the appointment of Thomas Rice as President and Chief
Operating Officer of RHA, we entered into an Option Grant Agreement, under which we granted to Mr.
Rice an incentive stock option to purchase up to 500,000 shares of Common Stock, at an exercise
price of $0.625 per share, which option shall expire on November 10, 2015. Mr. Rices option to
purchase Common Stock shall vest incrementally on the following vesting schedule: (1) 125,000
shares vested immediately on November 10, 2008; (2) 125,000 shares vested on November 10, 2009;
and (3) 250,000 shares shall vest on November 10, 2010. For the Fiscal Year Ended September 30,
2009, the amortization recognized was $86,000.
On April 22, 2009, pursuant to the terms of our 2001 Plan, we granted the 2009 Employee
Options to the 2009 Employee Optionees to purchase an aggregate of 1,319,390 shares of Common Stock
in variable individual amounts. Pursuant to the terms of the Option Grant Agreements, and subject
to the terms of the 2001 Plan, the 2009 Employee Option Shares vest according to the following
schedule: (1) one-quarter vested immediately upon the date of issuance; (2) an additional
one-quarter of the 2009 Employee Option Shares vest upon the passing of the one year anniversary of
the date of issuance; and (3) the remaining one-half of the 2009 Employee Option Shares vest upon
the second anniversary of the date of issuance. The 2009 Employee Options were issued at an
exercise price of $0.625 per share and are exercisable by the 2009 Employee Optionees with respect
to all or any of the vested 2009 Employee Option Shares until April 22, 2016, subject to the terms
and conditions of the 2001 Plan and the related Option Grant Agreements. For the Fiscal Year Ended
September 30, 2009, the amortization recognized was $201,000.
On May 27, 2009, in connection with the employment of David Jamin as the administrator of
Stroud Regional Medical Center, we entered into an Option Grant Agreement, under which we granted
to Mr. Jamin an incentive stock option to purchase up to 20,000 shares of Common Stock, at an
exercise price of $0.625 per share, which option shall expire on May 27, 2016. Mr. Jamins option
to purchase Common Stock shall vest incrementally on the following vesting schedule: (1) 6,667
shares vest on May 27, 2010; (2) 6,667 shares vest on May 27, 2011; and (3) 6,666 shares shall vest
on May 27, 2012. For the Fiscal Year Ended September 30, 2009, the amortization recognized was
$2,000.
33
Impairment of Long-Lived Assets and Goodwill
In the Fiscal Year Ended September 30, 2009, we determined that an impairment to the goodwill
previously recorded upon the acquisition of RHA had occurred and an impairment charge of $209,000
was recorded. In the Fiscal Year Ended September 30, 2008, we recorded an impairment of $308,000
in respect of fixed assets at
Point Loma arising from the termination of activities at this facility, as part of our review
of long-lived assets, certain identifiable intangible assets and goodwill. For the Fiscal Year
Ended January 31, 2007, we tentatively classified the excess of the purchase price over the
estimated fair value of the tangible net assets acquired as goodwill. We hired an outside
appraiser to assist in the determination of any impairment in goodwill as of September 30, 2007.
Based on this analysis, we determined that an impairment to the assigned values in the amount of
$228,000 had occurred at September 30, 2007. There were no impairment charges during the Fiscal
Year Ended January 31, 2007.
Operating Loss
As a result of the foregoing, we had an operating loss in the Fiscal Year Ended September 30,
2009 of $7.5 million compared to an operating loss of $5.0 million in the Fiscal Year Ended
September 30, 2008, or an increase of 50.0%. We had an operating loss of $2.0 million for the
Transition Period Ended September 30, 2007 and $1.8 million for the Fiscal Year Ended January 31,
2007. The operating loss increased as a result of costs associated with the RHA Acquisition and
the integration and operation of the RHA Healthcare Operations.
Other Income (Expense)
We recognized a $281,000 loss from the sale of a 10.9% equity interest in Del Mar in the
Fiscal Year Ended September 30, 2009.
Interest Income
We had interest income of $42,000 in the Fiscal Year Ended September 30, 2009, $320,000 in the
Fiscal Year Ended September 30, 2008, $2,000 in the Transition Period Ended September 30, 2007 and
$3,000 in the Fiscal Year Ended January 31, 2007. This represents a change of 86.9% compared with
the Fiscal Year Ended September 30, 2008, 2000% compared with the Transition Period Ended September
30, 2007 and 1300% compared with the Fiscal Year Ended January 31, 2007. The fluctuation in
interest income arose as a result of changes in the amount of cash held in interest-bearing
accounts during the period.
Interest Expense
We recorded interest expense of $2.1 million in the Fiscal Year Ended September 30, 2009 and
$0.9 million in the Fiscal Year Ended September 30, 2008, reflecting an increase of 133.3%. This
increase was due primarily to the increased borrowings under the loans entered into in December
2008 and the Bridge Financing. The interest expense in the Fiscal Year Ended September 30, 2008
arose from interest incurred from the promissory notes issued to finance the RHA Acquisition and
the RHA bank loans. We had no interest expenses in the Transition Period Ended September 30, 2007
or the Fiscal Year Ended January 31, 2007 because we had no loans outstanding during those periods.
Minority Interest
In the Fiscal Year Ended September 30, 2009, minority interest amounted to $0.2 million,
compared to ($1.4) million for the Fiscal Year Ended September 30, 2008, ($0.1) million in the
Transition Period Ended September 30, 2007 and ($0.2) million in the Fiscal Year Ended January 31,
2007. The increase in minority expense over the prior years is due to the our acquisition of the
minority ownership of RHA, which sustained operating losses during those prior periods.
Taxation
FASB ASC 740 creates a single model to address accounting for uncertainty in tax positions by
prescribing a minimum recognition threshold that a tax position is required to meet before being
recognized in the financial statements. FASB ASC 740 also provides guidance on derecognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and
transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated
financial statements.
34
Net Income or Loss Before Non-Cash Beneficial Conversion Feature
As a result of the foregoing, we recorded a net loss of $10.1 million, $4.2 million, $1.9
million and $1.6 million, in the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended
September 30, 2008, the Transition Period Ended September 30, 2007 and the Fiscal Year Ended
January 31, 2007, respectively. This represents a change of 140.5% compared with the Fiscal Year
Ended September 30, 2008, 431.6% compared with the Transition Period Ended September 30, 2007 and
531.3% compared with the Fiscal Year Ended January 31, 2007. The net loss increased as a result of
costs associated with the RHA Acquisition and the integration and operation of the RHA Healthcare
Operations.
Non-Cash Beneficial Conversion Feature Preferred Dividend
In the Fiscal Year Ended September 30, 2009, we recognized a $0.3 million non-cash beneficial
conversion feature preferred dividend expense compared to $2.9 million in the Fiscal year Ended
September 30, 2008, relating to the issuance of our 5-A Preferred and 6-A Preferred, each together
with warrants, during the periods. The expense, which arose from a beneficial conversion feature
resulting from the fact that such convertible securities could be converted into our Common Stock
at an amount below its market price on the commitment date of the securities, was recognized in
accordance with FASB standards on accounting for convertible securities with beneficial conversion
features. We recorded no beneficial conversion feature preferred dividend expense in the
Transition Period Ended September 30, 2007 or the Fiscal year Ended January 31, 2007.
Net Income or Loss Allocable to Common Stockholders
Net income or loss allocable to common stockholders is computed from net income or loss and
adding or deducting deemed non-cash dividend to preferred stockholders and credit on exchanges. We
had net loss allocable to common stockholders of $10.4 million, or ($0.94) per basic share in the
Fiscal Year Ended September 30, 2009, compared with $7.1 million, or $(0.86) per basic share in the
Fiscal Year Ended September 30, 2008, compared with $1.9 million, or $(0.50) per basic share, in
the Transition Period Ended September 30, 2007 and a net loss of $1.6 million, or $(0.43) per basic
share, in the Fiscal Year Ended January 31, 2007. This represents a change of 46.5% compared with
the Fiscal Year Ended September 30, 2008, 447.4% compared with the Transition Period Ended
September 30, 2007 and 550.0% compared with the Fiscal Year Ended January 31, 2007. The net loss
per basic share increased as a result of increases in net loss during the Fiscal Year Ended
September 30, 2009.
LIQUIDITY AND CAPITAL RESOURCES
Our cash and cash equivalents totaled $2.3 million as of September 30, 2009, compared with
$3.0 million as of September 30, 2008, $0.7 million as of September 30, 2007 and $0.3 million as of
January 31, 2007.
At September 30, 2009, we had a working capital deficit of $1.8 million and a stockholders
deficit of $9.0 million, as compared to a working capital of $2.9 million and a stockholders
deficit of $4.4 million at September 30, 2008, a working capital deficit of $1.0 million and a
stockholders deficit of $3.3 million at September 30, 2007 and a working capital deficit of $1.6
million and stockholders deficit of $1.6 million as of January 31, 2007.
The changes to stockholders equity are primarily due to costs associated with staffing,
administration and reporting, the RHA Acquisition, the integration and operation of the RHA
Healthcare Operations and the San Diego ambulatory surgical center. These costs were partially
offset by the revenues generated by the RHA Healthcare Operations, the San Diego ambulatory surgical
center, a management fee received in respect of the San Diego ambulatory surgical centers, and new
funds raised through the sale and issuance of new shares of our preferred stock. We have long-term
liabilities of $12.4 million as of September 30, 2009, $1.1 million as of September 30, 2008 and
had no long-term liabilities as of September 30, 2007 or January 31, 2007. To date, we have
financed our operations primarily through sales of preferred equity, issuance of promissory notes,
cash from operations and cash generated from the disposal of our interest in our subsidiary,
Vsource Asia.
35
Net cash used in operating activities totaled $3.5 million in the Fiscal Year Ended September
30, 2009, compared with $5.5 million in the Fiscal Year Ended September 30, 2008, $0.6 million in
the Transition Period Ended September 30, 2007 and $1.2 million in the Fiscal Year Ended
January 31, 2007. The increase in net cash used in the Fiscal Years Ended September 30, 2009 and
September 30, 2008 arose from the net operating costs associated with the RHA Healthcare
Operations, Del Mar and the costs associated with administration and reporting.
Net cash used by investing activities in the Fiscal Year Ended September 30, 2009 was $4.3
million, compared to $2.0 million in the Fiscal Year Ended September 30, 2008. Net cash used in
investing activities for the Transition Period Ended September 30, 2007 and for Fiscal Year Ended
January 31, 2007 amounted to $0.1 million for both periods. The net cash used by investing in the
Fiscal Year Ended September 30, 2009 was primarily due to the purchase of real property for our
hospital located in Stroud, Oklahoma and the acquisition of the remaining membership units in RHA,
which we did not previously own. The net cash used by investing in the Fiscal Year Ended September
30, 2008 resulted primarily from the RHA Acquisition and the acquisition of SPMC by RHA.
Net cash provided by financing activities was $7.2 million in the Fiscal Year Ended September
30, 2009, compared with $9.7 million in the Fiscal Year Ended September 30, 2008, $1.2 million in
the Transition Period Ended September 30, 2007 and $0.3 million in the Fiscal Year Ended January
31, 2007. Net cash provided by financing activities in the Fiscal Year Ended September 30, 2009
was providing primarily by the issuance of promissory notes. Net cash provided by financing
activities in the Fiscal Year Ended September 30, 2008 was provided by the issuance of new
preferred stock, the issuance of new Common Stock arising from the exercise of warrants and net
proceeds from borrowings. Net cash provided by financing activities in the Transition Period Ended
September 30, 2007 was provided by the issuance of new preferred stock. Net cash provided by
financing activities in the Fiscal Year Ended January 31, 2007 came from the issuance of 5-A
Preferred and other equity.
At September 30, 2009, we had total liabilities of $24.9 million and assets of $29.5 million.
OFF-BALANCE SHEET FINANCING
We currently have no off-balance sheet financing arrangements.
DISCLOSURE OF CONTRACTUAL OBLIGATIONS
Contractual Obligations (in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments due by period
|
|
|
|
Total
|
|
|
Less than 1 year
|
|
|
1-3 years
|
|
|
3-5 years
|
|
|
More than 5 years
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Long-term debt obligations
|
|
$
|
13,169
|
|
|
$
|
935
|
|
|
$
|
3,208
|
|
|
$
|
2,052
|
|
|
$
|
6,974
|
|
Capital lease obligations
|
|
|
300
|
|
|
|
93
|
|
|
|
176
|
|
|
|
31
|
|
|
|
|
|
Operating lease obligations
|
|
|
5,271
|
|
|
|
1,243
|
|
|
|
2,580
|
|
|
|
1,152
|
|
|
|
296
|
|
Other contractual obligations
|
|
|
345
|
|
|
|
120
|
|
|
|
153
|
|
|
|
72
|
|
|
|
|
|
Total
|
|
$
|
19,085
|
|
|
$
|
2,391
|
|
|
$
|
6,117
|
|
|
$
|
3,307
|
|
|
$
|
7,270
|
|
Other contractual obligations consist primarily of obligations to purchase goods or
services that are enforceable and legally binding on us. These obligations specify all significant
terms and are not cancellable without a penalty. Our obligations primarily relate to software
licensing, clinical coding, medical waste removal, equipment maintenance and linen service.
36
|
|
|
Item 7A.
|
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
INTEREST RATE RISK
Our exposure to market risk for changes in interest rates relates primarily to our cash on
deposit with high quality financial institutions and a portion of our long-term debt that is based
on prime rates. We are exposed with respect to interest rate fluctuations in the U.S. as changes
in U.S. interest rates affect the interest earned on our cash
and interest paid on our debt. However, changes in interest income and interest expense will
not have a material impact on our financial results.
FOREIGN CURRENCY RISK
We derive our revenues from operations in the United States. All of our revenues are
currently denominated in U.S. dollars. An increase or decrease in the value of the U.S. dollar
relative to foreign currencies does not have a material impact on the demand for our services or on
our expenses. Currently, we do not hedge against any foreign currencies and, as a result, could
incur unanticipated gains or losses.
|
|
|
Item 8.
|
|
CONSOLIDATED FINANCIAL STATEMENTS
|
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders
of First Physicians Capital Group, Inc.
We have audited the accompanying consolidated balance sheets of First Physicians Capital
Group, Inc. (formerly Tri-Isthmus Group, Inc.) (the
Company
), as of September 30, 2009
and 2008, and the related consolidated statements of operations, changes in stockholders equity
(deficit), and cash flows for the years then ended. The Companys management is responsible for
these financial statements. Our responsibility is to express an opinion on these financial
statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audits to
obtain reasonable assurance about whether the financial statements are free of material
misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its
internal control over financial reporting. An audit includes consideration of internal control
over financial reporting as a basis for designing audit procedures that are appropriate in the
circumstances, but not for the purpose of expressing an opinion on the effectiveness of the
Companys internal control over financial reporting. Accordingly, we express no such opinion. An
audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements, assessing the accounting principles used and significant estimates made
by management, and evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all
material respects, the financial position of the Company, as of September 30, 2009 and 2008, and
the results of their operations and their cash flows for the years then-ended in conformity with
accounting principles generally accepted in the United States of America.
|
|
|
/s/
Whitley Penn LLP
Dallas, Texas
|
|
|
January 11, 2010
|
|
|
37
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
ASSETS
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
2,324
|
|
|
$
|
2,970
|
|
Restricted cash
|
|
|
1,523
|
|
|
|
1,514
|
|
Accounts receivable, net of allowance for uncollectible accounts
|
|
|
4,891
|
|
|
|
6,289
|
|
Advance to affiliated entity (Note 7)
|
|
|
|
|
|
|
72
|
|
Prepaid expenses
|
|
|
111
|
|
|
|
103
|
|
Other current assets
|
|
|
1,772
|
|
|
|
1,754
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
10,621
|
|
|
|
12,702
|
|
Property and equipment, net
|
|
|
17,033
|
|
|
|
12,277
|
|
Goodwill (Note 8)
|
|
|
759
|
|
|
|
759
|
|
Other assets
|
|
|
1,078
|
|
|
|
760
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
29,491
|
|
|
$
|
26,498
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES, PREFERRED STOCK AND STOCKHOLDERS EQUITY/ (DEFICIT)
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Accounts payable
|
|
$
|
3,598
|
|
|
$
|
2,944
|
|
Accrued expenses
|
|
|
3,515
|
|
|
|
2,715
|
|
Notes payable
|
|
|
4,309
|
|
|
|
3,980
|
|
Current maturities of long term debt
|
|
|
1,028
|
|
|
|
164
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
12,450
|
|
|
|
9,803
|
|
Long term debt, net of current portion
|
|
|
12,441
|
|
|
|
1,091
|
|
Notes payable
|
|
|
|
|
|
|
4,364
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
24,891
|
|
|
|
15,258
|
|
|
|
|
|
|
|
|
Minority interest (Note 11)
|
|
|
1,083
|
|
|
|
967
|
|
|
|
Commitments and contingencies
|
|
|
|
|
|
|
|
|
Non-redeemable preferred stock:
|
|
|
|
|
|
|
|
|
Preferred stock Series 1-A ($0.01 par value, 67,600 shares
authorized; 67,600 shares issued and outstanding as of Sep. 30, 2009 and 2008)
|
|
|
166
|
|
|
|
166
|
|
Preferred stock Series 2-A ($0.01 par value, 3,900 shares
authorized; 3,900 shares issued and outstanding as Sep. 30, 2009
and 2008)
|
|
|
25
|
|
|
|
25
|
|
|
|
|
|
|
|
|
Total non-redeemable preferred stock
|
|
|
191
|
|
|
|
191
|
|
Redeemable preferred stock: (Note 14)
|
|
|
|
|
|
|
|
|
Preferred stock Series 5-A ($0.01 par value, 9,000 shares
authorized; 8,987 shares issued and outstanding as of Sep. 30, 2009 and 2008)
|
|
|
7,819
|
|
|
|
7,819
|
|
Preferred stock Series 6-A ($0.01 par value, 5,000 shares
authorized; 4,957 and 4,607 shares issued and outstanding as of
Sep. 30, 2009 and Sep. 30, 2008, respectively)
|
|
|
4,463
|
|
|
|
4,113
|
|
Series B preferred stock issued by subsidiary ($0.01 par value,
38,250 shares authorized, zero shares and 19,990 shares issued
and outstanding as of Sep. 30, 2009 and 2008, respectively)
|
|
|
|
|
|
|
2,500
|
|
|
|
|
|
|
|
|
Total redeemable preferred stock
|
|
|
12,282
|
|
|
|
14,432
|
|
Stockholders equity/(deficit):
|
|
|
|
|
|
|
|
|
Common stock ($0.01 par value, 100,000,000 shares authorized;
13,448,683 and 10,322,927 shares issued and outstanding as of
Sep. 30, 2009 and Sep. 30, 2008, respectively)
|
|
|
136
|
|
|
|
103
|
|
Additional paid-in-capital
|
|
|
77,109
|
|
|
|
71,301
|
|
Accumulated deficit
|
|
|
(86,070
|
)
|
|
|
(75,702
|
)
|
Other comprehensive income (loss)
|
|
|
(52
|
)
|
|
|
(52
|
)
|
Treasury stock, at cost (93,494 shares as of Sep. 30, 2009)
|
|
|
(79
|
)
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity/(deficit)
|
|
|
(8,956
|
)
|
|
|
(4,350
|
)
|
|
|
|
|
|
|
|
Total liabilities, preferred stock and stockholders equity/(deficit)
|
|
$
|
29,491
|
|
|
$
|
26,498
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
38
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share data)
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Revenue from services
|
|
$
|
39,090
|
|
|
$
|
29,641
|
|
Cost and expenses:
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses
|
|
|
39,514
|
|
|
|
29,544
|
|
|
|
|
|
|
|
|
|
|
Provision for doubtful accounts
|
|
|
4,561
|
|
|
|
3,792
|
|
|
|
|
|
|
|
|
|
|
Amortization of stock-based compensation (Note 15)
|
|
|
1,245
|
|
|
|
339
|
|
Impairment of long-lived assets and goodwill
|
|
|
209
|
|
|
|
308
|
|
Depreciation and amortization
|
|
|
1,102
|
|
|
|
706
|
|
|
|
|
|
|
|
|
|
|
Total costs and expenses
|
|
|
46,631
|
|
|
|
34,689
|
|
|
|
|
|
|
|
|
|
|
Operating loss
|
|
|
(7,541
|
)
|
|
|
(5,048
|
)
|
Interest income
|
|
|
42
|
|
|
|
320
|
|
Interest expense
|
|
|
(2,094
|
)
|
|
|
(873
|
)
|
Other income (expense)
|
|
|
(281
|
)
|
|
|
|
|
Minority interest
|
|
|
(177
|
)
|
|
|
1,368
|
|
|
|
|
|
|
|
|
|
|
Net loss from operations before taxation and non-cash
beneficial conversion feature
|
|
|
(10,051
|
)
|
|
|
(4,233
|
)
|
Taxation
|
|
|
|
|
|
|
|
|
Non-cash beneficial conversion feature preferred dividend
|
|
|
(317
|
)
|
|
|
(2,878
|
)
|
|
|
|
|
|
|
|
|
|
Net loss allocable to common stockholders
|
|
$
|
(10,368
|
)
|
|
$
|
(7,111
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per common share:
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(0.94
|
)
|
|
$
|
(0.86
|
)
|
Diluted
|
|
|
N/A
|
|
|
|
N/A
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
39
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY/(DEFICIT)
(in thousands, except for shares data)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
Total
|
|
|
|
Common Shares
|
|
|
Paid-in
|
|
|
Accumulated
|
|
|
Comprehensive
|
|
|
Treasury
|
|
|
Stockholders
|
|
|
|
Stock
|
|
|
Amount
|
|
|
Capital
|
|
|
Deficit
|
|
|
Income (Loss)
|
|
|
Stock
|
|
|
Deficit
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at Sep. 30, 2007
|
|
|
3,828,739
|
|
|
$
|
38
|
|
|
$
|
65,355
|
|
|
$
|
(68,591
|
)
|
|
$
|
(52
|
)
|
|
$
|
0
|
|
|
$
|
(3,250
|
)
|
Net Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,111
|
)
|
|
|
|
|
|
|
|
|
|
|
(7,111
|
)
|
Issuance of Common Stock
|
|
|
6,494,188
|
|
|
|
65
|
|
|
|
2,175
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,240
|
|
Issuance of warrants
|
|
|
|
|
|
|
|
|
|
|
554
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
554
|
|
Beneficial Conversion Feature
related to preferred stock issuance
|
|
|
|
|
|
|
|
|
|
|
2,878
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,878
|
|
Stock based compensation
|
|
|
|
|
|
|
|
|
|
|
339
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
339
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at Sept. 30, 2008
|
|
|
10,322,927
|
|
|
$
|
103
|
|
|
$
|
71,301
|
|
|
$
|
(75,702
|
)
|
|
$
|
(52
|
)
|
|
$
|
0
|
|
|
$
|
(4,350
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Loss
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10,368
|
)
|
|
|
|
|
|
|
|
|
|
|
(10,368
|
)
|
Issuance of Common Stock
|
|
|
160,000
|
|
|
|
2
|
|
|
|
98
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100
|
|
Conversion of Series B Preferred
to Common Stock
|
|
|
2,384,250
|
|
|
|
25
|
|
|
|
2,477
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,502
|
|
Proceeds from exercise of warrants
|
|
|
525,000
|
|
|
|
5
|
|
|
|
258
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
263
|
|
Beneficial Conversion Feature
related to preferred stock issuance
|
|
|
|
|
|
|
|
|
|
|
317
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
317
|
|
Stock based compensation
|
|
|
150,000
|
|
|
|
1
|
|
|
|
1,244
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,245
|
|
Issuance of warrants as discount
on convertible debt
|
|
|
|
|
|
|
|
|
|
|
1,184
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,184
|
|
Equity transactions in
consolidated affiliates (see note
11)
|
|
|
|
|
|
|
|
|
|
|
230
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
230
|
|
Purchase of treasury stock
|
|
|
(93,494
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(79
|
)
|
|
|
(79
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at Sept. 30, 2009
|
|
|
13,448,683
|
|
|
$
|
136
|
|
|
$
|
77,109
|
|
|
$
|
(86,070
|
)
|
|
$
|
(52
|
)
|
|
$
|
(79
|
)
|
|
$
|
(8,956
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
40
FIRST PHYSICIANS CAPITAL GROUP, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Cash flows from operating activities:
|
|
|
|
|
|
|
|
|
Net loss
|
|
$
|
(10,051
|
)
|
|
$
|
(4,233
|
)
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
|
|
|
|
|
|
|
|
Minority interest
|
|
|
177
|
|
|
|
(1,368
|
)
|
Depreciation and amortization
|
|
|
1,102
|
|
|
|
706
|
|
Bad debt provision/(writeback)
|
|
|
4,561
|
|
|
|
3,792
|
|
Loss from sale of investments
|
|
|
281
|
|
|
|
|
|
Impairment loss on property and equipment
|
|
|
|
|
|
|
308
|
|
Amortization of stock-based compensation
|
|
|
1,245
|
|
|
|
339
|
|
Amortization of debt discount
|
|
|
952
|
|
|
|
233
|
|
Impairment loss on goodwill
|
|
|
209
|
|
|
|
|
|
Changes in working capital components:
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(3,163
|
)
|
|
|
(4,275
|
)
|
Accounts payable and accrued expenses
|
|
|
1,455
|
|
|
|
348
|
|
Others
|
|
|
(275
|
)
|
|
|
(1,322
|
)
|
|
|
|
|
|
|
|
Net cash used in operating activities
|
|
|
(3,507
|
)
|
|
|
(5,472
|
)
|
Cash flows from investing activities:
|
|
|
|
|
|
|
|
|
Purchase of property and equipment
|
|
|
(4,515
|
)
|
|
|
(676
|
)
|
Purchase of equity interest in consolidated affiliate
|
|
|
(35
|
)
|
|
|
|
|
Payments from affiliated entity
|
|
|
|
|
|
|
33
|
|
Proceeds from sale of equity interests in consolidated affiliate
|
|
|
325
|
|
|
|
|
|
Restricted cash
|
|
|
(9
|
)
|
|
|
(1,514
|
)
|
Acquisition of subsidiaries, net of cash acquired
|
|
|
(55
|
)
|
|
|
175
|
|
|
|
|
|
|
|
|
Net cash used in investing activities
|
|
|
(4,289
|
)
|
|
|
(1,982
|
)
|
Cash flows from financing activities:
|
|
|
|
|
|
|
|
|
Borrowings on convertible loans
|
|
|
2,200
|
|
|
|
1,650
|
|
Payments on notes payable
|
|
|
(5,786
|
)
|
|
|
(2,613
|
)
|
Proceeds on notes payable
|
|
|
10,246
|
|
|
|
162
|
|
Distributions to minority partners
|
|
|
(144
|
)
|
|
|
|
|
Purchase of treasury stock
|
|
|
(79
|
)
|
|
|
|
|
Proceeds from exercise of warrants
|
|
|
263
|
|
|
|
440
|
|
Proceeds from issuance of preferred stock, net of cost
|
|
|
350
|
|
|
|
10,052
|
|
Proceeds from issuance of Common Stock
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
7,150
|
|
|
|
9,691
|
|
Net increase/(decrease) in cash and cash equivalents
|
|
|
(646
|
)
|
|
|
2,237
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at beginning of year
|
|
|
2,970
|
|
|
|
733
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
2,324
|
|
|
$
|
2,970
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information:
|
|
|
|
|
|
|
|
|
Cash paid for interest
|
|
$
|
1,204
|
|
|
$
|
873
|
|
Cash paid for taxes
|
|
|
|
|
|
|
|
|
Non-cash transaction Purchase of the 49% minority interest in RHA for a
promissory note of $1,800,000, first payment of $50,000 paid at closing.
|
|
|
|
|
|
|
|
|
The fair value of warrants issued in conjunction with the convertible
notes amounted to $932,000.
The beneficial conversion feature associated
with the convertible notes amounted to $253,000.
|
|
|
|
|
|
|
|
|
The fair value of
warrants issued in conjunction with the issuance of preferred stock
amounted $84,473. The beneficial conversion feature associated with the
preferred stock amounted to $317,000.
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these Consolidated Financial Statements.
41
FIRST PHYSICIANS CAPITAL GROUP, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Company Background
We were originally incorporated in Nevada in October 1980 and re-incorporated in Delaware in
November 2000. From 2001 to November 2004, we provided Fortune 500 and Global 500 companies with
customizable and comprehensive business process outsourcing (
BPO
) solutions into and
across the Asia-Pacific region. In November 2004, our active business operations ceased with the
sale of our BPO operations in Asia.
On December 16, 2005, at our Annual Meeting of Stockholders, our stockholders voted to amend
our Certificate of Incorporation to change our legal name from Vsource, Inc. to Tri-Isthmus
Group, Inc. (
TIGroup
) and to reduce the number of authorized shares of our common stock,
par value $0.01 per share (the
Common Stock
), from 500,000,000 shares to 100,000,000
shares, as described in our Proxy Statement filed with the Securities and Exchange Commission (the
SEC
) on November 28, 2005. The reduction of the number of authorized shares of our
Common Stock did not affect the number of shares of Common Stock issued and outstanding.
During the fiscal year ended January 31, 2007 (the
Fiscal Year Ended January 31,
2007
), we resumed active operations following the acquisition of two ambulatory surgical
centers located in Southern California. On December 2, 2005, through newly created indirect
subsidiaries, we entered into two separate purchase agreements to acquire from Surgical Ventures,
Inc., a California corporation, a controlling interest in two separate outpatient surgical centers
in San Diego, California, Point Loma Surgical Center, L.P. and Outpatient Surgery of Del Mar, L.P.,
and we completed these acquisitions on November 16, 2006. On February 9, 2007, we converted these
limited partnerships into Outpatient Surgery of Point Loma, L.L.C. (
Point Loma
) and
Outpatient Surgery of Del Mar, L.L.C. (
Del Mar
, and, together with Point Loma, the
San Diego ambulatory surgical centers
), respectively. In June 2007, we consolidated the
operations of the San Diego ambulatory surgical centers at the Del Mar facility.
On October 29, 2007, we acquired 51% of the issued and outstanding membership units of Rural
Hospital Acquisition, LLC, an Oklahoma limited liability company (
RHA
). Based in
Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic and an
ancillary support services unit, all focused on the delivery of healthcare services to rural
communities in Oklahoma. On May 1, 2008, RHA Anadarko, LLC, a wholly owned subsidiary of RHA,
purchased 100% of the issued and outstanding membership interests of Southern Plains Medical Center
(
SPMC
). Founded in 1915, SPMC is one of the oldest continuously operating
multi-specialty physician practices in the United States. Located in Chickasha, Oklahoma, SPMCs
15 physicians and other licensed healthcare providers deliver primary and specialty care in the
following areas: family medicine; pediatrics; internal medicine; acute care; occ/med; general
surgery; gynecology; ophthalmology; orthopedic surgery; radiology; oncology; cardiology and
urology. Ancillary services provided onsite include imaging (computer-assisted tomography
(
CT
), magnetic resonance imaging (
MRI
), mammography, x-ray, EKG, vascular and
ultra-sound bone densitometry) and laboratory services. SPMC also provides urgent care services
outside of normal business hours seven days a week through its Quick Care department. Beginning
November 18, 2008, RHA began operating under the trade name Southern Plains Medical Group. On
December 11, 2008, we acquired the remaining 49% of the issued and outstanding membership units of
RHA, making RHA an indirect wholly-owned subsidiary of ours.
On December 12, 2008, we and certain of our subsidiaries entered into three loan agreements,
effective November 6, 2008, with two Oklahoma-based lenders, Canadian State Bank and Valliance
Bank, resulting in an aggregate debt financing of $8.4 million. We obtained the financing to
purchase the building and real property of the Stroud Regional Medical Center Hospital and clinics,
refinance existing loans totaling $4.6 million, upgrade facilities at the Johnston Memorial
Hospital and improve the consolidated balance sheet and maintain general working capital. The
loans are evidenced by promissory notes issued by RHA Anadarko, LLC, RHA Stroud, LLC and RHA
Tishomingo, LLC, two of which mature on November 6, 2028 and one of which matures on November 6,
2024.
42
On May 1, 2009, we purchased The Chandler Clinic (
TCC
), a family medical practice
located in Chandler, Oklahoma. TCC is located within the service area of the Stroud Regional
Medical Center.
On September 29, 2009, at our Annual Meeting of Stockholders, our stockholders voted to amend
our Certificate of Incorporation to change our legal name from Tri-Isthmus Group, Inc. to First
Physicians Capital Group, Inc. to reflect our focus on the healthcare industry. We became First
Physicians Capital Group, Inc. on September 29, 2009.
Current Operations
Following the sale of our BPO operations in November 2004, we reduced our headcount
significantly to a two-person staff when David Hirschhorn and Todd Parker joined us as our Co-Chief
Executive Officers in July 2005. Our new management initiated a growth strategy defined by
acquisitions. Our management team and Board of Directors have been and are currently comprised of
a group of individuals with complementary talents across a broad range of disciplines, including
mergers and acquisitions, finance and operations.
During the Fiscal Years Ended January 31, 2006 and January 31, 2007, our management team
focused our acquisition strategy on the healthcare industry.
In December 2006, we resumed active operations following the acquisition of the San Diego
ambulatory surgical centers.
In 2007, we refined our acquisition strategy to focus on the delivery of financial and
managerial services to healthcare facilities in non-urban markets.
In September 2007, David Hirschhorn became our sole Chief Executive Officer upon Todd Parkers
resignation. Dennis M. Smith, formerly a director and senior consultant to us, re-joined us as our
Chief Financial Officer. On October 9, 2008, Mr. Smiths employment agreement with us was
terminated. Effective January 26, 2009, Mr. Smith ceased to be our Chief Financial Officer. Upon
the termination of his employment agreement, Mr. Smith had certain contractual rights, pursuant to
which we continued to pay Mr. Smith until April 9, 2009. Mr. Smith was offered a severance package
to continue his pay beyond April 9, 2009 in recognition for past services rendered, and Mr. Smith
accepted the severance package which entitled him to severance payments which began May 10, 2009
and lasted until October 20, 2009. Mr. Smith had and has no disagreements with us on any matter
related to our operations, policies or practices. On March 3, 2009, Mr. Smith resigned as a member
of our Board of Directors.
In November 2008, we appointed Thomas Rice as President of RHA. Mr. Rice has over 37 years
experience in the administration and operation of healthcare facilities, including key senior
management positions with major Oklahoma-based healthcare services companies. Also in November
2008, we announced the addition of Donald C. Parkerson as Chief Financial Officer of RHA, a
position he held until June 2009 when he ceased acting as the CFO of RHA. On January 30, 2009, Mr.
Parkerson was also appointed as our Chief Financial Officer. Mr. Parkerson has served in financial
leadership positions with companies in healthcare businesses during his more than 30-year career.
In November 2008, we hired Richard Rentsch as Vice President of Finance of RHA, and currently he
serves as the Chief Accounting Officer of RHA. Mr. Rentsch is an experienced financial leader with
more than 25 years of healthcare experience.
Our support staff at RHAs hospitals and Del Mar consists of registered nurses, operating room
technicians, an administrator who supervises the day-to-day activities of the surgery center and a
small number of office staff. Each operating unit also has appointed a medical director, who is
responsible for and supervises the quality of medical care provided at the center. Use of our
surgery centers is limited to licensed physicians. With the acquisition of SPMC in May 2008, we
added 15 physicians and other healthcare providers to our team at RHA as employees. Our business
depends upon the efforts and success of these physicians and non-employee physicians who provide
medical services at our facilities. Our business could be adversely affected by the loss of our
relationship with, or a reduction in use of our facilities by, a key physician or group of
physicians.
43
As discussed above, in December 2008, RHA became an indirect wholly-owned subsidiary of ours
with the acquisition by RHA of the interests not already held by us.
Strategy
Our initial strategy was to identify and invest in platform companies in the business
services and healthcare industries that provided essential core offerings, which could be expanded
over time. As we focused our efforts in the healthcare industry, two particular segments,
ambulatory surgical centers and rural hospitals, stood out in terms of fundamentally-favorable
economics, positive regulatory trends, inherent cost advantages, improving demographics and, for
non-urban healthcare opportunities, a large, under-served market. We determined that the top-down
trends and attractive cash flows of ambulatory surgical centers made this an area of particular
interest. Less well-known, however, is the non-urban sector, which has suffered from a long-term
lack of access to capital despite providing care to more than 50 million people in the United
States. We determined that focusing on rural healthcare would represent a significant long-term
opportunity for us. We believe that we have identified a differentiated approach based on the
recognition that the physician is at the center of the healthcare industry. Our operating
philosophy is tied to a belief that the provision of flexible financial solutions to rural
hospitals and ambulatory surgical centers through the alignment of our interests with those of the
physicians will result in a strong, predictable cash flow stream with excellent risk adjusted
returns.
On October 29, 2007, we acquired 51% of the issued and outstanding membership units of RHA.
Based in Oklahoma City, RHA owns and operates three critical access hospitals, one medical clinic
and an ancillary support services unit, all focused on the delivery of healthcare services to rural
communities in Oklahoma. Together, the acquisition of RHA and the subsequent acquisition of SPMC
by RHA are referred to herein collectively as the
RHA Acquisition
, and the three RHA
hospitals, the medical clinic, ancillary support services units and SPMC are referred to herein
collectively as the
RHA Healthcare Operations
. On May 1, 2008, RHA purchased 100% of the
issued and outstanding membership interests of SPMC. Beginning November 18, 2008, RHA began
operating under the trade name Southern Plains Medical Group. On December 11, 2008, through one
of our wholly-owned subsidiaries, we acquired the remaining 49% of the issued and outstanding
membership units of RHA, making RHA an indirect wholly-owned subsidiary. We believe that these
transactions are consistent with our current operating strategy.
Our portfolio is expected to consist of (i) majority interests in healthcare platforms or
facilities, such as RHA, the San Diego ambulatory surgical center and SPMC and (ii) equity positions
in a diversified portfolio of minority interests in ambulatory surgical centers with a history of
positive cash flows. In addition, we expect to selectively invest in business solutions providing
financial and processing services to healthcare providers and physicians and in support of new
treatment solutions.
In line with our strategy, we re-branded our activities. The operations in the non-urban
market previously known as RHA were re-branded Southern Plains Medical Group to leverage the old
and well-established recognition that SPMC has in the regional markets. In addition, effective
September 29, 2009, we changed our name to First Physicians Capital Group, Inc. to reflect our
focus on the healthcare industry.
Funding
We have sustained operating losses since our inception and had an accumulated deficit of
approximately $86.0 million as of September 30, 2009, which has been funded primarily through the
issuance of preferred stock, the issuance of promissory notes and cash generated from operations.
As of September 30, 2009 we had current liabilities of $12.5 million and current assets of
$10.6 million. Significant events relating to funding of operations in the twelve-month period
ended September 30, 2009 include:
|
|
|
In February 2009 we received $1,500,000 in connection with the issuance of two
promissory notes under the Bridge Financing (as defined in Item 7, Funding, in this
Form 10-K)
|
|
|
|
In March 2009 we received $500,000 in connection with the issuance of nine
promissory notes under the Bridge Financing.
|
44
|
|
|
In April 2009 we received $200,000 in connection with the issuance of three
promissory notes under the Bridge Financing.
|
|
|
|
In April and May 2009 we received $202,500 in connection with the exercise of
then-outstanding warrants to purchase 405,000 shares of our Common Stock.
|
|
|
|
In June 2009 we received $350,000 in connection with the subscription of 350 shares
of our Series 6-A Convertible Preferred Stock, par value $0.01 per share (the
6-A
Preferred
) and warrants to purchase our Common Stock.
|
Upon completion of the RHA Acquisition in October 2007, RHA assumed a bank obligation in the
amount of $4.4 million (the
RHA Loan
). With the completion of the SPMC acquisition by
RHA in May 2008, we acquired SPMC bank obligations in the amount of $4.5 million. In December
2008, subsidiaries of RHA obtained three loans totaling an aggregate of $8.4 million, the proceeds
of which were used for (i) the purchase of the real property and assets of the hospital operated by
RHA in Stroud, Oklahoma for a consideration of $3.2 million pursuant to an existing option
agreement; (ii) the repayment of the RHA Loan and (iii) the financing of capital expenditures, fees
associated with the financings and working capital requirements (the
2008 Loans
). The
2008 Loans carry amortization schedules of 16-years to 20-years and are guaranteed up to 80% by the
U.S. Department of Agriculture Rural Development 80% Business & Industry Loan Guarantee program
(
USDA
). The completion of the 2008 Loans had the effect of reducing our current
liabilities by $4.6 million.
Our management believes that we have adequate funding from the RHA Healthcare Operations and
Del Mar, cash and cash equivalents, the 2008 Loans and the Bridge Financing for us to continue in
operation for at least 12 months from the balance sheet date. Therefore, we have prepared our
financial statements on a going concern basis.
Our investment and acquisition targets will continue to derive their working capital from
their respective operations or financing efforts. We will assist our subsidiaries in expanding
their access to working capital as appropriate.
2. Summary of Significant Accounting Policies
We prepare our consolidated financial statements in conformity with accounting principles
generally accepted in the United States of America. As such, we are required to make certain
estimates, judgments and assumptions that we believe are reasonable based upon the information
available. These estimates and assumptions affect the reported amounts of assets and liabilities
at the date of the financial statements and the reported amounts of revenues and expenses during
the periods presented. The significant accounting policies which we believe are the most critical
to aid in fully understanding and evaluating our reported financial results include the following:
Principles of Consolidation and Basis of Presentation
The consolidated financial statements include our accounts and the accounts of our
subsidiaries. All significant intercompany balances and transactions have been eliminated.
Use of Estimates
The preparation of the consolidated financial statements in conformity with accounting
principles generally accepted in the United States requires our management to make estimates and
assumptions that affect the reported amounts of assets and liabilities, the disclosure of
contingent assets and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Our actual results could differ from
estimates and assumptions made.
Reclassifications
Certain reclassifications and format changes have been made to the prior period amounts in
order to conform to the current period presentation.
45
Cash and Cash Equivalents
Cash consists of cash on hand and amounts deposited with high quality financial institutions.
Amounts on deposit at times exceeds the insurance limits. Cash equivalents are highly liquid
instruments including cash in money market current accounts that are interest-bearing, capital
guaranteed and without any withdrawal restrictions.
Restricted cash consists of funds on deposit with a bank held as security for debt relating to
the SPMC acquisition.
Accounts Receivable
Accounts receivable are reported at estimated net realizable amounts from services rendered
from federal and state agencies (under the Medicare and Medicaid programs), managed care health
plans, commercial insurance companies, workers compensation, employers and patients. A significant
portion of our revenues are concentrated with federal and state agencies.
Additions to the allowance for doubtful accounts are made by means of the line item Provision
for Doubtful Accounts in our financial statements. We write off uncollectible accounts against the
allowance for doubtful accounts after exhausting collection efforts and adding subsequent
recoveries. Net accounts receivable include only those amounts we estimate we will collect.
We perform an analysis of our historical cash collection patterns and consider the impact of
any known material events in determining the allowance for doubtful accounts. In performing our
analysis, we considered the impact of any adverse changes in general economic conditions, business
office operations, payor mix, or trends in federal or state governmental healthcare coverage.
Property and Equipment
Property and equipment are stated at cost. Depreciation for property and equipment is
provided using the straight-line method over the estimated useful lives of the respective assets as
follows:
|
|
|
|
|
Computer hardware
|
|
|
2 to 5 years
|
|
Computer software
|
|
|
3 to 5 years
|
|
Office equipment, furniture and fixtures
|
|
5 years
|
|
Medical equipment
|
|
|
5 to 7 years
|
|
Buildings
|
|
|
30 to 40 years
|
|
Leasehold improvements
|
|
15 years
|
|
Depreciation for leasehold improvements is provided using the straight-line method over the
shorter of the estimated useful lives of the respective assets or the remaining lease term.
Impairment of Goodwill and Long-lived Assets
We review long-lived assets, certain identifiable intangible assets and goodwill related to
these assets for impairment. For assets to be held and used, including acquired intangibles, we
initiate a review whenever events or changes in circumstances indicate that the carrying value of a
long-lived asset may not be recoverable and annually for goodwill and other intangible assets not
subject to amortization. Recoverability of an asset is measured by comparison of its carrying
value to the future undiscounted cash flows that the asset is expected to generate. Any impairment
to be recognized is measured by the amount by which the carrying value exceeds the projected
discounted future operating cash flows. Assets to be disposed of and for which management has
committed a plan to dispose of the assets, whether through sale or abandonment, are reported at the
lower of carrying value or fair value less costs to sell.
46
In the fiscal year ended September 30, 2009 (the
Fiscal Year Ended September 30,
2009
), we determined that an impairment to the goodwill previously recorded upon the
acquisition of RHA had occurred. An impairment
charge of $209,000 was recorded. In the fiscal year ended September 30, 2008 (the
Fiscal
Year Ended September 30, 2008
), we recorded an impairment of $308,000 with respect to fixed
assets at Point Loma arising from the termination of activities at this facility as part of our
review of long-lived assets, certain identifiable intangible assets and goodwill.
Revenue Recognition
We recognize revenue when persuasive evidence of an arrangement exists, delivery or
performance has occurred, the sales price is fixed or determinable and collectibility is probable
or reasonably assured.
Income Taxes
The asset and liability approach is used to account for income taxes by recognizing deferred
tax assets and liabilities for the expected future tax consequences of temporary differences
between the carrying amounts and the tax bases of assets and liabilities. We record a valuation
allowance to reduce the deferred tax assets to the amount that is more likely than not to be
realized.
Accounting for Uncertainty in Income Taxes
Financial Accounting Standards Board (
FASB
) Accounting Standards Codification
(
ASC
) 740 creates a single model to address accounting for uncertainty in tax positions
by prescribing a minimum recognition threshold a tax position is required to meet before being
recognized in the financial statements. FASB ASC 740 also provides guidance on derecognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and
transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated
financial statements.
Functional Currency
Our functional currency is United States dollars.
Other Comprehensive Income (Loss)
Other comprehensive income (loss) refers to revenues, expenses, gains and losses that under
generally accepted accounting principles in the United States are included in comprehensive income
(loss) but are excluded from net income (loss), as these amounts are recorded directly as an
adjustment to stockholders equity, net of tax. Our other comprehensive income (loss) is composed
of unrealized gains and losses on foreign currency translation adjustments.
Stock-Based Compensation
Effective February 1, 2006, we adopted the fair value recognition provisions of FASB ASC 718,
Accounting for Compensation Arrangements, using the modified prospective application method. Our
stock option plans are described in Note 15 to our financial statements contained in Item 8 of this
Form 10-K.
Earnings Per Share
Basic earnings/(loss) per share is computed by dividing net income/(loss) by the weighted
average shares of Common Stock outstanding during the year. Diluted earnings per share is computed
by dividing net income by the weighted average shares of Common Stock and potential common shares
outstanding during the year. Potential common shares outstanding consist of dilutive shares
issuable upon the conversion of our preferred stock to Common Stock as computed using the
if-converted method and the exercise of outstanding options and warrants to purchase Common Stock,
computed using the treasury stock method.
47
Recent Accounting Pronouncements
In September 2006, the FASB issued authoritative guidance on Fair Value Measurements. The
new guidance sets forth the standards for using fair value to measure assets and liabilities. It
addresses the requests from investors for expanded disclosure about the extent to which companies
measure assets and liabilities at fair value, the information used to measure fair value and the
effect of fair value measurements on earnings. The new standard applies whenever other standards
require (or permit) assets or liabilities to be measured at fair value and does not expand the use
of fair value in any new circumstances. The standard is effective for financial statements issued
for fiscal years beginning after November 15, 2007 and was adopted by us in the first quarter of
the Fiscal Year Ended September 30, 2009. Adoption of the new standard did not have a material
impact on our financial condition or results of operations.
In February 2007, the FASB issued new standards regarding The Fair Value Option for Financial
Assets and Financial Liabilities Including an amendment of the previous standards relative to the
Fair Value Option for Financial Assets and Financial Liabilities. This statement permits entities
to choose to measure many financial instruments and certain other items at fair value. The
objective is to improve financial reporting by providing entities with the opportunity to mitigate
volatility in reported earnings caused by measuring related assets and liabilities differently
without having to apply complex hedge accounting provisions. This statement is effective as of the
beginning of an entitys first fiscal year that begins after November 15, 2007. Adoption of this
pronouncement is optional and management has elected not to adopt this standard.
In December 2007, the FASB issued guidance on Noncontrolling Interests in Consolidated
Financial Statementsan amendment of ARB No. 51. This guidance requires companies with
noncontrolling interests to disclose such interests clearly as a portion of equity but separate
from the parents equity. The noncontrolling interests portion of net income must also be clearly
presented on the income statement. This is effective for financial statements issued for fiscal
years beginning after December 15, 2008 and will be adopted by us in the first quarter of fiscal
year 2010. We do not expect that the adoption of the new rules will have a material impact on our
financial condition or results of operation.
In December 2007, the FASB issued updated guidance on business combinations. This guidance
applies the acquisition method of accounting for business combinations where the acquirer gains a
controlling interest, regardless of whether consideration was exchanged. The updated guidance
requires the acquirer to fair value the assets and liabilities of the acquiree and record goodwill
on bargain purchases and is effective for financial statements issued for fiscal years beginning
after December 15, 2008 and will be adopted by us in the first quarter of fiscal year 2010. We do
not expect that the adoption will have a material impact on our financial condition or results of
operation.
In June 2009, the FASB established the FASB ASC as the single authoritative source for GAAP.
The ASC was effective for financial statements that cover interim and annual reports ended after
September 15, 2009. While not intended to change GAAP, the ASC significantly changed the way in
which the accounting literature is organized. Because the ASC completely replaced existing
standards, it affected the way GAAP is referenced by companies in their financial statements and
accounting policies. Our adoption and use of the ASC beginning with the Fiscal Year Ended September
30, 2009 did not have an impact on our financial position, results of operations or cash flows.
Fair Value of Financial Instruments
Carrying amounts of certain of our financial instruments, including cash equivalents, accounts
receivable and accounts payable approximate fair value due to their short maturities. Carrying
value of notes payable and long-term debt approximate fair values as they bear market rates of
interest. None of our financial instruments are held for trading purposes.
48
3. Net Income/(Loss) Allocable to Common Stockholders and Comprehensive Income/(Loss)
The following table is a calculation of net income or loss allocable to common stockholders
(in thousands) and comprehensive loss:
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Net loss available to common stockholders
|
|
$
|
(10,368
|
)
|
|
$
|
(7,111
|
)
|
Other comprehensive (loss)/gain foreign currency translations
|
|
|
|
|
|
|
|
|
Comprehensive income/(loss)
|
|
$
|
(10,368
|
)
|
|
$
|
(7,111
|
)
|
Earnings Per Share
The amounts in the table below are in thousands except for per share amounts.
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Numerator for basic and diluted income/(loss) per share:
|
|
|
|
|
|
|
|
|
Net income/(loss)
|
|
$
|
(10,368
|
)
|
|
$
|
(7,111
|
)
|
Denominator for basic earnings/(loss) per share weighted average shares
|
|
|
10,977,770
|
|
|
|
8,223,865
|
|
Basic
|
|
$
|
(0.94
|
)
|
|
$
|
(0.86
|
)
|
Diluted
|
|
|
N/A
|
|
|
|
N/A
|
|
As we had a net loss for the Fiscal Year Ended September 30, 2009 and the Fiscal Year
Ended September 30, 2008, potential common shares outstanding are excluded from the computation of
diluted net loss per share as their effect is anti-dilutive per standards prescribed in the ASC.
4. Accounts receivable
Accounts receivable consisted of the following:
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Gross patient accounts receivable
|
|
$
|
18,470
|
|
|
$
|
16,309
|
|
Reserves for bad debt
|
|
|
(3,842
|
)
|
|
|
(2,721
|
)
|
Reserves for contractual allowances
|
|
|
(9,737
|
)
|
|
|
(7,299
|
)
|
|
|
|
|
|
|
|
Patient accounts receivable, net
|
|
$
|
4,891
|
|
|
$
|
6,289
|
|
|
|
|
|
|
|
|
5. Other current assets
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Other current assets:
|
|
|
|
|
|
|
|
|
Deposits
|
|
$
|
120
|
|
|
$
|
119
|
|
Medical supplies
|
|
|
510
|
|
|
|
558
|
|
Other receivables
|
|
|
1,142
|
|
|
|
1,077
|
|
|
|
|
|
|
|
|
Total other assets
|
|
$
|
1,772
|
|
|
$
|
1,754
|
|
|
|
|
|
|
|
|
49
6. Property and equipment
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Property and equipment:
|
|
|
|
|
|
|
|
|
Computer hardware
|
|
$
|
92
|
|
|
$
|
76
|
|
Furniture, fixtures and medical equipment
|
|
|
4,458
|
|
|
|
3,369
|
|
Land
|
|
|
834
|
|
|
|
694
|
|
Buildings
|
|
|
13,340
|
|
|
|
8,851
|
|
Construction in progress
|
|
|
124
|
|
|
|
|
|
Leasehold improvements
|
|
|
944
|
|
|
|
944
|
|
Accumulated depreciation
|
|
|
(2,759
|
)
|
|
|
(1,657
|
)
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
17,033
|
|
|
$
|
12,277
|
|
|
|
|
|
|
|
|
The gross value of leased capital assets was $608,704 at September 30, 2009 and September
30, 2008, which are included in Property and Equipment on the Consolidated Balance
Sheet. The accumulated amortization on leased capital assets was $113,012 and $70,998 at September
30, 2009 and September 30, 2008, respectively. Amortization of capital lease assets is recognized
over the term of the lease on a straight line basis and included in depreciation expense.
7. Advance to Affiliated Entity
On April 28, 2006, we entered into an agreement with CSA II, LLC, a Cayman Islands company
controlled by Dennis M. Smith, one of our former directors. Under the terms of this agreement, we
advanced $333,333 to CSA II, LLC to finance the purchase of securities issued by Cross Shore
Acquisition Corporation, a Delaware corporation (
Cross Shore
), pursuant to a private
placement of $112,000,008 of Cross Shores securities completed on April 24, 2006. The securities
were listed on the Alternative Investment Market of the London Stock Exchange (the
AIM
)
and started trading on April 28, 2006 and ceased trading on the AIM on September 4, 2009. On
August 29, 2007, Cross Shore completed an acquisition by way of a reverse merger with Research
Pharmaceutical Services, Inc. (
RPS
) and changed its name to RPS as part of the
transaction. At September 30, 2007, CSA II, LLC held 167,420 common shares in RPS. In addition,
for consideration of $239.38, we purchased warrants to purchase 239,375 membership units of CSA II,
LLC, constituting 22.5% of the total issued limited liability company interests outstanding on a
fully diluted basis upon payment of the exercise price equal to $0.001 per unit. On May 24, 2006,
we received a partial repayment of this advance in the amount of $60,654, leaving a balance of
approximately $272,000 at Jan. 31, 2007. On June 12, 2006, we were reimbursed $75,000,
representing expenses associated with this advance. In October 2007, approximately $33,000 was
reimbursed to us, leaving a balance outstanding of $239,000. Mr. Smiths interests in RPS
represent less than 2% of the issued and outstanding share capital of RPS as of the date of the
completion of the reverse merger in August 2007. In light of the disruption in the overall economy
at the time, the volatility in the financial markets and restrictions applicable to the sale of RPS
common shares by CSA II, LLC, we have recorded a charge of $167,730 as a reserve against the
repayment of this advance during the year ended September 30, 2008. We recorded an additional
reserve $71,635 as of September 30, 2009.
8. Goodwill
On December 11, 2008 we acquired the remaining 49% interest in RHA not owned by us. The
purchase price exceeded the value of the underlying assets at that time and we recorded goodwill in
the amount of $208,942. Per standards set forth by the ASC we evaluated the value of goodwill at
September 30, 2009 and it was determined that this was fully impaired. Therefore, we recorded an
impairment charge of $208,942. Our valuation was based on the present value of future cash flows.
9. Bridge Financing
During the Fiscal Year Ended September 30, 2009, we entered into a bridge financing
transaction (the
Bridge Financing
) which was consummated in three separate closings. On
February 11, 2009, we completed the first closing of the Bridge Financing, a transaction in which
we entered into the following two promissory notes, each dated as of February 6, 2009: (i) a
convertible promissory note with SMP Investments, LLC, a Michigan limited liability company
(
SMP
), in the principal amount of $500,000 and (ii) a convertible promissory note with
Anthony J. Ciabattoni, Trustee of the Ciabattoni Living Trust, dated August 17, 2000
(
Ciabattoni
), in the principal amount of $1,000,000 (collectively, the
Bridge
Notes
). SMP and Ciabattoni are each a
Bridge Lender
and are collectively referred
to herein as the
Bridge Lenders
.
50
On February 11, 2009, in addition to the issuance of the Bridge Notes, we issued four warrants
to purchase Common Stock to the Bridge Lenders as follows: (i) a warrant issued to SMP for the
purchase of up to 375,000 shares of Common Stock at an initial exercise price of $0.50 per share
and exercisable for a period of three years from the date of issuance; (ii) a warrant issued to SMP
for the purchase of up to 250,000 shares of Common Stock at an initial exercise price of $0.75 per
share and exercisable for a period of three years from the date of issuance; (iii) a warrant issued
to Ciabattoni for the purchase of up to 750,000 shares of Common Stock at an initial exercise price
of $0.50 per share and exercisable for a period of three years from the date of issuance and (iv) a
warrant issued to Ciabattoni for the purchase of up to 500,000 shares of Common Stock at an initial
exercise price of $0.75 per share and exercisable for a period of three years from the date of
issuance.
Each Bridge Note became due and payable on November 6, 2009 (the
Bridge Financing
Maturity Date
); we extended these notes under the terms of the extension option. Per the
terms of the extension option, we are required to issue warrants to the Bridge Lenders to purchase
shares of Common Stock in the following amounts: (i) to SMP, 125,000 shares at a price of $0.50
per share, and 83,333 shares at a price of $0.75 per share and (ii) to Ciabattoni, 250,000 shares
at a price of $0.50 per share, and 166,667 shares at a price of $0.75 per share. On the Bridge
Financing Maturity Date, we will pay the unpaid principal of each Bridge Note, together with
accrued and unpaid interest of 16% per annum.
The Bridge Notes include a conversion feature allowing each Bridge Lender to convert all or
any portion of the entire unpaid principal and any unpaid accrued interest at the date upon which
the conversion is to be effected into a number of shares of Common Stock, determined by dividing
the sum of the unpaid principal and unpaid accrued interest at the conversion date by the
conversion price in effect at the conversion date. The initial conversion price is $0.625, which
price is adjustable as set forth in the Notes.
The Bridge Notes include a provision granting the Bridge Lenders, to the extent that the
Bridge Lenders holding notes representing a majority of the aggregate outstanding principal amount
of the Bridge Notes agree, demand registration rights with respect to the resale of the shares of
Common Stock that would be issuable upon conversion of the Bridge Notes, which rights vest thirty
six (36) months after the date of issuance of the Bridge Notes. The registration statement would
be prepared by us at our expense and filed on Form S-1 or other appropriate form and, once declared
effective, allow the registered securities to be sold on a continuous basis and we will keep the
registration statement continuously effective until certain conditions are met which would allow us
to stop maintaining its effectiveness.
On March 3, 2009, we completed the second closing of the Bridge Financing, a transaction in
which we entered into nine (9) promissory notes, each dated as of March 3, 2009, in the aggregate
principal amount of $500,000 (the
Second Bridge Notes
), with various investors (the
Second Bridge Lenders
).
Each Second Bridge Note became due and payable on December 3, 2009 (the
Second Bridge
Maturity Date
); provided, however, that each of the Second Bridge Notes contained an extension
option to extend such note for an additional three months at our discretion. The Second Bridge
Notes include a conversion feature allowing each Second Bridge Lender to convert all or any portion
of the entire unpaid principal and any unpaid accrued interest at the date upon which the
conversion is to be effected into a number of shares of Common Stock determined by dividing the sum
of the unpaid principal and unpaid accrued interest at the conversion date by the conversion price
in effect at the conversion date. The initial conversion price is $0.625, which price is adjustable
as set forth in the Second Bridge Notes. We extended the Second Bridge Notes under the terms of the
extension option. By exercising this option, we are required to issue warrants to the Second
Bridge Lenders to purchase an aggregate of 208,333 shares of our Common Stock, 125,000 shares of
which will be issued at an exercise price of $0.50 per share and 83,333 shares of which will be
issued at an exercise price of $0.75 per share. The new due date for the Second Bridge Notes
pursuant to the extension is March 3, 2010.
The Second Bridge Notes also include a provision granting the Second Bridge Lenders, to the
extent holders of a majority of the aggregate outstanding principal amount of the Bridge Notes and
Second Bridge Notes agree, demand registration rights with respect to the resale of the shares of
Common Stock that would be issuable upon conversion of the Second Bridge Notes, which rights vest
thirty-six (36) months after the date of issuance of the Second Bridge Notes. The registration
statement would be prepared by us at our expense and filed on Form S-1 or other appropriate form
and, once declared effective, allow the registered securities to be sold on a continuous
basis and we will keep the registration statement continuously effective until certain
conditions are met which would allow us to stop maintaining its effectiveness.
51
On April 14, 2009, we completed the third closing of the Bridge Financing, a transaction in
which we entered into the following three (3) promissory notes: (i) a convertible promissory note,
dated as of March 31, 2009, with Frank Darras, Trustee of the Darras Family Trust
(
Darras
), in the principal amount of $100,000 (the
Darras Note
); (ii) a
convertible promissory note, dated as of March 31, 2009, with SFV, Inc., a California corporation
(
SFV
), in the principal amount of $50,000 (the
SFV Note
) and (iii) a
convertible promissory note, dated as of April 14, 2009, with NFS LLC/FMTC Rol IRA FBO Neal Katz
(
Katz
), in the principal amount of $50,000 (the
Katz Note
) (each, a
Third
Bridge Note
and collectively, the
Third Bridge Notes
). Darras, SFV and Katz are
each a
Third Bridge Lender
and are collectively referred to herein as the
Third
Bridge Lenders
.
The Darras Note and the SFV Note became due and payable on December 31, 2009 and the Katz Note
becomes due and payable on January 14, 2010 (collectively, the
Third Bridge Maturity
Dates
); provided, however, that the term of each of the Third Bridge Notes contained an
extension option to extend such notes for an additional three months at our discretion. We
extended the Darras Note and the SFV Note under the terms of the respective options, and therefore
are obligated to issue warrants to Darras and SFV as follows: (i) Darras 25,000 shares at an
exercise price of $0.50 per share, and 16,667 shares at an exercise price of $0.75 per share; (ii)
SFV 12,500 shares at an exercise price of $0.50 per share, and 8,333 shares at an exercise price
of $0.75 per share. In the event we exercise the extension option with respect to the Katz Note,
we will be required to issue warrants to Katz as follows: 12,500 shares at an exercise price of
$0.50 per share, and 8,333 shares at an exercise price of $0.75 per share. The new due date for
the SFV Note and the Darras Note is March 31, 2010. It is anticipated that the Katz Note, due on
January 12, 2010, will also be extended under the terms of the option.
The Third Bridge Notes include a conversion feature allowing each Third Bridge Lender to
convert all or any portion of the entire unpaid principal and any unpaid accrued interest at the
date upon which the conversion is to be effected into a number of shares of Common Stock,
determined by dividing the sum of the unpaid principal and unpaid accrued interest at the
conversion date by the conversion price in effect at the conversion date. The initial conversion
price is $0.625, which price is adjustable as set forth in the Third Bridge Notes.
The Third Bridge Notes include a provision granting the Third Bridge Lenders, to the extent
the holders of a majority of the aggregate outstanding principal amount of the notes issued in the
Bridge Financing agree, demand registration rights with respect to the resale of the shares of
Common Stock that would be issuable upon conversion of the Third Bridge Notes, which rights vest
thirty-six (36) months after the date of issuance of the Third Bridge Notes. The registration
statement would be prepared by us at our expense and filed on Form S-1 or other appropriate form
and, once declared effective, allow the registered securities to be sold on a continuous basis and
we will keep the registration statement continuously effective until certain conditions are met
which would allow us to stop maintaining its effectiveness.
The fair value of the warrants issued in conjunction with the convertible notes issued under
the Bridge Financing amounted to $932,000. The beneficial conversion feature associated with the
convertible notes totaled $253,000. Both the fair value of the warrants and the beneficial
conversion feature will be amortized over the term of the loans. Amortization for the Fiscal Year
September 30, 2009 was $952,000.
Sales of Unregistered Equity Securities
During the transition period ended September 30, 2007 (the
Transition Period Ended
September 30, 2007
), we sold and issued an aggregate of 1,175 shares of 5-A Preferred and
warrants to purchase an aggregate of 705,000 shares of Common Stock, pursuant to Series 5-A
Preferred Stock and Warrant Purchase Agreements to various investors through private placements.
Each investor represented to us in writing that it was an accredited investor, as that term is
defined in Rule 501 of Regulation D promulgated under the Securities Act.
52
On May 15, 2008, we sold and issued 25 shares of 5-A Preferred to an investor, pursuant to a
Series 5-A Preferred Stock and Warrant Purchase Agreement. Such investor represented to us in
writing that he was an accredited investor, as that term is defined in Rule 501 of Regulation D
promulgated under the Securities Act. On May 15, 2008, in connection with this issuance, we also
issued warrants to purchase 15,000 shares of our Common
Stock to an investor, pursuant to the same Series 5-A Preferred Stock and Warrant Purchase
Agreement. These warrants are exercisable for a period of 2 years at an exercise price of $0.50
per share. Such investor represented to us in writing that he was an accredited investor, as
that term is defined in Rule 501 of Regulation D promulgated under the Securities Act.
In May 2009, we accepted warrant exercises in the amount of 60,000 shares of Common Stock for
an aggregate amount of $30,000 from one investor, who represented to us in writing that he is an
accredited investor, as that term is defined in Rule 501(a) of Regulation D promulgated under the
Securities Act. The shares were issued pursuant to the exercise of warrants originally issued on
March 23, 2007, in connection with a private placement of our 5-A Preferred to various investors.
In September 2009, we accepted warrant exercises in the amount of 60,000 shares of Common
Stock for an aggregate amount of $30,000 from two investors, each of whom represented to us in
writing that he is an accredited investor, as that term is defined in Rule 501(a) of Regulation D
promulgated under the Securities Act. The shares were issued pursuant to the exercise of warrants
originally issued on August 10, 2007 and March 8, 2007 in connection with a private placement of
our 5-A Preferred to various investors.
10. Long-term Debt
Long-term debt consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
September 30, 2009
|
|
|
September 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Note payable,
secured by
equipment,
$4,558 payable
monthly,
including 8.25%
interest through
September 2011
|
|
$
|
89
|
|
|
$
|
139
|
|
Note payable,
secured by
equipment,
$13,456 payable
monthly,
including 8.75%
interest
|
|
|
|
|
|
|
249
|
|
8% Notes payable
to prior
shareholders for
stock
repurchases,
eleven notes
outstanding at
September 30,
2009, maturity
dates ranging
from 2008
through 2017
|
|
|
260
|
|
|
|
307
|
|
Note payable,
secured by
equipment,
$2,825 payable
monthly,
including 13.6%
interest through
April 2010
|
|
|
14
|
|
|
|
45
|
|
Note payable
secured by real
estate, $27,513
payable monthly,
including
interest based
on Wall Street
Journal prime
plus 2% adjusted
quarterly, floor
of 7%, rate is
currently 7%,
matures November
2028
|
|
|
3,453
|
|
|
|
|
|
Note payable
secured by real
estate, $34,144
payable monthly,
including
interest based
on Wall Street
Journal prime
plus 2% adjusted
quarterly, floor
of 7%, rate is
currently 7%,
matures November
2024
|
|
|
3,513
|
|
|
|
|
|
Note payable
secured by real
estate, $9,327
payable monthly,
including
interest based
on Wall Street
Journal prime
plus 2% adjusted
quarterly, floor
of 7%, rate is
currently 7%,
matures November
2028
|
|
|
1,164
|
|
|
|
|
|
Note payable,
secured by
equipment,
$2,660 payable
monthly
including 5.3%
interest through
March 2013
|
|
|
99
|
|
|
|
|
|
Note payable, 5%
interest payable
quarterly,
matures on or
before December
11, 2011
|
|
|
1,500
|
|
|
|
|
|
Capitalized
lease
obligations
six leases for
buildings and
medical
equipment with
imputed interest
rates ranging
from 4% to
17.2%, maturing
at various dates
through 2013
|
|
|
300
|
|
|
|
515
|
|
Note payable,
secured by
equipment,
$2,413 payable
monthly,
including 7.04%
interest through
March 2011
|
|
|
39
|
|
|
|
|
|
Note payable,
secured by
equipment,
$7,530 payable
monthly,
including 6.75%
interest through
June 15, 2013
|
|
|
298
|
|
|
|
|
|
Note payable,
secured by
equipment,
$5,116 payable
monthly,
including 7.05%
interest through
March 2011
|
|
|
83
|
|
|
|
|
|
Note payable,
16% interest,
matures on or
before December
3, 2012, face
value $1.5
million less
beneficial
conversion
feature and debt
discount of $84,000
|
|
|
1,416
|
|
|
|
|
|
Note payable, non-interest bearing
purchase obligation, annual payments of
$50,000, August 2010, $33,333, August
2011, $33,333, August 2012 and $33,334,
August 2013
|
|
|
150
|
|
|
|
|
|
Notes
payable, unsecured, 11.25% interest, matures October 2012
|
|
|
1,027
|
|
|
|
|
|
Note payable, secured by equipment, $1,567
payable monthly, including 6.75% interest
through July 2013
|
|
|
64
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
13,469
|
|
|
|
1,255
|
|
Less current maturities of long-term debt
|
|
|
(1,028
|
)
|
|
|
(164
|
)
|
|
|
|
|
|
|
|
Total long-term debt
|
|
$
|
12,441
|
|
|
$
|
1,091
|
|
|
|
|
|
|
|
|
53
The following chart shows scheduled principal payments due on long-term debt for the next
five years and thereafter:
|
|
|
|
|
Fiscal Year Ended September 30,
|
|
Payments
|
|
|
|
|
|
|
2010
|
|
$
|
1,028
|
|
2011
|
|
|
985
|
|
2012
|
|
|
2,399
|
|
2013
|
|
|
2,083
|
|
2014 and thereafter
|
|
|
6,974
|
|
|
|
|
|
Total
|
|
$
|
13,469
|
|
|
|
|
|
11. Minority Interests
Minority interest attributable to the equity interests in RHA and the San Diego ambulatory
surgical centers not held by us and recorded during the Fiscal Year Ended September 30, 2009
amounted to $177,000. Minority interests resulting from operating losses attributable to the
equity interests in RHA and the San Diego ambulatory surgical centers not held by us amounted to
$1.4 million in the Fiscal Year Ended September 30, 2008.
On December 11, 2008, we entered into a Membership Interest Purchase Agreement with RHA,
pursuant to which RHA repurchased 49% of the issued and outstanding voting membership units of RHA
for an aggregate purchase price of $1,800,000. In connection with the repurchase, RHA issued a
promissory note and we entered into a limited guaranty agreement of RHAs obligations under the
promissory note.
During the Fiscal Year Ended September 30, 2009, we entered into a series of equity
transactions at our San Diego ambulatory surgical center, which resulted in an increase in minority
interests held in the San Diego ambulatory surgical center. Minority interests increased from 39% at
September 30, 2008 to 65% at September 30, 2009. However, we have a 3:2 voting majority on the
board of managers, which gives us control of the management decisions of the center, and the San Diego ambulatory surgical center is still subject to consolidation.
54
12. Warrants
Outstanding exercisable warrants consisted of the following as of September 30, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Remaining
|
|
|
|
|
|
|
|
Description
|
|
Life
|
|
|
Exercise Price
|
|
|
Warrants
|
|
|
|
September 30, 2007 Preferred Stock Series 5-A warrants issued to
investor
|
|
1 year
|
|
$
|
0.50
|
|
|
|
90,000
|
|
September 30, 2007 warrants issued to advisory board
|
|
1 year
|
|
|
0.45
|
|
|
|
275,000
|
|
September 30, 2008 warrants issued in connection with notes payable
|
|
2 years
|
|
|
0.31
|
|
|
|
1,980,000
|
|
September 30, 2008 warrants issued in connection with notes payable
|
|
2 years
|
|
|
0.50
|
|
|
|
1,237,500
|
|
September 30, 2008 Preferred Stock Series 5-A warrants issued to
investor and placement agent
|
|
2 years
|
|
|
0.50
|
|
|
|
2,736,000
|
|
September 30, 2008 Preferred Stock Series 6-A warrants issued to
investor
|
|
2 years
|
|
|
0.50
|
|
|
|
3,589,200
|
|
September 30, 2008 Preferred Stock Series 5-A warrants issued to
placement agent
|
|
4 years
|
|
|
0.50
|
|
|
|
436,250
|
|
September 30, 2008 warrants issued to advisory board
|
|
2 years
|
|
|
0.45
|
|
|
|
714,285
|
|
February 6, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.50
|
|
|
|
1,125,000
|
|
February 6, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.75
|
|
|
|
750,000
|
|
March 3, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.50
|
|
|
|
375,000
|
|
March 3, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.75
|
|
|
|
250,000
|
|
March 16, 2009 warrants issued to advisory board
|
|
3 years
|
|
|
0.63
|
|
|
|
41,667
|
|
March 31, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.50
|
|
|
|
112,500
|
|
March 31, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.75
|
|
|
|
75,000
|
|
April 14, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.50
|
|
|
|
37,500
|
|
April 14, 2009 warrants issued in connection with notes payable
|
|
3 years
|
|
|
0.75
|
|
|
|
25,000
|
|
June 8, 2009 Preferred Stock Series 6-A warrants issued to investor
|
|
3 years
|
|
|
0.50
|
|
|
|
210,000
|
|
June 10, 2009 warrants issued to Medical Advisory Board
|
|
3 years
|
|
|
0.63
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
14,109,902
|
|
Warrants Issued Pursuant to the Sale and Issuance of Series 5-A Convertible Preferred Stock
During the fiscal year ended January 31, 2006 (the
Fiscal Year Ended January 31,
2006
), pursuant to the sale and issuance of 1,478 shares of Series 5-A Convertible Preferred
Stock, par value $0.01 per share (the
5-A Preferred
), we issued warrants to purchase an
aggregate of 991,800 shares of Common Stock to a group of investors, including an affiliate of our
Chief Executive Officer and our then Chief Financial Officer, Dennis M. Smith, and Mr. Parker, who
currently serves as a director. Each investor represented to us in writing to that it was an
accredited investor, as that term is defined in Rule 501 of Regulation D promulgated under the
Securities Act. These warrants have an exercise price of $0.50 per share. 200 shares of 5-A
Preferred and warrants to purchase 120,000 shares were subsequently cancelled. Of the remaining
warrants, 616,800 were exercised during the Fiscal Year Ended September 30, 2008, and 255,000
expired unexercised.
During the Fiscal Year Ended September 30, 2008, pursuant to the issuance of 6,085 shares of
5-A Preferred, we issued warrants to purchase an aggregate of 3,651,000 shares of Common Stock to a
group of investors. Each investor represented to us in writing that it was an accredited
investor, as that term is defined in Rule 501 of Regulation D promulgated under the Securities
Act. These warrants have an exercise price of $0.50 per share.
55
Warrants Issued Pursuant to the Sale and Issuance of Series 6-A Convertible Preferred Stock
During the Fiscal Year Ended September 30, 2008, pursuant to the sale and issuance of 4,607
shares of 6-A Preferred, we issued warrants to purchase an aggregate of 2,764,000 shares of Common
Stock to a group of investors. Each investor represented to us in writing that it was an
accredited investor, as that term is defined in Rule 501 of Regulation D promulgated under the
Securities Act. These warrants have an exercise price of $0.50 per share.
During the Fiscal Year Ended September 30, 2009, pursuant to the sale and issuance of 350
shares of 6-A Preferred, we issued warrants to purchase an aggregate of 210,000 shares of Common
Stock to an investor. The investor represented to us in writing that he is an accredited
investor, as that term is defined in Rule 501(a) of Regulation D promulgated under the Securities
Act. These warrants have an exercise price of $0.50 per share.
Warrants Issued Pursuant to the Individuals for Advisory Board Participation
During the Fiscal Year Ended January 31, 2006, we issued warrants to purchase 727,500 shares
of our Common Stock to individuals for participation on our Advisory Board. All warrants were
issued with Black-Scholes assumptions of 99% volatility, $0.35 share price, risk-free interest
rates of 4.1% and exercise price of $0.35. The warrants had a calculated value of $161,001,
recognized over the two-year vesting period. Of these warrants, 302,500 were exercised during the
Fiscal Year Ended September 30, 2008 and 425,000 expired unexercised.
During the Fiscal Year Ended January 31, 2007, we issued warrants to purchase 50,000 shares of
our Common Stock to an individual for participation on our Advisory Board. These warrants were
issued with Black-Scholes assumptions of 212% volatility, $0.42 share price, risk-free interest
rates of 4.5% and exercise price of $0.45. The warrants had a calculated value of $20,000,
recognized over the two-year vesting period. All of these warrants expired unexercised in December
2008.
During the Transition Period Ended September 30, 2007, we issued warrants to purchase 350,000
shares of our Common Stock to individuals for participation on our Advisory Board. These warrants
were issued with Black-Scholes assumptions of 52% volatility, $0.26 share price, risk-free interest
rates of 3.13% and exercise price of $0.45. The warrants had a calculated value of $13,000,
recognized over the two-year vesting period. As of September 30, 2009, 225,000 of these warrants
were in the process of being exercised and as of the filing date certain paperwork has not been
completed to affect the issuance of the shares.
During the Fiscal Year Ended September 30, 2008, we issued warrants to purchase 714,285 shares
of our Common Stock to Mr. Brian Potiker in consideration for his service on our Advisory Board.
These warrants are exercisable for a period of 2 years at an exercise price of $0.45 per share.
Mr. Potiker represented to us in writing that he was an accredited investor, as that term is
defined in Rule 501 of Regulation D promulgated under the Securities Act. These warrants were
issued with Black-Scholes assumptions of 101.3% volatility, $0.33 share price, risk-free interest
rates of 1.6% and exercise price of $0.45. The warrants had a calculated value of $71,234,
recognized over the two-year vesting period. As of September 30, 2008, all of these warrants
remained outstanding. These warrants were still outstanding as of September 30, 2009 and were
exercised on October 30, 2009.
During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 125,000 shares
of our Common Stock to individuals for participation on our Advisory Board. These warrants were
issued with Black-Scholes assumptions of 152% volatility, $0.50 share price, risk-free interest
rates of 1.39% and an exercise price of $0.625. The warrants had a calculated value of $50,000,
recognized over the two-year vesting period. As of September 30, 2009, all of these warrants
remained outstanding.
During the Fiscal Year Ended September 30, 2009, we issued warrants to purchase 150,000 shares
of our Common Stock to a member of the newly created Medical Advisory Board. These warrants were
issued with Black Scholes assumptions of 152% volatility, $0.52 share price, risk-free interest
rates of 2.0% and an exercise price of $0.625. The warrants had a calculated value of $62,000,
recognized over the one-year vesting period. As of September 30, 2009, all of these warrants
remain outstanding.
56
Other Warrant Issuances
In connection with the sale and issuance of promissory notes to finance the purchase of RHA on
October 29, 2007 during the Fiscal Year Ended September 30, 2008, we issued two groups of warrants
to the purchasers of these promissory notes (the
Holders
). The first group of warrants, a
certain number of which were issued to each of the Holders, allows the Holders to purchase up to an
aggregate of 1,980,000 shares of our Common Stock at an initial exercise price of $0.3125 per
share, exercisable for a period of three years from the date of issuance. The warrants were issued
with Black-Scholes assumptions of 52% volatility, $0.29 share price, risk-free interest rates of
3.13% and exercise price of $0.3125. The warrants had a calculated value of $203,648, recognized
over the vesting period. The second group of warrants, a certain number of which were issued to
each of the Holders, allows the Holders to purchase up to an aggregate of 1,237,500 shares of our
Common Stock at an initial exercise price of $0.50 per share, exercisable for a period of three
years from the date of issuance. The warrants were issued with Black-Scholes assumptions of 52%
volatility, $0.29 share price, risk-free interest rates of 3.13% and exercise price of $0.50. The
warrants had a calculated value of $76,000, to be recognized over the vesting period. Each of the
Holders represented to us in writing that it was an accredited investor, as that term is defined
in Rule 501 of Regulation D promulgated under the Securities Act. As of September 30, 2009, all of
these warrants remained outstanding.
During the Fiscal Year Ended September 30, 2008, we issued warrants to purchase 397,250 shares
of our Common Stock to Waveland Capital, LLC in connection with their service as placement agent in
the private placement of shares of our 5-A Preferred and 6-A Preferred sold and issued during the
Fiscal Year Ended September 30, 2008. These warrants are exercisable for a period of 5 years at an
exercise price of $0.50 per share. Waveland Capital, LLC represented to us in writing that it is
an accredited investor, as that term is defined in Rule 501 of Regulation D promulgated under the
Securities Act. As of September 30, 2009, all of these warrants remained outstanding. The warrants
had a calculated value of $123,000, netted against the proceeds of the above-described private
placement.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
Number of Shares of Common Stock
|
|
|
Exercise Price Per Share
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year
|
|
|
Year
|
|
|
Year
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding
at beginning of
the period
|
|
|
11,795,035
|
|
|
|
2,868,700
|
|
|
$
|
0.46
|
|
|
$
|
0.48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issued
|
|
|
3,235,000
|
|
|
|
10,744,035
|
|
|
$
|
0.60
|
|
|
$
|
0.46
|
|
Reinstated
|
|
|
166,400
|
|
|
|
|
|
|
$
|
0.48
|
|
|
|
|
|
Exercised
|
|
|
525,000
|
|
|
|
970,300
|
|
|
$
|
0.50
|
|
|
$
|
0.46
|
|
Cancelled or expired
|
|
|
266,000
|
|
|
|
847,400
|
|
|
$
|
0.48
|
|
|
$
|
0.47
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding
at end of the
period
|
|
|
14,405,435
|
|
|
|
11,795,035
|
|
|
$
|
0.49
|
|
|
$
|
0.46
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13. Commitments and Contingencies
We lease our operating facilities under non-cancelable operating leases that expire at various
dates through 2013. We also lease certain equipment under capital leases. Rent expense was $1.6
million in the Fiscal Year Ended September 30, 2009 and $1.0 million in the Fiscal Year Ended
September 30, 2008.
57
Future minimum lease obligations at September 30, 2009 for those leases having an initial or
remaining non-cancelable lease term in excess of one year, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
|
|
|
Capital Lease
|
|
|
|
|
Year Ending September 30,
|
|
Leases
|
|
|
Obligations
|
|
|
Total
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
|
$
|
1,243
|
|
|
$
|
93
|
|
|
$
|
1,336
|
|
2011
|
|
|
1,556
|
|
|
|
98
|
|
|
|
1,654
|
|
2012
|
|
|
1,024
|
|
|
|
78
|
|
|
|
1,102
|
|
2013
|
|
|
807
|
|
|
|
31
|
|
|
|
838
|
|
2014
|
|
|
345
|
|
|
|
|
|
|
|
345
|
|
2015 and thereafter
|
|
|
296
|
|
|
|
|
|
|
|
296
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,271
|
|
|
$
|
300
|
|
|
$
|
5,571
|
|
We have other contractual obligations that consist primarily of obligations to purchase goods
or services that are enforceable and legally binding on us. These obligations specify all
significant terms and are not cancellable without a penalty. Our obligations primarily relate to
software licensing, clinical coding, medical waste removal, equipment maintenance and linen service
(see Disclosure of Contractual Obligations in Item 7 of this Form 10-K).
We are not aware of any legal proceedings against us.
14. Preferred Stock
Non-Redeemable Preferred Stock and Redeemable Preferred Stock
Effective February 24, 2000, we authorized 5,000,000 shares of preferred stock. The preferred
stock is divided into several series. The Series 1-A Convertible Preferred Stock consists of
2,802,000 shares, the Series 2-A Convertible Preferred Stock consists of 1,672,328 shares, the
Series 3-A Convertible Preferred Stock consists of 500,000 shares, the Series 4-A Preferred
consists of 25,000 shares, the 5-A Preferred consists of 9,000 shares and the 6-A Preferred
consists of 5,000 shares. Following completion of the sale of our BPO operations in Asia, no
Series 3-A Preferred Stock or Series 4-A Preferred Stock remained outstanding and no shares of
Series 3-A Preferred Stock or Series 4-A Preferred Stock were subsequently issued. During the
Fiscal Year Ended September 30, 2008, we began issuing preferred stock designated as 6-A Preferred.
Series 1-A Convertible Preferred Stock, Series 2-A Convertible Preferred Stock, 5-A Preferred and
Series 6-A Preferred Stock outstanding as of end of the Fiscal Year Ended September 30, 2009 and
the Fiscal Year Ended September 30, 2008 is described below.
Series 1-A Convertible Preferred Stock
As of the end of the Fiscal Year Ended September 30, 2009 and the Fiscal Year Ended September
30, 2008, we had 67,600 shares of Series 1-A Convertible Preferred Stock outstanding with an
aggregate liquidation value of $169,000. In the event of any liquidation or dissolution, either
voluntary or involuntary, the holders of the Series 1-A Convertible Preferred Stock shall be
entitled to receive, prior and in preference to any distribution of any of the assets or surplus
funds, to the holders of the Common Stock by reason of their ownership thereof, a preference amount
per share consisting of the sum of (A) $2.50 for each outstanding share of Series 1-A Convertible
Preferred Stock and (B) an amount equal to declared but unpaid dividends on such shares, if any.
Each share of Series 1-A Convertible Preferred Stock shall be convertible at any time after the
date of issuance of such shares, into such number of fully paid shares of Common Stock as is
determined by dividing the original issue price by the then-applicable conversion price in effect
on the date the certificate evidencing such share is surrendered for conversion. Each share of
Series 1-A Convertible Preferred Stock, subject to the surrendering of the certificates of the
Series 1-A Convertible Preferred Stock, shall be automatically converted into shares of Common
Stock at the then-effective conversion price, immediately upon closing of a public offering of our
Common Stock with aggregate gross proceeds of at least $10.0 million and a per share price of at
least $5.00, or at the election of the holders of a majority of the outstanding shares of Series
1-A Convertible Preferred Stock. The holder of each share of Series 1-A Convertible Preferred
Stock has the right to that number of votes equal to the number of shares of Common Stock
which would be issued upon conversion of the Series 1-A Convertible Preferred Stock. Holders
of the Series 1-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared
by our Board of Directors, of $0.20 per share annually. Under certain circumstances, such as stock
splits or issuances of Common Stock at a price less than the issuance price of the Series 1-A
Convertible Preferred Stock, these shares are subject to stated Series 1-A Convertible Preferred
Stock conversion price adjustments. There are currently three holders of Series 1-A Convertible
Preferred Stock.
58
Series 2-A Convertible Preferred Stock
As of the end of the Fiscal Year Ended September 30, 2009 and the Fiscal Year Ended September
30, 2008, we had 3,900 shares of Series 2-A Convertible Preferred Stock outstanding with an
aggregate liquidation value of $24,999. In the event of any liquidation or dissolution, either
voluntary or involuntary, the holders of the Series 2-A Convertible Preferred Stock shall be
entitled to receive, prior and in preference to any distribution of any of the assets or surplus
funds, to the holders of the Common Stock by reason of their ownership thereof, a preference amount
per share consisting of the sum of (A) $6.41 for each outstanding share of Series 2-A Convertible
Preferred Stock and (B) an amount equal to declared but unpaid dividends on such shares, if any.
Each share of Series 2-A Convertible Preferred Stock shall be convertible at any time after the
date of issuance of such shares, into such number of fully paid shares of Common Stock as is
determined by dividing the original issue price by the then-applicable conversion price in effect
on the date the certificate evidencing such share is surrendered for conversion. Each share of
Series 2-A Convertible Preferred Stock, subject to the surrendering of the certificates of the
Series 2-A Convertible Preferred Stock, shall be automatically converted into shares of Common
Stock at the then-effective conversion price, immediately upon closing of a public offering of our
Common Stock with aggregate gross proceeds of at least $20.0 million and a per share price of at
least $13.00, or at the election of the holders of a majority of the outstanding shares of Series
2-A Convertible Preferred Stock. The holder of each share of Series 2-A Convertible Preferred
Stock has the right to that number of votes equal to the number of shares of Common Stock which
would be issued upon conversion of the Series 2-A Convertible Preferred Stock. Holders of the
Series 2-A Convertible Preferred Stock are entitled to non-cumulative dividends, if declared by our
Board of Directors, of $0.20 per share annually. Under certain circumstances, such as stock splits
or issuances of Common Stock at a price less than the issuance price of the Series 2-A Convertible
Preferred Stock, these shares are subject to stated Series 2-A Convertible Preferred Stock
conversion price adjustments. There is currently one holder of Series 2-A Convertible Preferred
Stock.
Series 5-A Convertible Preferred Stock
Under the terms of the Series 5-A Preferred Stock and Warrant Purchase Agreement, in the event
of any liquidation or dissolution, either voluntary or involuntary, the holders of the 5-A
Preferred shall be entitled to receive,
pari passu
with the 6-A Preferred, after distribution of
all amounts due to the holders of the Series 1-A Convertible Preferred Stock and Series 2-A
Convertible Preferred Stock, but prior and in preference to any distribution of any of the assets
or surplus funds to the holders of the Common Stock by reason of their ownership thereof, a
preference amount per share consisting of the sum of (A) the original issue price, which initially
is $1,000 (as adjusted for stock splits, stock dividends, combinations and the like) plus (B) an
amount equal to all declared but unpaid dividends on such shares, if any. Each share of 5-A
Preferred shall be convertible at any time after the date of issuance of such shares, into such
number of fully paid shares of Common Stock as is determined by dividing the original issue price
by the then-applicable conversion price in effect on the date the certificate evidencing such share
is surrendered for conversion. Each share of 5-A Preferred, subject to the surrendering of the
certificates of the 5-A Preferred, shall be automatically converted into shares of Common Stock at
the then-applicable conversion price, upon the election of the holders of not less than a majority
of the outstanding shares of 5-A Preferred electing to effect such conversion. The holder of each
share of 5-A Preferred shall have the right to that number of votes equal to the number of shares
of Common Stock which would be issued upon conversion of the 5-A Preferred. Holders of the 5-A
Preferred are entitled to non-cumulative dividends, if declared by our Board of Directors, of $40
per share annually. Under certain circumstances, such as stock splits or issuances of Common Stock
at a price less than the issuance price of the Series 5-A Convertible Preferred Stock, these shares
are subject to stated Series 5-A Convertible Preferred Stock conversion price adjustments. Shares
of 5-A Preferred had an initial conversion price of $0.3125 per share.
59
As of September 30, 2009 and September 30, 2008, there were 8,987 shares 5-A Preferred
outstanding, convertible into 28,758,400 common shares with an aggregate liquidation value of $9.0
million and an aggregate redemption value of $9.4 million. There are currently 62 holders of 5-A
Preferred.
Series 6-A Convertible Preferred Stock
On March 31, 2008, we entered into a Series 6-A Preferred Stock and Warrant Purchase Agreement
(the
6-A Purchase Agreement
), pursuant to which we issued and sold 3,585 shares of newly
created class of convertible preferred stock, known as the 6-A Preferred and warrants to purchase
an aggregate of 2,151,000 shares of Common Stock to a group of investors. Net proceeds from the
issuance totaled $3.3 million. As of September 30, 2009, none of the shares or warrants from the
March 31, 2008 issuance have been cancelled.
Under the terms of the 6-A Purchase Agreement, in the event of any liquidation or dissolution,
either voluntary or involuntary, the holders of the 6-A Preferred shall be entitled to receive,
pari passu
with the 5-A Preferred, after distribution of all amounts due to the holders of the
Series 1-A Convertible Preferred Stock and Series 2-A Convertible Preferred Stock, but prior and in
preference to any distribution of any of the assets or surplus funds to the holders of the Common
Stock by reason of their ownership thereof, a preference amount per share consisting of the sum of
(A) the original issue price, which initially is $1,000 (as adjusted for stock splits, stock
dividends, combinations and the like) plus (B) an amount equal to all declared but unpaid dividends
on such shares, if any. The holders of 6-A Preferred shall be entitled to receive dividends
pari
passu
with the 5-A Preferred stockholders. Each share of 6-A Preferred shall be convertible at any
time after the date of issuance of such shares, into such number of fully paid shares of Common
Stock as is determined by dividing the original issue price by the then-applicable conversion price
in effect on the date the certificate evidencing such share is surrendered for conversion. Each
share of 6-A Preferred, subject to the surrendering of the certificates of the 6-A Preferred, shall
be automatically converted into shares of Common Stock at the then-applicable conversion price,
upon the election of the holders of not less than a majority of the outstanding shares 6-A
Preferred electing to effect such conversion. The holder of each share of 6-A Preferred shall have
the right to that number of votes equal to the number of shares of Common Stock, which would be
issued upon conversion of the 6-A Preferred. Holders of the 6-A Preferred are entitled to
non-cumulative dividends, if declared by our Board of Directors, of $40 per share annually. Under
certain circumstances, such as stock splits or issuances of Common Stock at a price less than the
issuance price of the Series 6-A Convertible Preferred Stock, these shares are subject to stated
Series 6-A Convertible Preferred Stock conversion price adjustments. Shares of 6-A Preferred have
an initial conversion price of $0.3125 per share.
As of September 30, 2009, there were 4,957 shares of 6-A Preferred outstanding, convertible
into 15,862,400 common shares with an aggregate liquidation value of $5.0 million and an aggregate
redemption value of $5.9 million. As of September 30, 2008, there were 4,607 shares of 6-A
Preferred outstanding, convertible into 14,742,400 common shares with an aggregate liquidation
value of $4.6 million and an aggregate redemption value of $5.5 million. There are currently 42
holders of 6-A Preferred.
Series B Preferred Stock issued by subsidiary
As noted above, on December 2, 2005, through newly created indirect subsidiaries, we entered
into two Surgical Center Acquisition Agreements to acquire from Surgical Ventures, Inc., a
California corporation, a controlling interest in the San Diego ambulatory surgical centers. These
acquisitions were completed on November 16, 2006.
This preferred stock is exchangeable into shares of our Common Stock under certain terms and
conditions, at $2.00 per common share. Additionally, this preferred stock became redeemable at the
option of the holder under certain terms and conditions, by notice to the subsidiaries, as of March
2009. At September 30, 2008, the total shares of Series B Preferred Stock outstanding was 19,990
shares. During the Fiscal Year Ended September 30, 2009, the Series B Preferred Stock was exchanged
for 2,384,250 shares of our Common Stock. Accordingly, there are no Series B shares outstanding at
September 30, 2009.
60
Related Party Interests in Preferred Stock
Our executive officers and affiliates held no shares of either Series 1-A Convertible
Preferred Stock or Series 2-A Convertible Preferred Stock as of September 30, 2009 and September
30, 2008. They held 2,235 shares of 5-A Preferred and 1600 shares of 6-A Preferred as of September
30, 2008. They held 2,360 shares of 5-A Preferred and 1,600 shares of 6-A Preferred as of
September 30, 2009.
15. Stock Options
Stock-Based Compensation
Options to purchase 1,839,390 shares of our Common Stock were granted in the Fiscal Year Ended
September 30, 2009, and 6,850,000 shares of our Common Stock were granted in the Fiscal Year Ended
September 30, 2008. The weighted average fair value of stock options granted during the Fiscal
Year Ended September 30, 2009 and the Fiscal Year Ended September 30, 2008 was $0.63 and $0.60,
respectively. The weighted average fair value of these stock options was estimated using the
Black-Scholes Option Pricing Model with the following weighted-average assumptions:
|
|
|
|
|
|
|
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year Ended
|
|
|
Year Ended
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Dividend yield
|
|
|
0.0
|
%
|
|
|
0.0
|
%
|
Expected volatility
|
|
|
161
|
%
|
|
|
140
|
%
|
Risk-free rate of return
|
|
|
1.7
|
%
|
|
|
3.3
|
%
|
Expected life (years)
|
|
|
3.6
|
|
|
|
5.0
|
|
Stock Option Plans
In July 2000, our Board of Directors approved a stock option plan (the
2000 Plan
).
Our stockholders have not approved the 2000 Plan. The 2000 Plan authorizes the grant of incentive
stock options and non-statutory stock options covering an aggregate of 39,750 shares of Common
Stock, as adjusted for our November 2002 reverse stock split (subject to limitations of applicable
laws and adjustment in the event of stock dividends, stock splits, reverse stock splits and certain
other corporate events). The 2000 Plan expires on July 6, 2010, unless it is terminated earlier or
suspended by the Board of Directors. The 2000 Plan is not subject to any provisions of the
Employee Retirement Income Security Act of 1974. As of each of September 30, 2009 and September
30, 2008 options to purchase an aggregate of 27,171 shares of Common Stock were outstanding under
the 2000 Plan, with a weighted average exercise price of $15.25. We do not intend to issue any
further options under the 2000 Plan or warrants to purchase stock to additional individuals or
vendors as compensation for services rendered.
In 2001, our Board of Directors approved the 2001 Stock Options/Stock Issuance Plan (the
2001 Plan
). Stockholders at the 2001 Annual Meeting approved the 2001 Plan in November
2001. The maximum number of shares of Common Stock that may be issued under the 2001 Plan cannot
exceed 20% of the total shares of Common Stock outstanding at the time the calculation is made
(including, on an as-converted basis, all convertible preferred stock, convertible debt securities,
warrants, options and other convertible securities that are exercisable), but in no event can the
maximum number of shares of Common Stock which may be issued under this plan as incentive stock
options exceed 20,000,000. As of September 30, 2008 and 2009, based on the 20% calculation, the
maximum number of shares issuable under the 2001 Plan was 13,210,993 and 17,756,180 respectively.
Options are generally granted for a term of ten years and generally vest over periods ranging from
one to three years. We have granted various non-qualified stock options to key executives,
management and other employees at exercise prices equal to or below the market price at the date of
grant.
On November 10, 2008, in connection with the appointment of Thomas Rice as President and Chief
Operating Officer of RHA, we entered into an Option Grant Agreement, under which we granted to Mr.
Rice an incentive stock option to purchase up to 500,000 shares of Common Stock, at an exercise
price of $0.625 per share,
which option shall expire on November 10, 2015. Mr. Rices option to purchase Common Stock
shall vest incrementally on the following vesting schedule: (1) 125,000 shares vested immediately
on November 10, 2008; (2) 125,000 shares vested on November 10, 2009; and (3) 250,000 shares shall
vest on November 10, 2010. For the Fiscal Year Ended September 30, 2009, the amortization
recognized was $86,000.
61
On April 22, 2009, pursuant to the terms of our 2001 Plan, we granted options (the
2009
Employee Options
) to employees of our indirect wholly-owned subsidiary, RHA (the
2009
Employee Optionees
), to purchase an aggregate of 1,319,390 shares of Common Stock in variable
individual amounts. Pursuant to the terms of the Option Grant Agreements, and subject to the terms
of the 2001 Plan, the shares underlying the 2009 Employee Options vest according to the following
schedule: (1) one-quarter vested immediately upon the date of issuance, (2) an additional
one-quarter of the 2009 Employee Option Shares vest upon the passing of the one year anniversary of
the date of issuance and (3) the remaining one-half of the 2009 Employee Option Shares vest upon
the second anniversary of the date of issuance. The 2009 Employee Options were issued at an
exercise price of $0.625 per share and are exercisable by the 2009 Employee Optionees with respect
to all or any of the vested 2009 Employee Option Shares until April 22, 2016, subject to the terms
and conditions of the 2001 Plan and the related Option Grant Agreements. For the Fiscal Year Ended
September 30, 2009, the amortization recognized was $201,000.
On May 27, 2009, in connection with the employment of David Jamin as the administrator of RHA
Stroud, LLC, we entered into an Option Grant Agreement, under which we granted to Mr. Jamin an
incentive stock option to purchase up to 20,000 shares of Common Stock, at an exercise price of
$0.625 per share, which option shall expire on Mary 27, 2016. Mr. Jamins option to purchase
Common Stock shall vest incrementally on the following vesting schedule: (1) 6,667 shares vest on
May 27, 2010, (2) 6,667 shares vest on May 27, 2011 and (3) 6,666 shares shall vest on May 27,
2012. For the Fiscal Year Ended September 30, 2009, the amortization recognized was $1,574.
The following summarizes activities under the stock option plans:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average
|
|
|
|
Number of Options
|
|
|
Exercise Price Per Share
|
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
Fiscal
|
|
|
|
Year
|
|
|
Year
|
|
|
Year
|
|
|
Year
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
Sep. 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at
beginning of the period
|
|
|
7,333,750
|
|
|
|
483,750
|
|
|
$
|
0.59
|
|
|
$
|
0.42
|
|
Granted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at above fair market value
|
|
|
1,839,390
|
|
|
|
|
|
|
|
0.63
|
|
|
|
|
|
at fair market value
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
at below fair market value
|
|
|
|
|
|
|
6,850,000
|
|
|
|
|
|
|
$
|
0.60
|
|
Exercised
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cancelled
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
924,138
|
|
|
|
|
|
|
|
0.40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding at
end of the period
|
|
|
8,249,002
|
|
|
|
7,333,750
|
|
|
$
|
0.62
|
|
|
$
|
0.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options
vested/exercisable at
end of the period
|
|
|
2,037,613
|
|
|
|
513,750
|
|
|
$
|
0.59
|
|
|
$
|
0.31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62
The following summarizes information for stock options outstanding as of September 30, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average
|
|
|
Weighted-average
remaining
|
|
Exercise price
|
|
Number of options
|
|
|
exercise price
|
|
|
contractual life
|
|
|
|
$0.40
|
|
|
360,000
|
|
|
$
|
0.40
|
|
|
|
6.1
|
|
$0.63
|
|
|
7,885,252
|
|
|
$
|
0.63
|
|
|
|
5.9
|
|
$2.00
|
|
|
3,750
|
|
|
$
|
2.00
|
|
|
|
0.7
|
|
The
intrinsic value of options that have an exercise price below the market price at
September 30, 2009 is $72,000.
As of September 30, 2009, there
was $3,168,000 in unrecognized
compensation cost related to outstanding options, net of forecasted forfeitures. This
amount is expected to be recognized over a weighted average of 3.3 years.
Employee Stock Purchase Plan
In November 2001, our stockholders approved the Employee Stock Purchase Plan (the
ESPP
), which provides (after adjustment to reflect our November 20, 2002 reverse stock
split) for the issuance of a maximum of 350,000 shares of Common Stock. Eligible employees can
have up to 10% of their earnings withheld, up to certain maximum limits, to be used to purchase
shares of Common Stock at certain plan-defined dates. The price of Common Stock purchased under
the ESPP is equal to 85% of the lower of the fair market value of the Common Stock on the
commencement date and specified purchase date of each six-month offering period. We have
discontinued offering the ESPP and no shares have been issued subsequent to the original issuance,
and we have no current intention to issue any more shares under the ESPP.
16. 401(k) Plan
We sponsor a 401(k) employee savings plan (
401(k) Plan
) under which eligible U.S.
employees may choose to defer a portion of their eligible compensation on a pre-tax basis, subject
to certain IRS limitations.
17. Income Taxes
Rate reconciliation:
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Statutory federal income tax rate
|
|
$
|
(3,525,140
|
)
|
|
$
|
(2,265,005
|
)
|
Increase (reduction) in taxes resulting from:
|
|
|
|
|
|
|
|
|
State income taxes, net of federal benefit
|
|
|
(149,804
|
)
|
|
|
(211,140
|
)
|
Permanent differences
|
|
|
563,375
|
|
|
|
1,227,024
|
|
Change in valuation allowance
|
|
|
3,068,472
|
|
|
|
1,282,351
|
|
Other
|
|
|
43,097
|
|
|
|
(33,230
|
)
|
|
|
|
|
|
|
|
Income tax provision
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
The deferred tax assets and liabilities were comprised of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2009
|
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
net operating loss carry forward
|
|
$
|
17,519
|
|
|
$
|
14,193
|
|
Accounts receivable reserves
|
|
|
4,238
|
|
|
|
2,080
|
|
|
|
|
|
|
|
|
Gross deferred tax assets
|
|
|
21,757
|
|
|
|
16,273
|
|
Deferred tax liabilities
|
|
$
|
3,169
|
|
|
$
|
828
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
18,588
|
|
|
$
|
15,445
|
|
Valuation allowance
|
|
|
18,588
|
|
|
|
15,445
|
|
|
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
The valuation allowance at September 30, 2009 principally applies to federal tax loss
carry-forwards that, in the opinion of the management, are more likely than not to expire before we
can use them.
63
As of September 30, 2009, we had net operating loss carry-forwards of approximately $43.2
million, available to offset future regular, alternative minimum and foreign taxable income, if
any. Change of ownership of more than 50% occurred on June 22, 2001 and according to applicable
U.S. tax laws, losses that occurred before that date are limited to $0.3 million per year for up to
20 years, totaling approximately $6.5 million. The loss carryovers will expire between 2011 and
2028. Changes in our ownership may lead to further restrictions in respect of the availability and
use of these tax losses.
FASB ASC 740 creates a single model to address accounting for uncertainty in tax positions by
prescribing a minimum recognition threshold a tax position is required to meet before being
recognized in the financial statements. FASB ASC 740 also provides guidance on derecognition,
measurement, classification, interest and penalties, accounting in interim periods, disclosure and
transition. There are no unrecognized tax benefits to disclose in the notes to the consolidated
financial statements.
18. Acquisitions
On October 30, 2007, we acquired 51% of the issued and outstanding membership units of RHA
pursuant to a Membership Interest Purchase Agreement. We paid $260 in cash to RHA and issued
4,250,000 restricted shares of our Common Stock to Carol Schuster, the sole member of RHA prior to
the acquisition, in consideration for the membership units. We privately placed the shares with
Ms. Schuster in reliance on the exemptions from registration requirements provided by Section 4(2)
of the Securities Act and Rule 506 of Regulation D promulgated thereunder. In connection with the
acquisition of RHA, we provided Valliance Bank with a limited guaranty of debt financing obtained
by RHA of up to $750,000. Based in Oklahoma City, RHA owns and operates three critical access
hospitals, one medical clinic and an ancillary support services unit, all focused on the delivery
of healthcare services to rural communities in Oklahoma. No goodwill was recognized as a result of
this acquisition.
The purchase price allocation was calculated as follows (in thousands):
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
348
|
|
Accounts receivable, net
|
|
|
2,524
|
|
Other current assets
|
|
|
550
|
|
Property and equipment, net
|
|
|
6,067
|
|
Accounts payable
|
|
|
(556
|
)
|
Accrued expenses
|
|
|
(1,106
|
)
|
Notes payable
|
|
|
(5,283
|
)
|
|
|
|
|
Total
|
|
$
|
2,544
|
|
Less: Minority interest - 49%
|
|
|
(1,246
|
)
|
|
|
|
|
Share of net assets
|
|
$
|
1,298
|
|
|
|
|
|
Purchase consideration
|
|
|
|
|
Issuance of restricted shares
|
|
$
|
(1,233
|
)
|
Incidental costs
|
|
|
(65
|
)
|
|
|
|
|
|
|
$
|
(1,298
|
)
|
|
|
|
|
As RHA was acquired out of bankruptcy, no proforma income statement information is presented.
On April 24, 2008, we entered into an Agreement and Plan of Merger (the
Merger
Agreement
) with RHA Anadarko, LLC (the
Parent
), an Oklahoma limited liability
company and our indirect subsidiary, SPMC Acquisition Company (the
Merger Sub
), an
Oklahoma corporation and ultimate subsidiary of RHA, Southern Plains Medical Center, PC, an
Oklahoma corporation (the
SPMC
), and thirteen shareholders of SPMC (each a
SPMC
Shareholder
and collectively, the
SPMC Shareholders
), each of which owned two shares
of SPMC.
On May 1, 2008, the Merger Sub merged with and into SPMC (the
Merger
), with SPMC as
the surviving corporation. In conjunction with the Merger, we contributed to RHA (i) 975,000 shares
(the
Shares
) of the Common Stock and (ii) a cash payment of $910,000, which stock and
cash RHA in turn contributed to Parent to capitalize the Merger Sub, and which was used as
consideration for the Merger.
64
The following table summarizes the initial fair values of the assets acquired and liabilities
assumed, in thousands, at the date of acquisition (in thousands):
|
|
|
|
|
Cash
|
|
$
|
644
|
|
Accounts receivable
|
|
|
1,692
|
|
Other current assets
|
|
|
258
|
|
Property and equipment
|
|
|
5,385
|
|
Other assets
|
|
|
329
|
|
Current liabilities
|
|
|
(2,655
|
)
|
Long-term liabilities
|
|
|
(4,305
|
)
|
|
|
|
|
|
|
$
|
1,348
|
|
|
|
|
|
The following unaudited pro forma information presents our 2008 results of operations as if
the acquisition had occurred on October 1, 2007. The unaudited pro forma results are not
necessarily indicative of results that would have occurred had the acquisition been in effect for
the periods presented, nor are they necessarily indicative of future results (in thousands except
per share amounts).
|
|
|
|
|
|
|
September 30,
|
|
|
|
2008
|
|
|
|
|
|
|
Revenues
|
|
$
|
36,612
|
|
Net Loss
|
|
$
|
(7,965
|
)
|
Net loss per common (basic and diluted)
|
|
$
|
(0.87
|
)
|
|
|
|
|
|
Weighted average common shares common
shares outstanding (basic and diluted)
|
|
|
9,198,865
|
|
65
19. Subsequent Events
In
preparing these financial statements, the Company has evaluated
events and transactions for potential recognition or disclosure
through January 11, 2009, the date on which the financial
statements became available to be issued. The Company noted the
following items for disclosure.
On October 19, 2009, we entered into a Series 5-A Preferred Stock and Warrant Purchase
Agreement, whereby we issued and sold an additional 7 shares of our 5-A Preferred and 4,200
warrants to purchase shares of Common Stock at an exercise price of $0.50 per share, exercisable
for a period of two years from the date of issuance, in a private placement for an aggregate
purchase price of $7,000. The transaction closed on October 19, 2009.
Also on October 19, 2009, we entered into a Series 6-A Preferred Stock and Warrant Purchase
Agreement, whereby we issued and sold an additional 43 shares of 6-A Preferred and 25,800 warrants
to purchase shares of Common Stock at an exercise price of $0.50 per share, exercisable for a
period of two years from the date of issuance, in a private placement for aggregate proceeds of
$43,000.
On December 8, 2009, we entered into a Subscription Agreement with Richardson E. Sells, a
member of our Board of Directors, whereby we sold and issued 200,000 shares of Common Stock and
warrants to purchase 60,000 shares of Common Stock at an exercise price of $0.50 per share,
exercisable for a period of two years from the date of issuance in a private placement. The
purchase price for the Common Stock and warrants was $0.50 per share of Common Stock, for an
aggregate purchase price of $100,000.
On December 11, 2009, our indirect wholly-owned subsidiary, RHA, received insurance proceeds
in the amount of $429,105 related to wind, hail and lightning damage which was sustained on May 13,
2009 to our hospital located in Anadarko, Oklahoma.
On December 14, 2009, we entered into a Series 5-A Preferred Stock and Warrant Purchase
Agreement with David Hirschhorn, our chief executive officer, whereby we issued and sold an
additional 6 shares of our 5-A Preferred and 3,600 warrants to purchase shares of Common Stock at
an exercise price of $0.50 per share, exercisable for a period of two years from the date of
issuance, in a private placement for an aggregate purchase price of $6,000. The transaction closed
on December 14, 2009.
On October 30, 2009, SMP and Brian Potiker, in his capacity as the manager of SMP with sole
power to vote and dispose of such securities, completed paperwork to exercise advisory board
warrants to acquire 714,285 shares of Common Stock at a price per share of $0.45 pursuant to the
exercise of warrants and we are in the process of issuing such shares of Common Stock.
|
|
|
Item 9.
|
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
|
On February 5, 2008, our Audit Committee unanimously approved the dismissal of Mendoza Berger
& Company LLP (
MBC
) as our independent registered public accounting firm. The Audit
Committee then elected Whitley Penn LLP as our independent registered principal accountant.
No accountants report issued by MBC on the financial statements for the Fiscal Year Ended
September 30, 2008 contained an adverse opinion or a disclaimer of opinion or was qualified or
modified as to uncertainty, audit scope or accounting principles, except for a going concern
opinion expressing substantial doubt about the ability of us to continue as a going concern.
66
During our immediately prior fiscal periods (the Transition Period Ended September 30, 2007
and the Fiscal Year Ended January 31, 2007) and from January 1, 2008 through February 19, 2008,
there were no disagreements with MBC on any matter of accounting principles or practices, financial
disclosure, or auditing scope or procedure. There were no reportable events, as described in Item
304(a)(1)(v) of Regulation S-K, during our fiscal periods (the Transition Period Ended September
30, 2007 and the Fiscal Year Ended January 31, 2007) and from January 1, 2008 through February 19,
2008.
We furnished a copy of a disclosure substantially similar to the preceding three paragraphs to
MBC and requested MBC to furnish us with a letter addressed to the SEC stating whether it agreed
with the statements made by us herein in response to Item 304(a) of Regulation S-K and, if not,
stating the respect in which it does not agree. A copy of the letter was filed by us as Exhibit
16.1 on our Form 8-K/A on February 19, 2008.
|
|
|
Item 9A(T).
|
|
CONTROLS AND PROCEDURES
|
Evaluation of Disclosure Controls and Procedures
Our Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of
our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) under the
Exchange Act), as of September 30, 2009. Based on such evaluation, such executive officers have
concluded that, as of September 30, 2009, our disclosure controls and procedures are effective in
alerting them on a timely basis to material information relating to us, including our consolidated
subsidiaries, required to be included in our reports filed or submitted under the Exchange Act. Our
Chief Executive Officer and Chief Financial Officer also concluded that the controls and procedures
were effective in ensuring that information required to be disclosed by us in the reports that we
file or submit under the Exchange Act are accumulated and communicated to our management, including
our principal executive and financial officers or persons performing similar functions, as
appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Controls
There were no changes in our internal controls over financial reporting that occurred during
the quarter ended September 30, 2009, that have materially affected, or are reasonably likely to
materially affect, our internal control over financial reporting.
Managements Assessment of Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over
financial reporting, as defined in Exchange Act Rule 13a-15(e). Our management assessed the
effectiveness of our internal control over financial reporting as of September 30, 2009. The
criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in
Internal Control Integrated Framework were used to make this assessment. Management believes
that our internal control over financial reporting as of September 30, 2009 is effective based on
those criteria.
This Firm 10-K does not include an attestation report of our registered public accounting firm
regarding internal control over financial reporting. Managements report was not subject to
attestation by our registered public accounting firm pursuant to temporary rules of the Securities
and Exchange Commission that permit us to provide only managements report in this Annual Report.
|
|
|
Item 9B.
|
|
OTHER INFORMATION
|
None.
67
PART III
|
|
|
Item 10.
|
|
DIRECTORS AND EXECUTIVE OFFICERS OF
|
The following table sets forth the names, ages and certain information regarding each of our
current directors and executive officers. There are no family relationships among our directors or
executive officers.
|
|
|
|
|
|
|
Name
|
|
|
Age
|
|
|
Position
|
|
|
|
|
|
|
|
David Hirschhorn
|
|
|
48
|
|
|
Chairman and Director
Chief Executive Officer
|
Donald C. Parkerson
|
|
|
59
|
|
|
Chief Financial Officer
|
|
|
|
|
|
|
|
Todd Parker (1)
|
|
|
46
|
|
|
Director
|
Robert N. Schwartz, PhD.(2)
|
|
|
70
|
|
|
Director
|
Richardson E. Sells(2)
|
|
|
63
|
|
|
Director
|
William Houlihan(1)
|
|
|
54
|
|
|
Director
|
Thomas Rice
|
|
|
63
|
|
|
President and Chief Operating Officer
of RHA
|
|
|
|
(1)
|
|
Member of the Audit Committee.
|
|
(2)
|
|
Member of the Audit Committee and Compensation Committee.
|
David Hirschhorn.
Since September 2005, Mr. Hirschhorn has been our Chairman and CEO and was
recently reappointed by the Board of Directors in July 2008 as CEO. Previously, Mr. Hirschhorn
served on our Board of Directors and as Co-Chairman, Co-Chief Executive Officer and Co-Chief
Financial Officer from July 2005 through September 2007, when he was appointed as sole Chairman and
Chief Executive Officer. Prior to that, Mr. Hirschhorn co-managed a private equity firm from July
2001 through July 2005. During his career, he has been CEO and chairman of a number of turnarounds
and start-ups. He was a managing director at Cruttenden Roth (now Roth Capital Partners) from May
1994 to March 1997. Mr. Hirschhorn also worked for The Nikko Securities Co. International, Inc. as
an investment banker in their New York office from 1991 to 1994, where as part of a team he built a
new department that provided financial advice and raised capital for domestic and international
clients. He began his career as a consultant for KPMG Peat Marwick and later worked as a senior
consultant for Deloitte & Touche from 1997 to 2000. Mr. Hirschhorn earned a BA from the University
of Michigan in Political Science.
Donald C. Parkerson.
Mr. Parkerson currently serves as our Chief Financial Officer. Mr. Parkerson
has been a partner in the Nashville practice of Tatum, LLC since March of 2008 and he currently
still holds this position. His 34-year career in the healthcare industry includes serving as the
Vice President of Accounting and Corporate Controller of public companies in the healthcare segment
and 25 years as audit and technology consulting partner in a public accounting firm serving clients
in healthcare, telecommunications, distribution and a number of other industries. Between November
2007 and February 2008, Mr. Parkerson was searching for a suitable employment opportunity
consistent with his years of experience and educational background. From July 2007 to October
2007, he worked as Senior Vice President, Corporate Controller, of Surgical Care Affiliates, LLC.
From May 2004 to June 2007, he served as Senior Vice President, Surgery Division Controller, of
HealthSouth Corporation. Prior to that, he was a partner at the accounting firm of Young,
Parkerson & Co., LLP. Mr. Parkerson graduated with a degree in accounting from Delta State
University.
Todd Parker.
Mr. Parker served on our Board of Directors and as Co-Chairman, Co-Chief Executive
Officer and Co-Chief Financial Officer from July 2005 until September 2007. He continues on our
board as a non-executive
director. Since 2002, Mr. Parker has been a Managing Director at Hidden River LLC, a firm
specializing in investments and services provided to the wireless and communications industry.
Previously, Mr. Parker was the founder and CEO of HR One, a human resources solutions provider. He
has held senior executive and general manager positions with AirTouch Corporation where he managed
over 15 corporate transactions and joint venture formations with a total value of over $6 billion
and participated in over 30 acquisitions, including AirTouchs merger with US West in a $10 billion
dollar transaction. Prior to AirTouch, Mr. Parker worked for Arthur D. Little as a consultant.
Mr. Parker earned a BS from Babson College in Entrepreneurial Studies and Communications.
68
Robert N. Schwartz, Ph.D.
Dr. Schwartz has served on our Board of Directors since January 1998.
Since 1979, Dr. Schwartz has been a visiting professor at U.C.L.A. and, since December 2000, the
owner of a scientific consulting company, Channel Islands Scientific Consulting. From 1981 to
2000, Dr. Schwartz was a Senior Research Scientist at HRL Laboratories, LLC, Malibu, California.
Prior to joining HRL Laboratories he was a Professor of Physical Chemistry at the University of
Illinois, Chicago from 1968 until 1981. Since 2006 Dr. Schwartz has served as a Senior Scientist
at the Aerospace Corporation in El Segundo, California. He has a B.A. in Mathematics, Chemistry
and Physics, an M.S. in Chemical Physics from the University of Connecticut and a Ph.D. in Chemical
Physics from the University of Colorado.
Richardson E. Sells.
Mr. Sells has served on our Board of Directors since April 2005. Mr. Sells
served as Vice President Global Sales, Cargo, of Northwest Airlines, Inc. from January 29, 2001
until his retirement at the end of calendar year 2006. Mr. Sells is currently the Managing Partner
of Transition Management, LLC, a transportation-related consulting firm. Prior to joining
Northwest Airlines, Mr. Sells was Managing Director, Hong Kong and China, for CV Transportation
Services, LDC, from 1995 through December 31, 2000. Mr. Sells has a Bachelors of Science degree in
Business Management from East Tennessee State University.
William A. Houlihan.
Mr. Houlihan has served on our Board of Directors since September 29, 2009.
Mr. Houlihan has more than 30 years of business and financial experience. For the periods from
February 2006 to July 2006, February 2007 to May 2007 and December 2008 through present, Mr.
Houlihan was a private investor while he evaluated opportunities to be the Chief Financial Officer
of certain companies. Mr. Houlihan has served as Chief Financial Officer for several companies,
which were Sixth Gear, Inc. from October 2007 to November 2008, Sedgwick Claims Management Services
in Memphis, Tennessee from August 2006 until January 2007, Metris Companies from August 2004 to
January 2006, and Hudson United Bancorp from January 2001 to November 2003. He also worked as an
investment banker at UBS in New York, New York from June 2007 to September 2007, at J.P. Morgan
Securities from November 2003 to July 2004, KBW, Inc. from October 1996 to January 2001, Bear,
Stearns & Co., Inc. from April 1991 to October 1996, and Goldman Sachs & Co. from June 1981 to
April 1991. Mr. Houlihan received a B.S. in Accounting in 1977 from Manhattan College, became
licensed as a C.P.A. in 1979, and received his M.B.A. in Finance in 1983 from New York University
Graduate School of Business.
Thomas Rice.
Mr. Rice currently serves as President and Chief Operating Officer of RHA, an
indirect subsidiary of ours. From 2000 to 2008, Mr. Rice served as Vice President of Healthcare
Partners Investments, a partnership based in Oklahoma City, which owns and manages two hospitals,
one surgery center, three sleep study centers, three outpatient physical therapy clinics and two
imaging centers. From 1995-2000, Mr. Rice served as President of Integris Baptist Medical Center
and Integris Southwest Medical Center, two large medical centers operating in Oklahoma City, where
he grew revenue by 32% to over $450 million in a difficult reimbursement environment. Prior to
that, Mr. Rice was President and CEO of Southwest Medical Center in Oklahoma City, which he led
into a successful merger with Integris Health. Previously, Mr. Rice was Senior Vice President of
St. Davids Healthcare System in Austin, Texas and administrator of various medical facilities in
cities around the United States. Mr. Rice is a graduate of Lamar University and has a Masters
Degree in Health Administration from Duke University. He has been certified as a Fellow in the
American College of Healthcare Executives.
Board Meetings and Committees
The Board of Directors held three meetings, during the Fiscal Year Ended September 30, 2009.
On 18 other occasions, the Board of Directors took actions through unanimous written consents.
Each director attended all meetings of the Board of Directors and the committees of the Board of
Directors on which he was a member, if any, held during the Fiscal Year Ended September 30, 2009.
The Audit Committee, which held four meetings during the Fiscal Year Ended September 30, 2009,
and which took actions through unanimous written consents on two other occasions, assists the
Boards oversight of our financial statements and compliance with legal and regulatory requirements
and the qualifications and performance of our independent auditor. The Audit Committee currently
has four members, Dr. Schwartz and Messrs. Parker, Sells and Houlihan. Each of Dr. Schwartz and
Messrs. Sells and Houlihan would be an independent director under the standards of the NYSE
Amex (formerly known as the American Stock Exchange or the AMEX; we have used the independence
standards of the NYSE Amex since we are not listed on a national securities exchange), and Mr.
Houlihan is considered an audit committee financial expert, as such term is currently defined
under the applicable rules and regulations of the SEC.
69
In September 2007, we formed a Compensation Committee comprising of Dr. Schwartz and Mr.
Sells. The primary purpose of the Compensation Committee is to determine, or recommend to the
Board of Directors for its determination, the compensation of our Chief Executive Officer and our
other executive officers to ensure that our executive officers are fairly compensated based upon
their performance and contribution to us. In addition, the Compensation Committee will produce an
annual report on executive compensation for inclusion in our proxy statement filed with the SEC, in
accordance with applicable rules and regulations. The Compensation Committee held one meeting
during the Fiscal Year Ended September 30, 2009 and took actions through unanimous written consents
on three other occasions.
Stockholder Communications with the Board of Directors
Our stockholders may communicate with the members of our Board of Directors and may recommend
nominees to our Board of Directors by writing directly to our Board of Directors or specified
individual directors at the following address:
First Physicians Capital Group, Inc.
Attn: Corporate Secretary
9663 Santa Monica Boulevard, #959
Beverly Hills, California 90210
Our Secretary will deliver stockholder communications to the specified individual director, if
so addressed, or to one of our directors who can address the matter.
Compensation of Directors
Mr. Hirschhorn is the only director also serving as a full-time employee of ours as of
September 30, 2009. He receives no additional compensation for serving as a director. With
respect to non-employee, independent directors, our philosophy is to provide competitive
compensation necessary to attract and retain qualified non-employee, independent directors.
In addition, on November 17, 2005, our Board of Directors approved the grants of options to
acquire an aggregate of 360,000 shares of our Common Stock to two independent directors. The
shares underlying these options vested in quarterly increments over three years, with an effective
grant date of August 1, 2005. The exercise price of these options is $0.40 per share, which was
the closing price of our Common Stock on November 17, 2005. These options were granted with
Black-Scholes assumptions of 99% volatility, $0.37 share price, risk-free interest rates of 4.1%
and exercise price of $0.40.
Section 16(a) Beneficial Ownership Reporting Compliance
Section 16(a) of the Exchange Act requires our directors and officers and persons who
beneficially own more than ten percent of our Common Stock to file with the SEC reports of
beneficial ownership on Forms 3 and changes in beneficial ownership of our Common Stock and other
equity securities on Form 4s or Forms 5. SEC regulations require all officers, directors and
greater than 10% stockholders to furnish us with copies of all Section 16(a) forms they file.
70
Based solely upon a review of Forms 3 and 4 and amendments thereto furnished to us during, and
Forms 5 and amendments thereto furnished to us with respect to, the Fiscal Year Ended September 30,
2009, and any written representations from reporting persons that no Form 5 is required, the
following table sets forth information regarding each person who, at any time during the Fiscal
Year Ended September 30, 2009, was a director, officer or beneficial owner of more than 10% of our
Common Stock who failed to file on a timely basis, as disclosed in the above forms, reports
required by Section 16(a) of the Exchange Act during the Fiscal Year Ended September 30, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
|
|
|
|
Transactions Not
|
|
|
Known Failures
|
|
|
|
Number of Late
|
|
|
Reported On a
|
|
|
To File a
|
|
Name
|
|
Reports
|
|
|
Timely Basis
|
|
|
Required Form
|
|
|
|
(#)
|
|
|
(#)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Hirschhorn
|
|
|
1
|
|
|
|
1
|
|
|
|
0
|
|
Todd Parker
|
|
|
0
|
|
|
|
1
|
|
|
|
1
|
|
Code of Ethics
On April 22, 2008, we adopted a Corporate Code of Business Conduct and Ethics for Directors,
executive officers and Employees (the
Code of Ethics
). The Code of Ethics applies to the
Board, the Chief Executive Officer, the President, the Chief Operations Officer (should one be
appointed), the Chief Financial Officer, each financial or accounting officer at the level of the
principal accounting officer or controller and all other Section 16 reporting executive officers
and all of our employees. A copy of the Code of Ethics is attached as an exhibit to the Form 10-K
for the Fiscal Year Ended September 30, 2008.
|
|
|
Item 11.
|
|
EXECUTIVE COMPENSATION
|
COMPENSATION DISCUSSION AND ANALYSIS
Compensation Philosophy and Compensation Program Objectives
As a growing public company operating in the competitive healthcare industry, we place high
value on attracting and retaining our executives since it is their talent and performance that is
responsible for our success. Therefore, our compensation philosophy is to create a
performance-based culture that attracts and retains a superior team. We aim to achieve this goal
by designing a competitive and fiscally responsible compensation program to:
|
|
|
Attract the highest caliber of talent required for the success of our business;
|
|
|
|
Retain those individuals capable of achieving challenging performance standards;
|
|
|
|
Incent our executives to strive for superior company-wide and individual
performance; and
|
|
|
|
Align management and stockholder interests over both the short and long-term.
|
Our executive compensation program is designed in a manner to offer a compensation package
that utilizes three key elements: (1) base salary, (2) annual cash incentives and (3) long-term
equity incentives. We believe that together these performance-based elements support the
objectives of our compensation program.
|
|
|
Base Salaries.
We seek to provide competitive base salaries factoring in the
position, the executives skills and experience, the executives performance, as well
as other factors. We believe appropriate base salary levels are critical in helping us
to attract and retain talented executives.
|
|
|
|
Annual Cash Incentives.
The aim of this element of compensation is to reward
individual contributions to align with our annual operating performance and to
recognize the achievement of challenging performance standards.
|
|
|
|
Long-Term Equity Incentives.
The long-term element of our compensation program
consists of discretionary grants of equity awards which are reviewed annually. These
are designed to align our interests with those of management, employees and our
stockholders by directly linking individual compensation to our long-term performance,
as reflected in stock price appreciation and increased stockholder value.
|
71
Below is a description of our executive compensation process and a detailed discussion of each
of the key elements of our compensation program as they apply to the executive officers named in
the Summary Compensation Table set forth below. Because we are a growing public company, we will
continue to review the overall design of our executive compensation program to ensure that it is
structured to most effectively meet our compensation philosophy and objectives. We will also
evaluate the program in the context of competitive market practice, as well as applicable legal and
regulatory guidelines, including IRS rules governing the deductibility of compensation. This
review may result in changes to the program we use today.
The Executive Compensation Process
The Board of Directors
We established a Compensation Committee in September 2007 with responsibility for determining
all aspects of officer and director compensation, which goes through the following process prior to
determining equity compensation:
|
|
|
Reviewing and approving our compensation philosophy;
|
|
|
|
Determining executive compensation levels;
|
|
|
|
Annually reviewing and assessing performance goals and objectives for all executive
officers, including our Chief Executive Officer and Chief Financial Officer; and
|
|
|
|
Determining short-term and long-term incentive compensation for all executive
officers, including our Chief Executive Officers and Chief Financial Officer.
|
Upon recommendation of the Compensation Committee, the Board of Directors is responsible for
making all decisions with respect to the compensation of the Chief Executive Officer and the Chief
Financial Officer. In the first quarter of each the fiscal year, the Compensation Committee
reviews base salaries, determines payout amounts for annual cash incentives and reviews long-term
equity for the Chief Executive Officer and the Chief Financial Officer. In the first quarter of
the Fiscal Year Ended September 30, 2009, the Compensation Committee did not need to meet because
our five employees compensation had already been determined by pre-existing employment contracts.
The Compensation Committee met as needed to consider specific contracts of executive officers, as
revised from time to time, including a meeting to discuss David Hirschhorns employment agreement.
Upon recommendation from the Compensation Committee, the Board of Directors reviews and establishes
performance metrics for the current years annual incentive plan.
Outside Compensation Advice
The Compensation Committee may also seek compensation advice from our Advisory Board. These
individuals advise the Board of Directors on compensation plan design issues, regulatory changes
and best practices related to compensation.
Benchmarking Process
When making compensation decisions, the Compensation Committee considers the competitive
market for executives and compensation levels provided by comparable companies. Though we
generally target salary levels at the median of our peer group, total compensation may exceed or
fall below the median for our Chief Executive Officer and Chief Financial Officer. Since one of
the objectives of our compensation program is to consistently reward and retain top performers,
actual compensation will vary depending on individual and our overall performance.
72
Compensation of Executive Officers
Mr. Hirschhorn joined us as Co-Chief Executive Officer and Co-Chief Financial Officer in July
2005, during a period when we were discontinuing active operations and entering a new industry. In
order to attract Mr. Hirschhorn, we negotiated a compensation package with Mr. Hirschhorn that
provided increasing annual salaries as we grow and other incentives that align his interests with
those of our stockholders. Mr. Hirschhorn entered into an initial employment agreement, effective
July 18, 2005, in which he received annual base salaries for the years ending July 18, 2006, 2007
and 2008, of $204,000, $240,000 and $360,000, respectively, and was eligible for an annual target
incentive bonus of up to 300% of the applicable base salary. This bonus was payable upon
achievement of certain performance targets set by the Board of Directors. Under his employment
agreement, Mr. Hirschhorn was guaranteed annual incentive bonuses of $50,000, $75,000 and $100,000.
Mr. Hirschhorn was also issued no less than 50,000 vested shares of our restricted Common Stock
annually beginning with the second year of his employment agreement. At the time of his hire, Mr.
Hirschhorn was also issued 1,250,000 restricted shares of our Common Stock. The cash components of
Mr. Hirschhorns compensation package were intentionally set below market with performance
incentives that would compensate him as we grew. The combination of Mr. Hirschhorns compensation
structure and the equity awards granted to him at the time of his hire created a heavy weighting on
long-term incentives. Mr. Hirschhorn entered into a second employment agreement, effective July 1,
2008, in which he will receive annual base salaries for the years ending July 1, 2009, 2010, 2011,
2012 and 2013 of $480,000.00, $540,000.00, $600,000.00, $630,000.00 and $661,500, respectively, and
he is eligible for an annual incentive bonus as determined by the Compensation Committee of an
amount not exceeding three times the base salary or 10% of our EBITDA for the immediately preceding
fiscal year. Mr. Hirschhorn has also received options to purchase up to 6,250,000 shares of Common
Stock at an initial exercise price of $0.625 per share. Mr. Hirschhorns shares vest according to
the following schedule: 1,250,000 shares vested on July 1, 2009; 1,250,000 shares vest on July 1,
2010; 1,250,000 shares vest on July 1, 2011; 1,250,000 shares vest on July 1, 2012 and the last
1,250,000 vest on July 1, 2013.
Mr. Parker joined us as Co-Chief Executive Officer and Co-Chief Financial Officer in July 2005
during a period when we were discontinuing active operations and entering a new industry. Mr.
Parker entered into an employment agreement, effective July 18, 2005, in which he received a base
salary of $96,000 per year, and was eligible for guaranteed annual bonuses in which he would
receive guaranteed bonuses for the years ending July 18, 2006, 2007 and 2008 of $25,000, $50,000
and $75,000, respectively. At the time of his hire, Mr. Parker was issued 350,000 restricted
shares of our Common Stock. Mr. Parker has not yet been provided equity grants in the form of
stock options, warrants or premium-priced options. The equity awards granted to Mr. Parker at the
time of his hire created a heavy weighting on long-term incentives. Mr. Parker resigned as
Co-Chief Executive Officer and Co-Chief Financial Officer in September 2007 and continues to serve
on the Board of Directors as a non-executive director with no salary. Pursuant to his resignation,
48,611 of his shares have been cancelled and returned to authorized but unissued status.
Details regarding Mr. Hirschhorns current compensation package are contained in the tables
that follow, and a description of Mr. Hirschhorns employment agreement is described below as well.
We continue to evaluate the components and level of compensation for our executive management.
Components of the Executive Compensation Program
Though we feel it is important to provide competitive cash compensation, we believe that a
substantial portion of executive compensation should be performance-based. We believe it is
essential for executives to have a meaningful equity stake linked to our long-term performance and,
therefore, we have created compensation
packages that aim to foster an owner-operator culture. Other than base salary, compensation
of our executive officers and other key associates is also largely comprised of variable or at
risk incentive pay linked to our financial and stock performance and individual contributions.
Other factors we consider in evaluating executive compensation include internal equity, external
market and competitive information, assessment of individual performance, level of responsibility
and the overall expense of the program. In addition, we also strive to offer competitive benefits
and appropriate perquisites.
73
Base Salary
Base salary represents the fixed component of our executive officers compensation. Following
the review and recommendation of the Compensation Committee, the Board of Directors sets base
salary levels based upon experience and skills, position, level of responsibility, the ability to
replace the individual and market practices. The Compensation Committee reviews base salaries of
the executive officers annually and approves all salary increases for the executive officers.
Increases are based on several factors, including the Compensation Committees assessment of
individual performance and contribution, promotions, level of responsibility, scope of position and
competitive market data. These salaries are below the salary level normally provided to a Chief
Executive Officer and/or Chief Financial Officer of a company of comparable size, complexity and
performance and below the median level of our peer group.
Annual Cash Incentives
Our executive officers have the opportunity to earn cash incentives for meeting annual
performance goals. Following review and recommendation of the Compensation Committee, the Board of
Directors establishes financial and performance targets and opportunities linked to our overall
performance.
Long-Term Equity Incentives
Our executive officer compensation is heavily weighted in long-term equity, as we believe
superior stockholder returns are achieved through an ownership culture that encourages a focus on
long-term performance by our executive officers. By providing our executive officers with an
equity stake in our future, we are better able to align the interests of our executive officers and
our stockholders. In establishing long-term equity incentive grants for our executive officers,
the Compensation Committee reviews certain factors, including the outstanding equity grants held
both by the individual and by our executives as a group, total compensation, performance,
accumulated wealth analysis that includes projections of the potential value of vested equity
(which is prepared reflecting assumptions about future stock price growth rates), the vesting dates
of outstanding grants, tax and accounting costs, potential dilution and other factors.
Perquisites and Other Benefits
We do not generally provide material perquisites that are not, in the Board of Directors
view, integrally and directly related to the executive officers duties. Our executive officers
also participate in other broad-based benefit programs that are generally available to our salaried
employees, including health, dental and life insurance programs.
Retirement Plans
The Board of Directors believes that an important aspect of attracting and retaining qualified
individuals to serve as executive officers involves providing methods for those individuals to save
for retirement. We currently do not have an established a retirement plan for our executive
officers, but may create one in the future.
74
Benefits Upon Termination of Employment
We have employment agreements with Mr. Hirschhorn, our Chief Executive Officer and Mr. Rice,
an executive officer of RHA. The agreement with Mr. Hirschhorn provides that in the event Mr.
Hirschhorn is terminated without cause we are obligated to pay Mr. Hirschhorn certain lump sum
payments, as set forth below in
the table entitled The Fiscal Year Ended September 30, 2009 Potential Payments Upon
Termination or Change in Control. Mr. Rice joined us as President and Chief Operating Officer of
RHA in November of 2008. Mr. Rice entered into an employment agreement, effective November 10,
2008, pursuant to which he will receive an annual base salary of $275,000 per fiscal year. In the
event Mr. Rices employment is terminated without cause or upon death or disability, RHA is
obligated to pay Mr. Rice certain severance payments. If the termination occurs after Mr. Rice has
been employed for less than twelve consecutive months, he shall receive the continued payment of
his base salary for six months following the termination date. If the termination occurs after Mr.
Rice has been employed for at least twelve consecutive months, he shall receive the continued
payment of his base salary for twelve months following the termination date. Mr. Parkerson has no
benefits upon termination.
The Board of Directors believes that the severance provisions contained in the employment
agreements are an important element in attracting and retaining executive officers. See The
Fiscal Year Ended September 30, 2009 Potential Payments Upon Termination or Change in Control
below for information with respect to potential payments and benefits under these employment
agreements and our other compensation arrangements upon the termination of our executive officers.
Tax and Accounting Matters
Section 162(m) of the Internal Revenue Code of 1986 (the
Code
), enacted as part of
the Omnibus Budget Reconciliation Act of 1993, generally disallows a tax deduction to public
companies for compensation over $1,000,000 paid to the Chief Executive Officer and the four other
most highly compensated executive officers. Under Internal Revenue Service regulations, qualifying
performance-based compensation will not be subject to the deduction limit if certain requirements
are met. The Compensation Committee does not believe that any of the executive compensation
arrangements for the Fiscal Year Ended September 30, 2009 will result in the loss of a tax
deduction pursuant to Section 162(m). The Compensation Committee expects to continue to monitor
the application of Section 162(m) to executive compensation and will take appropriate action if it
is warranted in the future.
We operate our compensation programs with the intention of complying with Section 409A of the
Code. Effective February 1, 2006, we began accounting for stock-based compensation with respect to
our long-term equity incentive award programs in accordance with the requirements of existing
accounting standards.
75
THE FISCAL YEAR ENDED SEPTEMBER 30, 2009, SEPTEMBER 30, 2008 AND SEPTEMBER 30, 2007 SUMMARY
EXECUTIVE COMPENSATION TABLE
The following table sets forth information concerning total compensation paid or earned during
the Fiscal Year Ended September 30, 2009, September 30, 2008 and September 30, 2007 for the persons
who served during the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended September 30,
2008 and the Transition Period Ended September 30, 2007 as our Chief Executive Officers and Chief
Financial Officers. These are our only two Executive Offices. As reflected in the tables below,
the primary components of our compensation program are cash compensation, consisting of a mix of
base salary and cash bonus compensation, and equity compensation, consisting of restricted stock
grants.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Value and
|
|
|
|
|
|
|
|
Name
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
Nonqualified
|
|
|
All other
|
|
|
|
|
and
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
Compen-
|
|
|
Deferred
|
|
|
Compen-
|
|
|
|
|
Principal
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Awards
|
|
|
Awards
|
|
|
sation
|
|
|
Compensation
|
|
|
sation
|
|
|
Total
|
|
Position
|
|
Year
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
Earnings
|
|
|
($)
|
|
|
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Hirschhorn
|
|
The Transition Period
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Executive Officer
|
|
ended Sep. 30, 2007
|
|
$
|
183,508
|
|
|
|
|
(1)
|
|
$
|
99,041
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
282,549
|
|
(formerly Co-Chief Executive Officer
|
|
Sep. 30, 2008
|
|
$
|
360,000
|
|
|
$
|
225,000
|
|
|
|
|
|
|
$
|
3,704,807
|
|
|
|
|
|
|
|
|
|
|
$
|
37,163
|
|
|
$
|
4,326,970
|
|
and Co-Chief Financial Officer)
|
|
Sep. 30, 2009
|
|
$
|
495,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
24,526
|
|
|
$
|
519,526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Donald C Parkerson
|
|
The Transition Period
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Chief Financial Officer
|
|
ended Sep. 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2008
|
|
$
|
63,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
63,000
|
|
|
|
Sep. 30, 2009
|
|
$
|
252,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
5,303
|
|
|
$
|
257,303
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dennis M. Smith
|
|
The Transition Period
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Former Chief Financial Officer
|
|
ended Sep. 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
200,000
|
(2)
|
|
$
|
200,000
|
|
|
|
Sep. 30, 2008
|
|
$
|
275,000
|
|
|
|
|
|
|
|
|
|
|
$
|
50,000
|
|
|
|
|
|
|
|
|
|
|
$
|
8,230
|
|
|
$
|
333,230
|
|
|
|
Sep. 30, 2009
|
|
$
|
229,170
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
2,931
|
|
|
$
|
232,101
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas Rice
|
|
The Transition Period
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
President/Chief Operating Officer,
|
|
ended Sep. 30, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
RHA
|
|
Sep. 30, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sep. 30, 2009
|
|
$
|
189,962
|
|
|
|
|
|
|
|
|
|
|
$
|
153,236
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
343,198
|
|
|
|
|
(1)
|
|
Mr. Hirschhorn was entitled to a guaranteed bonus payment in the amount of $56,250 during the
Transition Period Ended September 30, 2007. He did not receive this bonus during the
Transition Period Ended September 30, 2007, we have reserved this bonus amount in its
financial statements.
|
|
(2)
|
|
Mr. Smith earned $200,000 in consulting fees in respect of consulting services he provided to
us during the Transition Period Ended September 30, 2007 prior to becoming our Chief Financial
Officer.
|
76
EMPLOYMENT AGREEMENTS
Mr. Hirschhorn is party to an employment agreement with us dated effective as of July 1, 2008
and approved by our Compensation Committee. The employment agreement expires on July 1, 2013.
Under the employment agreement, Mr. Hirschhorn receives annual base salaries for the years ending
July 1, 2009, 2010, 2011, 2012 and 2013 of $480,000, $540,000, $600,000, $630,000 and $661,500,
respectively, and is eligible for an annual incentive bonus as determined by the Compensation
Committee in an amount not to exceed three times his base salary for that fiscal year or 10% of our
EBITDA for the immediately preceding fiscal year. Mr. Hirschhorn entered into an Option Grant
Agreement pursuant to the 2001 Plan, effective July 1, 2008, pursuant to which Mr. Hirschhorn was
granted the option to acquire 6,250,000 shares of our Common Stock at an exercise price of $0.625.
The shares underlying this option vest according to the following schedule: 1,250,000 vested on
July 1, 2009, 1,250,000 on July 1, 2010, 1,250,000 on July 1, 2011, 1,250,000 on July 1, 2012, and
the remaining 1,250,000 on July 1, 2013; Mr. Hirschhorn was not terminated for Misconduct (as that
term is defined in the Option Grant Agreement, filed as Exhibit 10.2 to the Form 8-K filed with the
SEC on July 7, 2008), nor has he, to our knowledge, engaged in Misconduct through the date of this
Form 10-K. Either party may terminate Mr. Hirschhorns employment by providing written notice to
the other party. If we terminate the employment, our notice shall include a statement indicating
whether the termination was because of disability or for cause or without cause. In the event Mr.
Hirschhorn is terminated, we are obligated to pay Mr. Hirschhorn certain lump sum payments, as set
forth below in the table entitled The Fiscal Year Ended September 30, 2009 Potential Payments
Upon Termination or Change in Control.
The employment agreement with Mr. Hirschhorn also states that Mr. Hirschhorn shall receive a
term life insurance policy with a death benefit of $1.0 million for the first year of the
agreement, $1.5 million for the second and third years of the agreement and $2.0 million for each
of the forth and fifth years of the agreement. The premiums for this policy are to be paid by us as
long as Mr. Hirschhorn remains employed by us pursuant to the Agreement. We are not the
beneficiary of the policy. The life insurance policy has not been purchased at this time, and in
the event that Mr. Hirschhorn passes away, we may be liable to his estate in an amount to be
determined, which may be up to $2.0 million.
Mr. Smiths employment agreement was terminated on October 9, 2008. Mr. Smiths employment
terminated January 26, 2009.
THE FISCAL YEAR ENDED SEPTEMBER 30, 2009 GRANTS OF PLAN-BASED AWARDS
On November 10, 2008, our Compensation Committee approved the issuance of options to purchase
500,000 shares of our Common Stock pursuant to the 2001 Plan to Thomas Rice. These options are
exercisable for a period of seven years at an exercise price of $0.625 per share
.
GRANTS OF PLAN-BASED AWARDS
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
|
Option
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
Number
|
|
|
Exercise
|
|
|
Grant
|
|
|
|
|
|
|
|
Estimated Future Payouts
|
|
|
Estimated Future Payouts
|
|
|
Number
|
|
|
of
|
|
|
or Base
|
|
|
Date Fair
|
|
|
|
|
|
|
|
Under Non-Equity
|
|
|
Under Equity
|
|
|
of Shares of
|
|
|
Securities
|
|
|
Price of
|
|
|
Value of
|
|
|
|
|
|
|
|
Incentive Plan Awards
|
|
|
Incentive Plan Awards
|
|
|
Stock
|
|
|
Underlying
|
|
|
Option
|
|
|
Stock and
|
|
|
|
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
or Units
|
|
|
Options
|
|
|
Awards
|
|
|
Option
|
|
Name
|
|
Grant Date
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
(#)
|
|
|
(#)
|
|
|
(#)
|
|
|
(#)
|
|
|
(#)
|
|
|
($/Sh)
|
|
|
Awards
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
(k)
|
|
|
(l)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas Rice,
President and Chief
Operating officer
of our indirect
wholly owned
subsidiary, Rural
Hospital
Acquisition, L.L.C.
|
|
|
11/10/2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
|
|
500,000
|
|
|
$
|
0.625
|
|
|
$
|
153,236
|
|
77
THE FISCAL YEAR ENDED SEPTEMBER 30, 2009 OUTSTANDING EQUITY AWARDS
The following table summarizes information with respect to our outstanding equity awards held
by executive officers at September 30, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Market or
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
Payout
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
Value
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
of
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unearned
|
|
|
Unearned
|
|
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares,
|
|
|
Shares,
|
|
|
|
Number of
|
|
|
Number of
|
|
|
of
|
|
|
|
|
|
|
|
|
|
|
Number of
|
|
|
|
|
|
|
Units
|
|
|
Units
|
|
|
|
Securities
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
|
|
Shares or
|
|
|
Market Value
|
|
|
or Other
|
|
|
or Other
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
|
|
Units of
|
|
|
of Shares or
|
|
|
Rights
|
|
|
Rights
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
|
|
|
|
Stock
|
|
|
Units of Stock
|
|
|
That
|
|
|
That Have
|
|
|
|
Options
|
|
|
Options
|
|
|
Unearned
|
|
|
Exercise
|
|
|
Option
|
|
|
That Have
|
|
|
That Have
|
|
|
Have Not
|
|
|
Not
|
|
|
|
(#)
|
|
|
(3)
|
|
|
Options
|
|
|
Price
|
|
|
Expiration
|
|
|
Not Vested
|
|
|
Not Vested
|
|
|
Vested
|
|
|
Vested
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
(#)
|
|
|
($)
|
|
|
Date
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David Hirschhorn
Chief Executive
Officer (formerly
Co-Chief Executive
Officer and
Co-Chief Financial
Officer)
|
|
|
1,250,000
|
|
|
|
5,000,000
|
|
|
|
|
|
|
$
|
0.625
|
|
|
|
07/01/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Thomas Rice,
President and Chief
Operating officer
of our indirect
wholly owned
subsidiary, Rural
Hospital
Acquisition, L.L.C.
|
|
|
125,000
|
|
|
|
375,000
|
|
|
|
|
|
|
$
|
0.625
|
|
|
|
11/10/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
On July 1, 2008, our Compensation Committee approved the issuance of options to purchase
6,250,000 shares of our Common Stock pursuant to the 2001 Plan to David Hirschhorn. These
options are exercisable for a period of seven years at an exercise price of $0.625 per share.
|
|
(2)
|
|
On November 10, 2008, our Compensation Committee approved the issuance of options to purchase
500,000 shares of our Common Stock pursuant to the 2001 Plan to Thomas Rice. These options
are exercisable for a period of seven years at an exercise price of $0.625 per share
.
|
78
(2) THE FISCAL YEAR ENDED SEPTEMBER 30, 2009 POTENTIAL PAYMENTS UPON TERMINATION OR A CHANGE IN
CONTROL
The following tables show the estimated amount of potential payments, as well as estimated
value of continuing benefits, assuming the executive officers employment terminated effective
September 30, 2009, and based on compensation and benefit levels in effect on September 30, 2009.
Due to the numerous factors involved in estimating these amounts, the actual benefits and amounts
payable can only be determined at the time of an executive officers termination.
DAVID HIRSCHHORN, CHIEF EXECUTIVE OFFICER (FORMERLY CO-CEO and CO-CFO)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination
|
|
|
|
|
|
|
Voluntary
|
|
|
Involuntary Not
|
|
|
|
|
|
|
Without Cause
|
|
|
|
|
|
|
Termination
|
|
|
For
|
|
|
|
|
|
|
or Termination
|
|
|
|
|
Benefits/Payments
|
|
(including
|
|
|
Cause
|
|
|
For Cause
|
|
|
for Good
|
|
|
Death or
|
|
Upon Termination
|
|
Retirement)
|
|
|
Termination
|
|
|
Termination
|
|
|
Reason
|
|
|
Disability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salary(1)
|
|
$
|
120,000
|
|
|
$
|
120,000
|
|
|
$
|
120,000
|
|
|
$
|
1,620,000
|
|
|
$
|
120,000
|
|
Accelerated Vesting
of Deferred
Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,500,000
|
(3)
|
Accelerated Vesting
of Options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuation of
Insurance Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
In the event of Mr. Hirschhorns voluntary termination, we are required to pay Mr. Hirschhorn
any amount of base salary earned by, but not yet paid to, Mr. Hirschhorn through the effective
date of termination.
|
|
(2)
|
|
In the event of Mr. Hirschhorns voluntary termination, we are additionally required to pay
to Mr. Hirschhorn (i) all benefits that have been earned by or vested in, and are payable to,
Mr. Hirschhorn under and subject to the terms (including all eligibility requirements) of, the
compensation and benefit plans in which Mr. Hirschhorn participated through the effective date
of termination; (ii) all reimbursable expenses due, but not yet paid, to Mr. Hirschhorn as of
the effective date of termination and (iii) an amount equal to all accrued and unused paid
vacation or time off, calculated in accordance with our paid vacation or time off policies,
practices and procedures (including authorized deductions and the deductions required by law),
as of the effective date of termination.
|
|
(3)
|
|
Mr. Hirschhorns employment agreement provides that he shall receive a term life insurance
policy with a death benefit of $1,000,000 for the first year of the agreement; $1,500,000 for
the second and third years of the agreement and $2,000,000 for each of the fourth and fifth
years of the agreement.
|
79
DONALD C. PARKERSON, CHIEF FINANCIAL OFFICER
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Termination
|
|
|
|
|
|
|
Voluntary
|
|
|
Involuntary Not
|
|
|
|
|
|
|
Without Cause
|
|
|
|
|
|
|
Termination
|
|
|
For
|
|
|
|
|
|
|
or Termination
|
|
|
|
|
Benefits/Payments
|
|
(including
|
|
|
Cause
|
|
|
For Cause
|
|
|
for Good
|
|
|
Death or
|
|
Upon Termination
|
|
Retirement)
|
|
|
Termination
|
|
|
Termination
|
|
|
Reason
|
|
|
Disability
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Salary(1)
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
|
$
|
0
|
|
Accelerated Vesting
of Deferred
Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accelerated Vesting
of Options
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuation of
Insurance Benefits
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We did not compensate Mr. Parkerson during the Fiscal Year Ended September 30, 2009; however
Mr. Parkerson did receive compensation from Tatum, LLC, pursuant to an Executive Services
Agreement between us and Tatum, LLC.
THE FISCAL YEAR ENDED SEPTEMBER 30, 2009 DIRECTOR COMPENSATION
We did not compensate non-employee members of our Board of Directors during the Fiscal Year
Ended September 30, 2009.
80
|
|
|
Item 12.
|
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS
|
Common Stock, Series 1-A Convertible Preferred Stock, Series 2-A Convertible Preferred Stock,
Series 5-A Convertible Preferred Stock and Series 6-A Convertible Preferred Stock
The following table sets forth certain information, as of January 7, 2010, regarding the
beneficial ownership of our Common Stock, including Common Stock issuable upon conversion of all
preferred convertible securities, options, warrants and other convertible securities, by (i) all
persons or entities who beneficially own 5% or more of our Common Stock, (ii) each of our current
directors, (iii) the executive officers listed in the Summary Compensation Table herein and (iv)
all of our current executive officers and directors as a group, in each case, to the best of our
knowledge. As of January 7, 2010, there were (i) 14,807,851 shares of Common Stock outstanding,
(ii) 86,770,798 shares of Common Stock on a fully as-converted basis and (iii) on a fully
as-converted basis, 81,600,253 shares of Preferred Stock, options, warrants and other securities
convertible into Common Stock currently exercisable within 60 days of January 7, 2010, with each
share of Common Stock being entitled to one vote.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount and Nature of
|
|
|
Percent of
|
|
Title of Class
|
|
Name of Beneficial Owner(1)
|
|
Beneficial Ownership
|
|
|
Class
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5% Holders or Potential 5% Holders of Common Stock
|
|
|
|
|
|
|
|
|
Common(2)
|
|
SMP Investments I, LLC
|
|
|
12,847,618
|
|
|
|
47.7
|
%
|
|
|
c/o HSP Group, LLC
|
|
|
|
|
|
|
|
|
|
|
875 Prospect Street, Suite 220
|
|
|
|
|
|
|
|
|
|
|
La Jolla, CA 92037 (4)
|
|
|
|
|
|
|
|
|
Common
|
|
Carol Schuster
|
|
|
4,250,000
|
|
|
|
28.7
|
%
|
|
|
3555 NW 58th Street
|
|
|
|
|
|
|
|
|
|
|
Suite 700
|
|
|
|
|
|
|
|
|
|
|
Oklahoma City, OK 73112
|
|
|
|
|
|
|
|
|
Common
|
|
Ciabattoni Living Trust 8/17/2000
|
|
|
8,801,667
|
|
|
|
37.3
|
%
|
|
|
16 Lagunita Drive
|
|
|
|
|
|
|
|
|
|
|
Laguna Beach, CA 92561 (5)
|
|
|
|
|
|
|
|
|
Common
|
|
The Kupfer Family Trust UTD May 3, 2009
|
|
|
2,384,250
|
|
|
|
16.1
|
%
|
|
|
P.O. Box 9330
|
|
|
|
|
|
|
|
|
|
|
Rancho Santa Fe, CA 92067
|
|
|
|
|
|
|
|
|
|
|
Current Directors
|
|
|
|
|
|
|
|
|
Common
|
|
David Hirschhorn (3)
|
|
|
4,232,800
|
|
|
|
23.9
|
%
|
Common
|
|
Todd Parker (6)
|
|
|
793,389
|
|
|
|
5.2
|
%
|
Common
|
|
Robert N. Schwartz, Ph.D (7)
|
|
|
185,857
|
|
|
|
1.2
|
%
|
Common
|
|
Richardson E. Sells (8)
|
|
|
440,000
|
|
|
|
2.9
|
%
|
Common
|
|
William Houlihan (12)
|
|
|
1,100,000
|
|
|
|
7.0
|
%
|
|
|
Current Officers
|
|
|
|
|
|
|
|
|
Common
|
|
David Hirschhorn (3)
|
|
|
4,232,800
|
|
|
|
23.9
|
%
|
Common
|
|
Donald C. Parkerson
|
|
|
|
|
|
|
|
|
Common
|
|
Thomas Rice (9)
|
|
|
250,000
|
|
|
|
1.7
|
%
|
Common
|
|
Current directors and officers as a group (7 persons) (11)
|
|
|
7,002,046
|
|
|
|
41.9
|
%
|
|
|
Former Officers and Directors
|
|
|
|
|
|
|
|
|
Common
|
|
Dennis M. Smith (10)
|
|
|
475,000
|
|
|
|
3.1
|
%
|
|
|
5% Holders of Series 1-A Convertible Preferred Stock
|
|
|
|
|
|
|
|
|
Series 1-A Preferred
|
|
First Clearing Corporation
|
|
|
20,000
|
|
|
|
29.6
|
%
|
|
|
P.O. Box 6570
|
|
|
|
|
|
|
|
|
|
|
Glen Allen, VA 23058
|
|
|
|
|
|
|
|
|
Series 1-A Preferred
|
|
Susan Lacerra & Steven Tingey, as joint tenants
|
|
|
7,600
|
|
|
|
11.2
|
%
|
|
|
c/o Jefferies & Co, Inc.
|
|
|
|
|
|
|
|
|
|
|
650 California Street
|
|
|
|
|
|
|
|
|
|
|
San Francisco, CA 94108
|
|
|
|
|
|
|
|
|
81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount and Nature of
|
|
|
Percent of
|
|
Title of Class
|
|
Name of Beneficial Owner(1)
|
|
Beneficial Ownership
|
|
|
Class
|
|
|
|
|
|
|
|
|
|
|
|
|
Series 1-A Preferred
|
|
Ron Soderling
|
|
|
40,000
|
|
|
|
59.2
|
%
|
|
|
901 Dove Street, Suite 270
|
|
|
|
|
|
|
|
|
|
|
Newport Beach, CA 92660
|
|
|
|
|
|
|
|
|
|
|
5% Holders of Series 2-A Preferred Stock
|
|
|
|
|
|
|
|
|
Series 2-A Preferred
|
|
Ali R. Moghaddami
|
|
|
3,900
|
|
|
|
100
|
%
|
|
|
333 E. GlenOaks Boulevard
|
|
|
|
|
|
|
|
|
|
|
Suite 202
|
|
|
|
|
|
|
|
|
|
|
Glendale, CA 91207
|
|
|
|
|
|
|
|
|
|
|
5% Holders of Series 5-A Preferred Stock
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Ciabattoni Living Trust 8/17/2000
|
|
|
600
|
|
|
|
6.7
|
%
|
|
|
16 Lagunita Drive
|
|
|
|
|
|
|
|
|
|
|
Laguna Beach, CA 92561
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Richard Sambora Living Trust 4/13/00
|
|
|
500
|
|
|
|
5.6
|
%
|
|
|
c/o Gelfand Rennert & Feldman LLP
|
|
|
|
|
|
|
|
|
|
|
360 Hamilton Avenue, Suite 100
|
|
|
|
|
|
|
|
|
|
|
White Plains, New York 10601
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
SMP Investments I, LLC
|
|
|
1,250
|
|
|
|
13.9
|
%
|
|
|
c/o HSP Group, LLC
|
|
|
|
|
|
|
|
|
|
|
875 Prospect Street, Suite 220
|
|
|
|
|
|
|
|
|
|
|
La Jolla, CA 92037
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
South Bay Capital LLC
|
|
|
500
|
|
|
|
5.6
|
%
|
|
|
c/o Keith Lehman, Managing Member
|
|
|
|
|
|
|
|
|
|
|
960 Third Street, Apt. 204
|
|
|
|
|
|
|
|
|
|
|
Santa Monica, CA 90403
|
|
|
|
|
|
|
|
|
|
|
Current Directors
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
David Hirschhorn
|
|
|
131
|
|
|
|
1.5
|
%
|
Series 5-A Preferred
|
|
Todd Parker
|
|
|
135
|
|
|
|
1.5
|
%
|
Series 5-A Preferred
|
|
William Houlihan
|
|
|
250
|
|
|
|
2.8
|
%
|
Series 5-A Preferred
|
|
Richardson E. Sells
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Robert N. Schwartz, Ph.D
|
|
|
|
|
|
|
|
|
|
|
Current Officers
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
David Hirschhorn
|
|
|
125
|
|
|
|
1.4
|
%
|
Series 5-A Preferred
|
|
Donald C. Parkerson
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Thomas Rice
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Current directors and officers as a group (7 persons) (11)
|
|
|
516
|
|
|
|
5.8
|
%
|
|
|
Former Officers and Directors
|
|
|
|
|
|
|
|
|
Series 5-A Preferred
|
|
Dennis M. Smith
|
|
|
125
|
|
|
|
1.4
|
%
|
82
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount and Nature of
|
|
|
Percent of
|
|
Title of Class
|
|
Name of Beneficial Owner(1)
|
|
Beneficial Ownership
|
|
|
Class
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5% Holders of Series 6-A Preferred Stock
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Ciabattoni Living Trust 8/17/2000
|
|
|
600
|
|
|
|
12.3
|
%
|
|
|
16 Lagunita Drive
|
|
|
|
|
|
|
|
|
|
|
Laguna Beach, CA 92561
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Darras Revocable Trust dated 9/2/94
|
|
|
250
|
|
|
|
5.1
|
%
|
|
|
600 South Indian Hill Boulevard
|
|
|
|
|
|
|
|
|
|
|
Claremont, CA 91711
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
SMP Investments I, LLC
|
|
|
1,000
|
|
|
|
20.5
|
%
|
|
|
c/o HSP Group, LLC
|
|
|
|
|
|
|
|
|
|
|
875 Prospect Street, Suite 220
|
|
|
|
|
|
|
|
|
|
|
La Jolla, CA 92037
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Hector S. Torres
|
|
|
300
|
|
|
|
6.2
|
%
|
|
|
c/o Joseph Apuzzo, CPA
|
|
|
|
|
|
|
|
|
|
|
150 Airport Road, Suite 1000
|
|
|
|
|
|
|
|
|
|
|
Lakewood, NJ 08701
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
James Chao
|
|
|
350
|
|
|
|
7.2
|
%
|
|
|
5471 Kearny Villa Road, # 200
|
|
|
|
|
|
|
|
|
|
|
San Diego, CA 92123
|
|
|
|
|
|
|
|
|
|
|
Current Directors
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
David Hirschhorn
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Todd Parker
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
William Houlihan
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Richardson E. Sells
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Robert N. Schwartz, Ph.D
|
|
|
|
|
|
|
|
|
|
|
Current Officers
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
David Hirschhorn
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Donald C. Parkerson
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Thomas Rice
|
|
|
|
|
|
|
|
|
Series 6-A Preferred
|
|
Current directors and officers as a group (7 persons) (11)
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
Except as otherwise indicated, we believe that the beneficial owners of the securities listed
have sole investment and voting power with respect to their shares.
|
|
(2)
|
|
The number of shares of Common Stock shown as beneficially owned by any person or entity
includes all Preferred Stock, options, warrants and other convertible securities currently
exercisable by that person or entity within 60 days of January 7, 2010. The percentages of
beneficial ownership of Common Stock shown assume the exercise or conversion of all preferred
stock, options, warrants and other securities convertible into Common Stock held by such
person or entity currently exercisable within 60 days of January 7, 2010, but not the exercise
or conversion of preferred stock, options, warrants and other convertible securities held by
other holders of such securities.
|
|
(3)
|
|
Consists of (a) 1,250,000 restricted shares of Common Stock granted in connection with Mr.
Hirschhorns Employment Agreement, dated as of July 18, 2005; (b) 419,200 shares beneficially
owned by Mr. Hirschhorn in his capacity as President of Hope & Abel Investments, LLC, which
directly holds 125 shares of 5-A Preferred and 6 shares of 5-A Preferred owned by him
individually, which are convertible into 400,000 shares of Common Stock; (c) 60,000 shares of
Common Stock issued to Mr. Hirschhorn in his capacity as President of Hope & Abel Investments,
LLC, pursuant to the exercise of a warrant dated July 18, 2005; (d) 2,500,000 vested options
convertible into shares of Common Stock and (e) 3,600 warrants dated January 7, 2010.
|
83
|
|
|
(4)
|
|
Consists of (a) 1,250 shares of 5-A Preferred, which are convertible into 4,000,000 shares of
Common Stock; (b) 1,000 shares of 6-A Preferred which are convertible into 3,200,000 shares of
Common Stock; (c) an Advisory Board warrant to purchase an aggregate of 150,000 shares of
Common Stock at a price of $0.45 per share; (d) 714,285 shares of Common Stock at $0.45 per
share; (e) a warrant to purchase 1,200,000 shares of Common Stock at a price of $0.3125 per
share; (f) warrants to purchase an aggregate of 2,450,000 shares of Common Stock at a price of
$0.50 per share; (g) warrants to purchase an aggregate of 333,333 shares of Common Stock at a
price of $0.75 per share and (h) $500,000 of debt convertible at $0.625 per share into 800,000
shares of Common Stock.
|
|
(5)
|
|
Consists of (a) 600 shares of 5-A Preferred, which are convertible into 1,920,000 shares of
Common Stock; (b) 600 shares of 6-A Preferred, which are convertible into 1,920,000 shares of
Common Stock; (c) a warrant to purchase 600,000 shares of Common Stock at a price of $0.3125
per share; (d) warrants to purchase an aggregate of 2,095,000 shares of Common Stock at a
price of $0.50 per share; (e) warrants to purchase an aggregate of 666,667 shares of Common
Stock at a price of $0.75 per share and (f) $1,000,000 of debt convertible at $0.625 per share
into 1,600,000 shares of Common Stock.
|
|
(6)
|
|
Consists of (a) 361,389 shares of Common Stock, of which (i) 350,000 restricted shares were
granted in connection with Mr. Parkers employment agreement, dated as of July 18, 2005, of
which 48,611 have been cancelled pursuant to termination of Mr. Parkers employment agreement,
and (ii) 60,000 were issued pursuant to the exercise of a warrant dated July 18, 2005, and (b)
135 shares of 5-A Preferred, which are convertible into 432,000 shares of Common Stock.
|
|
(7)
|
|
Consists of (a) 982 shares directly owned by Dr. Schwartz; (b) 1,125 shares owned in a trust
on behalf of Dr. Schwartz and (c) 183,750 shares of Common Stock issuable upon exercise of Dr.
Schwartzs stock options.
|
|
(8)
|
|
Consists of (a) 180,000 shares of Common Stock issuable upon exercise of Mr. Sells stock
options; (b) 200,000 shares of Common Stock and which are currently vested.
|
|
(10)
|
|
Consists of (a) 125 shares of 5-A Preferred which are convertible into 400,000 shares of
Common Stock; (b) 60,000 shares of Common Stock issued pursuant to the exercise of a warrant
dated July 18, 2005 and (c) 15,000 shares of Common Stock granted pursuant to the exercise of
a warrant dated September 18, 2006.
|
|
(11)
|
|
Includes shares held directly, as well as shares held jointly with family members, held in
retirement accounts, held in a fiduciary capacity, held by certain of the group members
families, or held by trusts of which the group member is a trustee or substantial beneficiary,
with respect to which shares the group member may be deemed to have sole or shared voting or
investment powers.
|
|
(12)
|
|
Consists of (a) 250 shares of 5-A Preferred, which are convertible into 800,000 shares of
Common Stock and (b) 300,000 shares of Common Stock.
|
|
|
|
Item 13.
|
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
|
Since we are not listed on a national securities exchange, we have decided to use the
independence standards of the NYSE Amex (formerly known as the American Stock Exchange or AMEX).
We believe that the Board of Directors would determine that Richardson E. Sells,
Robert N. Schwartz and William Houlihan would be independent directors under the rules of the
NYSE Amex if we were listed on the NYSE Amex and asked to make such a determination.
84
Advisory Board
On August 22, 2005, we announced the creation of an Advisory Board with seven initial members.
We issued warrants to purchase up to 900,000 shares of Common Stock to Advisory Board members as
compensation for their service. On November 9, 2005, we delivered 727,500 of such warrants to our
seven initial Advisory Board members, with an effective issuance date of August 2, 2005. All such
warrants were issued with Black-Scholes assumptions of 99% volatility, $0.35 share price, risk-free
interest rates of 4.1% and an exercise price of $0.35. The warrants become one-third vested upon
issuance and vest an additional third after each calendar year. The shares underlying these
warrants became fully vested in August 2007. In December 2006, our Board of Directors approved the
issuance of a warrant to purchase 50,000 shares of our Common Stock at an exercise price of $0.45
per share to Steven Spector, upon his addition as a member to the Advisory Board. The shares
underlying the warrant issued to Mr. Spector became fully vested on December 12, 2008 and are
currently in the process of being exercised. On September 11, 2007, our Board of Directors
approved the issuance of warrants to purchase an aggregate of 350,000 shares of our Common Stock at
an exercise price of $0.45 per share to six new members of our Advisory Board.
The shares underlying these warrants become fully vested on September 13, 2009. 125,000 of
these warrants expired and 225,000 are in the process of being exercised On February 15, 2008, our
Board of Directors approved the issuance of a warrant to purchase a total of 714,285 shares of our
Common Stock at an exercise price of $0.45 per share to Brian Potiker, in consideration for his
continued service as a member of our Advisory Board. The shares underlying the warrant issued to
Mr. Potiker became fully vested on October 30, 2008 and expired on October 30, 2009.
In March 2009, in consideration for their strategic advice and assistance, Messrs. Jay
Beaghan, Rod Rivera, I. Bobby Majumder and Dr. Harley Liker, as members of our Advisory Board, were
issued Advisory Board warrants to purchase an aggregate of 125,000 shares of Common Stock at an
exercise price of $0.625 per share. These warrants will expire on March 16, 2012 and were issued
in the following individual amounts: (i) 25,000 warrants to Mr. Beaghan; (ii) 25,000 warrants to
Mr. Rivera; (iii) 25,000 warrants to Mr. Majumder and (iv) 50,000 warrants to Dr. Liker.
One-third of the warrants vested immediately, one-third vest on March 16, 2010 and one-third vest
on March 16, 2011. These warrants expire on March 16, 2012. As of September 30, 2009 all of these
warrants remain outstanding.
In June 2009, we issued warrants to purchase 150,000 shares of Common Stock to a member of the
newly created Medical Advisory Board. These warrants were issued an exercise price of $0.625.
One-third of the warrants vested immediately upon issuance on June 10, 2009 and the remaining
two-thirds vest on June 10, 2010. These warrants expire on June 10, 2012. As of September 30, 2009
all of these warrants remain outstanding.
Advance to Affiliated Entity
On April 28, 2006, we entered into an agreement with CSA II, LLC, a Cayman Islands company
controlled by Dennis M. Smith, one of our directors at that time. Under the terms of this
agreement, we advanced $333,333 to CSA II, LLC to finance the purchase of securities issued by
Cross Shore Acquisition Corporation, a Delaware corporation, pursuant to a private placement of
$112,000,008 of securities completed on April 24, 2006. The securities were listed on the
Alternative Investment Market of the London Stock Exchange (the
AIM
) and started trading
on April 28, 2006 and ceased trading on the AIM on September 4, 2009. In addition, for
consideration of $239.38, we purchased warrants to purchase 239,375 membership units of CSA II,
LLC, constituting 22.5% of the total issued limited liability company interests outstanding on a
fully diluted basis upon payment of the exercise price equal to $0.001 per unit. On May 24, 2006,
we received a partial repayment of this advance in the amount of $60,654. In addition, on June 12,
2006, we were reimbursed $75,000, representing expenses associated with this advance. As of
September 30, 2009 we have written the remaining amounts due on this advance off as uncollectible.
Sub-Lease from HSP, Inc.
We are subleasing office space located at 433 N. Camden, Suite 810, Beverly Hills, California
90210 from HSP, Inc. which is a related entity to SMP, an affiliate of ours. The sub-lease is for
a term of 5 years at a monthly rental of $4,800 per month, subject to adjustment downward based on
other subtenants occupying space at the same location.
85
Repurchase of 49% Interest in RHA
Beginning November 18, 2008, RHA began operating under the trade name Southern Plains Medical
Group. On December 11, 2008, through our subsidiary RHA, we purchased the remaining 49% issued and
outstanding membership units of RHA not owned by us from Carol Schuster, an individual residing in
Oklahoma and holder of approximately forty-two percent (42%) of our Common Stock. RHA repurchased
the remainder of its issued and outstanding membership units for $1,800,000 through a series of
cash payments and the issuance of a promissory note. We serve as guarantor for those payment
obligations.
Exercise of Warrants
In August 2008, three of the initial seven Advisory Board members exercised their warrants in
full and a total of 302,500 shares of Common Stock were issued. The other four initial Advisory
Board members, holding a
total of 425,000 shares of Common Stock, allowed their warrants to expire unexercised. The
Advisory Board warrant issued to Mr. Spector vested on December 12, 2008 and is in the process of
being exercised. The warrants issued to six new Advisory Board members on September 13, 2007, and
the warrant issued to Mr. Potiker, remain outstanding.
|
|
|
Item 14.
|
|
PRINCIPAL ACCOUNTANT FEES AND SERVICES
|
We have engaged Whitley Penn LLP to audit our financial statements for the Fiscal Years Ended
September 30, 2009 and September 30, 2008. MBC conducted the annual audits of our financial
statements included in our Annual Report on Form 10-K for the Transition Period Ended September 30,
2007, filed with the SEC on February 11, 2008 and the Annual Report on Form 10-K for the Fiscal
Year Ended January 31, 2007, filed with the SEC on May 17, 2007. Whitley Penn LLP conducted the
quarterly reviews of our financial statements included in our Quarterly Report on Form 10-Q for the
Fiscal Quarter Ended December 31, 2007, filed with the SEC on February 20, 2008; the Quarterly
Report on Form 10-Q for the Fiscal Quarter Ended March 31, 2008, filed with the SEC on May 20, 2008
and the Quarterly Report on Form 10-Q for the Fiscal Quarter Ended June 30, 2008, filed with the
SEC on August 19, 2008. The decision to engage Whitley Penn LLP as our independent auditors for
Fiscal Year Ended September 30, 2009 has been approved by the Board of Directors, the Audit
Committee and our stockholders.
Fees
Aggregate fees for professional services rendered to us by Whitey Penn LLP and MBC as of or
for the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended September 30, 2008, and for
the Transition Period Ended September 30, 2007, respectively, were:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year
|
|
|
Year
|
|
|
Transition
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Period Ended
|
|
|
|
September 30,
|
|
|
September 30,
|
|
|
September 30,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Audit Fees
|
|
$
|
234,141
|
|
|
$
|
335,137
|
|
|
$
|
70,350
|
|
Audit-Related Fees
|
|
$
|
|
|
|
$
|
8,565
|
|
|
$
|
|
|
Tax Fees
|
|
$
|
36,410
|
|
|
$
|
|
|
|
$
|
68,300
|
|
All Other Fees
|
|
$
|
19,366
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
289,917
|
|
|
$
|
343,702
|
|
|
$
|
138,650
|
|
|
|
|
|
|
|
|
|
|
|
Audit
fees for the Fiscal Year Ended September 30, 2009 and the Fiscal Year Ended September
30, 2008, respectively, were for professional services rendered for the audits of our consolidated
financial statements and the reviews of certain subsidiary companies and the quarterly reviews of
the financial statements included in our Forms 10-Q. For the Fiscal Year Ended September 30,
2008, $184,501 of the audit fees related to recurring audit costs. The other $150,636 related to
one-time audit costs related to our acquisition of interests in RHA and SPMC.
86
Audit Related
fees for the Fiscal Year Ended September 30, 2009, Fiscal Year Ended September
30, 2008 and the Transition Period Ended September 30, 2007, respectively, were for accounting
consultations, capital issuances and review of responses to various SEC comment letters.
Tax
fees for the Fiscal Year Ended September 30, 2009, Fiscal Year Ended September 30, 2008
and the Transition Period Ended September 30, 2007 were for services related to tax compliance and
advisory services including assistance with review of tax returns, advice on goods and services
taxes and duties in various jurisdictions and ad hoc corporate tax planning and advice.
Other
fees
for the Fiscal Year Ended September 30, 2009 were related to fees associated with potential
acquisitions.
We had no other fees for professional services rendered by our independent auditors during the
Fiscal Year Ended September 30, 2009, the Fiscal Year Ended September 30, 2008 or the Transition
Period Ended September 30, 2007.
The Audit Committee has advised us that it has determined that the non-audit services rendered
by our independent auditors during the Fiscal Year Ended September 30, 2009, the Fiscal Year Ended
September 30, 2008 and the Transition Period Ended September 30, 2007 are compatible with
maintaining the independence of the auditors.
Audit Committee Pre-Approval Policies and Procedures
Our Audit Committee pre-approves audit and non-audit services provided by our independent
auditors at its quarterly meetings.
PART IV
Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES
The following documents are filed as part of this Form 10-K:
|
|
|
|
|
(1) Consolidated Financial Statements
|
|
|
|
|
|
|
|
|
|
|
|
|
37
|
|
|
|
|
|
|
|
|
|
38
|
|
|
|
|
|
|
|
|
|
39
|
|
|
|
|
|
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
41
|
|
|
|
|
|
|
|
|
|
42
|
|
|
|
|
|
|
(2) Financial Statement Schedules
|
|
|
|
|
|
|
|
|
|
All schedules have been omitted because they are not required or the required information is
shown in the financial statements or notes thereto.
|
|
|
|
|
87
(3)
|
|
The following documents are filed as exhibits to this Form 10-K (exhibits marked with an
asterisk (*) have been previously filed with the SEC as indicated and are incorporated herein
by reference):
|
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
2.1*
|
|
|
Membership Interest Purchase Agreement (filed as Exhibit 2.1 to the Form 8-K, as filed with
the SEC on November 5, 2007)
|
|
|
|
|
|
|
3.1*
|
|
|
Certificate of Incorporation (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on
November 14, 2000)
|
|
|
|
|
|
|
3.2*
|
|
|
Amended and Restated Bylaws dated October 25, 2002 (filed as Exhibit 3.2 to the Form 8-K, as
filed with the SEC on October 28, 2002)
|
|
|
|
|
|
|
3.3*
|
|
|
Certificate of Designation of Rights and Preferences of Series 2-A Convertible Preferred
Stock filed November 8, 2000 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on
November 14, 2000)
|
|
|
|
|
|
|
3.4*
|
|
|
Certificate of Merger filed November 8, 2000, merging Vsource, Inc. (a Nevada corporation)
with and into the Vsource, Inc. (a Delaware corporation) (filed as Exhibit 4.2 to the Form
8-K, as filed with the SEC on November 14, 2000)
|
|
|
|
|
|
|
3.5*
|
|
|
Agreement and Plan of Merger dated as of December 14, 2000, among the Registrant, OTT
Acquisition Corp., Online Transaction Technologies, Inc. and its Shareholders (filed as
Exhibit 10.11 to the Form 10-Q, as filed with the SEC on December 15, 2000)
|
|
|
|
|
|
|
3.6*
|
|
|
Certificate of Designation of Rights and Preferences of Series 3-A Convertible Preferred
Stock filed June 20, 2001 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on
July 2, 2001)
|
|
|
|
|
|
|
3.7*
|
|
|
Amendment to Certificate of Incorporation, dated January 16, 2002 (filed as Exhibit 3.3 to
the Form 8-K, as filed with the SEC on January 23, 2002)
|
|
|
|
|
|
|
3.8*
|
|
|
Certificate of Designation of Rights and Preferences of Series 4-A Convertible Preferred
Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on October 28, 2002)
|
|
|
|
|
|
|
3.9*
|
|
|
Amendment to Certificate of Incorporation, dated November 20, 2002 (filed as Exhibit 3.1 to
the Form 10-Q for the period ending October 31, 2002, as filed with the SEC on December 5,
2002)
|
|
|
|
|
|
|
3.10*
|
|
|
Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred
Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on July 21, 2005)
|
|
|
|
|
|
|
3.11*
|
|
|
Amendment to Certificate of Incorporation, dated December 16, 2005 (filed as Exhibit 3.5 to
the Form 10-Q for the period ending October 31, 2005, as filed with the SEC on December 20,
2005)
|
|
|
|
|
|
|
3.12*
|
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences Series
5-A Convertible Preferred Stock filed January 10, 2008 (filed as Exhibit B to the Form of
Series 5-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.52 herein)
|
|
|
|
|
|
|
3.13*
|
|
|
Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred
Stock filed April 2, 2008 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on
April 3, 2008)
|
|
|
|
|
|
|
3.14*
|
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 5-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit 4.2 to the Form
10-Q, as filed with the SEC on May 20, 2008)
|
|
|
|
|
|
|
3.15*
|
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 6-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit B to the Form of
Series 6-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.54 herein)
|
88
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
3.16*
|
|
|
Amendment to Certificate of Incorporation, dated September 29, 2009 (filed as Exhibit 3.1 to
the Form 8-K, as filed with the SEC on October 1, 2009)
|
|
|
|
|
|
|
4.1*
|
|
|
Certificate of Decrease of Shares Designated as Series 1-A Convertible Preferred Stock (filed
as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.2*
|
|
|
Certificate of Decrease of Shares Designated as Series 2-A Convertible Preferred Stock (filed
as Exhibit 4.2 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.3*
|
|
|
Certificate of Decrease of Shares Designated as Series 3-A Convertible Preferred Stock (filed
as Exhibit 4.3 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.4*
|
|
|
Certificate of Decrease of Shares Designated as Series 4-A Convertible Preferred Stock (filed
as Exhibit 4.4 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.5*
|
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of July 7, 2005, by and
among Vsource, Inc. and the investors listed therein (filed as Exhibit 4.1 to the Form 8-K,
as filed with the SEC on July 21, 2005)
|
|
|
|
|
|
|
4.6*
|
|
|
Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on July 21, 2005)
|
|
|
|
|
|
|
4.7*
|
|
|
Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on August 23, 2005)
|
|
|
|
|
|
|
4.8*
|
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of September, 18, 2006,
by and among First Physicians Capital Group, Inc. and certain Series 5-A Preferred Stock
Investors (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on September 22, 2006)
|
|
|
|
|
|
|
4.9*
|
|
|
Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on September 22, 2006)
|
|
|
|
|
|
|
4.10*
|
|
|
Amended and Restated Articles of Organization of Rural Hospital Acquisition LLC (filed as
Exhibit 4.1 to the Form 8-K, as filed with the SEC on November 5, 2007)
|
|
|
|
|
|
|
4.11*
|
|
|
Amended and Restated Operating Agreement Rural Hospital Acquisition LLC (filed as Exhibit 4.2
to the Form 8-K, as filed with the SEC on November 5, 2007)
|
|
|
|
|
|
|
4.12*
|
|
|
Form of Extension of Warrant, dated July 18, 2007 (filed as Exhibit 4.1 to Form 8-K as filed
with the SEC on December 18, 2008)
|
|
|
|
|
|
|
10.1*
|
|
|
Form of First Group Notes (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on
November 2, 2007)
|
|
|
|
|
|
|
10.2*
|
|
|
Form of Second Group Notes (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
November 2, 2007)
|
|
|
|
|
|
|
10.3*
|
|
|
Form of First Group Warrants (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on
November 2, 2007)
|
|
|
|
|
|
|
10.4*
|
|
|
Form of Second Group Warrants (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC
on November 2, 2007)
|
89
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.5*
|
|
|
Form of Limited Guaranty by Tri-Isthmus Group, Inc. (filed as Exhibit 10.1 to the Form 8-K,
as filed with the SEC on November 5, 2007)
|
|
|
|
|
|
|
10.6*
|
|
|
Employment Agreement of Dennis M. Smith, dated effective as of October 10, 2007 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on December 21, 2007)
|
|
|
|
|
|
|
10.7*
|
|
|
Option Agreement of Dennis M. Smith, dated effective as of October 10, 2007 (filed as Exhibit
10.2 to the Form 8-K, as filed with the SEC on December 21, 2007)
|
|
|
|
|
|
|
10.8*
|
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated January 14, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on January 22, 2008)
|
|
|
|
|
|
|
10.9*
|
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
January 22, 2008)
|
|
|
|
|
|
|
10.10*
|
|
|
Form of Warrant issued to SMP Investments I, LLC (filed as Exhibit 10.1 to the Form 8-K, as
filed with the SEC on March 26, 2008)
|
|
|
|
|
|
|
10.11*
|
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated March 31, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
|
|
|
|
10.12*
|
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
April 3, 2008)
|
|
|
|
|
|
|
10.13*
|
|
|
Form of Waveland Warrant (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on
April 3, 2008)
|
|
|
|
|
|
|
10.14*
|
|
|
Agreement and Plan of Merger, dated April 24, 2008 (filed as Exhibit 10.1 to the Form 8-K, as
filed with the SEC on April 30, 2008)
|
|
|
|
|
|
|
10.15*
|
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to
the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
|
|
|
|
10.16*
|
|
|
Form of Warrant issued to each of SMP Investments I, LLC and Ciabattoni Living Trust dated
August 17, 2000 (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
|
|
|
|
10.17*
|
|
|
Form of Letter Agreement for the issuance of shares of Series 6-A Convertible Preferred Stock
in complete satisfaction of that certain convertible promissory note dated as of October 29,
2007 between Tri-Isthmus Group, Inc., Surgical Center Acquisition Holdings, Inc., Del Mar
Acquisition, Inc., Del Mar GenPar, Inc., Point Loma Acquisition, Inc., and Point Loma GenPar,
Inc. (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
|
|
|
|
10.18*
|
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated May 29, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on June 4, 2008)
|
|
|
|
|
|
|
10.19*
|
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
June 4, 2008)
|
|
|
|
|
|
|
10.20*
|
|
|
Employment Agreement of David Hirschhorn, dated as of July 1, 2008 (filed as Exhibit 10.1 to
the Form 8-K, as filed with the SEC on July 7, 2008)
|
|
|
|
|
|
|
10.21*
|
|
|
Form of Option Grant Agreement of David Hirschhorn, dated as of July 1, 2008 (filed as
Exhibit 10.2 to the Form 8-K, as filed with the SEC on July 7, 2008)
|
90
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.22*
|
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated September 8, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on September 12, 2008)
|
|
|
|
|
|
|
10.23*
|
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
September 12, 2008)
|
|
|
|
|
|
|
10.24*
|
|
|
Employment Agreement of Thomas Rice, dated effective as of November 10, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on November 14, 2008)
|
|
|
|
|
|
|
10.25*
|
|
|
Option Grant Agreement of Thomas Rice, dated effective as of November 10, 2008 (filed as
Exhibit 10.2 to the Form 8-K, as filed with the SEC on November 14, 2008)
|
|
|
|
|
|
|
10.26*
|
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Anadarko, LLC, Tri-Isthmus
Group, Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services,
Inc., RHA Stroud, LLC, RHA Tishomingo, LLC, TSG Physicians Group, LLC, and Canadian State
Bank (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.27*
|
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Stroud, LLC, Tri-Isthmus Group,
Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services, Inc.,
RHA Anadarko, LLC, RHA Tishomingo, LLC, TSG Physicians Group, LLC, and Valliance Bank (filed
as Exhibit 10.3 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.28*
|
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Tishomingo, LLC, Tri-Isthmus
Group, Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services,
Inc., RHA Stroud, LLC, RHA Anadarko, LLC, TSG Physicians Group, LLC, and Canadian State Bank
(filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.29*
|
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Anadarko, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on December
17, 2008)
|
|
|
|
|
|
|
10.30*
|
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Stroud, LLC, in favor of
Valliance Bank (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on December 17,
2008)
|
|
|
|
|
|
|
10.31*
|
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Tishomingo, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.7 to the Form 8-K, as filed with the SEC on December
17, 2008)
|
|
|
|
|
|
|
10.32*
|
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Anadarko, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.8 to the Form 8-K, as filed with the SEC on December
17, 2008)
|
|
|
|
|
|
|
10.33*
|
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Stroud, LLC, in favor of
Valliance Bank (filed as Exhibit 10.9 to the Form 8-K, as filed with the SEC on December 17,
2008)
|
|
|
|
|
|
|
10.34*
|
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Anadarko, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.10 to the Form 8-K, as filed with the SEC on
December 17, 2008)
|
91
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.35
|
*
|
|
Form of Promissory Note, dated December 11, 2008, by Rural Hospital Acquisition, LLC, in
favor of Carol Schuster (filed as Exhibit 10.11 to the Form 8-K, as filed with the SEC on
December 17, 2008)
|
|
|
|
|
|
|
10.36
|
*
|
|
Form of Guaranty of Tri-Isthmus Group, Inc., dated December 11, 2008, in favor of Carol
Schuster (filed as Exhibit 10.12 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.37
|
*
|
|
Form of Convertible Promissory Note Issued in Favor of SMP Investments I, LLC (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
|
|
|
|
10.38
|
*
|
|
Form of Convertible Promissory Note Issued in Favor of Anthony J. Ciabattoni, Trustee of the
Ciabattoni Living Trust dated August 17, 2000 (filed as Exhibit 10.2 to the Form 8-K, as
filed with the SEC on February 13, 2009)
|
|
|
|
|
|
|
10.39
|
*
|
|
Form of Warrant No. 108 (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.40
|
*
|
|
Form of Warrant No. 109 (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.41
|
*
|
|
Form of Warrant No. 110 (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.42
|
*
|
|
Form of Warrant No. 111 (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.43
|
*
|
|
Form of Convertible Promissory Note (filed as Exhibit 10.1 to the Form 8-K, as filed with the
SEC on March 5, 2009)
|
|
|
|
|
|
|
10.44
|
*
|
|
Form of Warrant (exercisable at $0.50 per share) issued to each of Michael Ciabattoni, Scott
Casey, Jean Heaton, Stephanie Heaton, Jennifer Heaton, Cobea Associates, LLC, William
Wallace, Trustee of the Wallace Family Revocable Trust dated April 23, 2001, Otto J.
Claricurzio, and Phillip J. Ciabattoni (filed as Exhibit 10.2 to the Form 8-K, as filed with
the SEC on March 5, 2009)
|
|
|
|
|
|
|
10.45
|
*
|
|
Form of Warrant (exercisable at $0.75 per share) issued to each of Michael Ciabattoni, Scott
Casey, Jean Heaton, Stephanie Heaton, Jennifer Heaton, Cobea Associates, LLC, William
Wallace, Trustee of the Wallace Family Revocable Trust dated April 23, 2001, Otto J.
Claricurzio, and Phillip J. Ciabatton (filed as Exhibit 10.3 to the Form 8-K, as filed with
the SEC on March 5, 2009)
|
|
|
|
|
|
|
10.46
|
*
|
|
Form of Convertible Promissory Note issued to each of Frank Darras, Trustee of the Darras
Family Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on April 20, 2009)
|
|
|
|
|
|
|
10.47
|
*
|
|
Form of Warrant (exercisable at $0.50 per share) Frank Darras, Trustee of the Darras Family
Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit
10.2 to the Form 8-K, as filed with the SEC on April 20, 2009)
|
|
|
|
|
|
|
10.48
|
*
|
|
Form of Warrant (exercisable at $0.75 per share) Frank Darras, Trustee of the Darras Family
Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit
10.3 to the Form 8-K, as filed with the SEC on April 20, 2009)
|
|
|
|
|
|
|
10.49
|
*
|
|
Form of Series 6-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to
the
Form 8-K,
as filed with the SEC on June 12, 2009)
|
92
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.50
|
*
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
June 12, 2009)
|
|
|
|
|
|
|
10.51
|
*
|
|
Form of Medical Advisory Board Warrant (filed as Exhibit 10.3 to the Form 8-K, as filed with
the SEC on June 12, 2009)
|
|
|
|
|
|
|
10.52
|
*
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement, dated October 19, 2009
(filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.53
|
*
|
|
Form of Warrant issued in connection with 5-A (filed as Exhibit 10.2 to the Form 8-K, as
filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.54
|
*
|
|
Form of Series 6-A Preferred Stock and Warrant Purchase Agreement, dated October 19, 2009
(filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.55
|
*
|
|
Form of Warrant issued in connection with 6-A (filed as Exhibit 10.4 to the Form 8-K, as
filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.56
|
*
|
|
Form Subscription Agreement, dated December 3, 2009 (filed as Exhibit 10.1 to the Form 8-K,
as filed with the SEC on December 14, 2009)
|
|
|
|
|
|
|
10.57
|
*
|
|
Form of Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on December 14,
2009)
|
|
|
|
|
|
|
14.1
|
*
|
|
Corporate Code of Business Conduct and Ethics for Directors, Executive Officers, and
Employees, dated effective as of April 22, 2008 (filed as Exhibit 14.1 to the Form 10-K, as
filed with the SEC on January 13, 2009)
|
|
|
|
|
|
|
21.1
|
|
|
Subsidiaries of First Physicians Capital Group, Inc. (f/k/a Tri-Isthmus Group, Inc.)
|
|
|
|
|
|
|
31.1
|
|
|
Certification Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
|
|
|
|
31.2
|
|
|
Certification Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
|
|
|
|
32.1
|
|
|
Certification Pursuant to 18 U.S.C. 1350
|
|
|
|
|
|
|
32.2
|
|
|
Certification Pursuant to 18 U.S.C. 1350
|
|
|
|
*
|
|
Previously filed with the SEC as indicated, and hereby incorporated herein by reference.
|
|
|
|
Certain portions of these documents have been omitted based on a request for confidential
treatment submitted to the SEC. The non-public information that has been omitted from these
documents has been separately filed with the SEC. Each redacted portion of these documents is
indicated by a [*] and is subject to the request for confidential treatment submitted to
the SEC. The redacted information is confidential information of the Registrant.
|
93
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
|
|
|
|
|
|
First Physicians Capital Group, Inc.
|
|
|
|
|
|
|
|
|
|
Date: January 12, 2010
|
|
By:
|
|
/s/ David Hirschhorn
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the Registrant and in the capacities and dates
indicated.
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ David Hirschhorn
David Hirschhorn
|
|
Chairman of the Board, Chief Executive Officer
|
|
January 12, 2010
|
|
|
|
|
|
|
|
|
|
|
Donald C. Parkerson
|
|
Chief Financial Officer
|
|
January 12, 2010
|
|
|
|
|
|
|
|
|
|
|
Todd Parker
|
|
Director
|
|
January 12, 2010
|
|
|
|
|
|
|
|
|
|
|
Robert N. Schwartz
|
|
Director
|
|
January 12, 2010
|
|
|
|
|
|
|
|
|
|
|
Richardson E. Sells
|
|
Director
|
|
January 12, 2010
|
|
|
|
|
|
|
|
|
|
|
William Houlihan
|
|
Director
|
|
January 12, 2010
|
94
EXHIBIT INDEX
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
2.1*
|
|
|
Membership Interest Purchase Agreement (filed as Exhibit 2.1 to the Form 8-K, as filed with
the SEC on November 5, 2007)
|
|
|
|
|
|
|
3.1*
|
|
|
Certificate of Incorporation (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on
November 14, 2000)
|
|
|
|
|
|
|
3.2*
|
|
|
Amended and Restated Bylaws dated October 25, 2002 (filed as Exhibit 3.2 to the Form 8-K, as
filed with the SEC on October 28, 2002)
|
|
|
|
|
|
|
3.3*
|
|
|
Certificate of Designation of Rights and Preferences of Series 2-A Convertible Preferred
Stock filed November 8, 2000 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on
November 14, 2000)
|
|
|
|
|
|
|
3.4*
|
|
|
Certificate of Merger filed November 8, 2000, merging Vsource, Inc. (a Nevada corporation)
with and into the Vsource, Inc. (a Delaware corporation) (filed as Exhibit 4.2 to the Form
8-K, as filed with the SEC on November 14, 2000)
|
|
|
|
|
|
|
3.5*
|
|
|
Agreement and Plan of Merger dated as of December 14, 2000, among the Registrant, OTT
Acquisition Corp., Online Transaction Technologies, Inc. and its Shareholders (filed as
Exhibit 10.11 to the Form 10-Q, as filed with the SEC on December 15, 2000)
|
|
|
|
|
|
|
3.6*
|
|
|
Certificate of Designation of Rights and Preferences of Series 3-A Convertible Preferred
Stock filed June 20, 2001 (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on
July 2, 2001)
|
|
|
|
|
|
|
3.7*
|
|
|
Amendment to Certificate of Incorporation, dated January 16, 2002 (filed as Exhibit 3.3 to
the Form 8-K, as filed with the SEC on January 23, 2002)
|
|
|
|
|
|
|
3.8*
|
|
|
Certificate of Designation of Rights and Preferences of Series 4-A Convertible Preferred
Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on October 28, 2002)
|
|
|
|
|
|
|
3.9*
|
|
|
Amendment to Certificate of Incorporation, dated November 20, 2002 (filed as Exhibit 3.1 to
the Form 10-Q for the period ending October 31, 2002, as filed with the SEC on December 5,
2002)
|
|
|
|
|
|
|
3.10*
|
|
|
Certificate of Designation of Rights and Preferences of Series 5-A Convertible Preferred
Stock (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on July 21, 2005)
|
|
|
|
|
|
|
3.11*
|
|
|
Amendment to Certificate of Incorporation, dated December 16, 2005 (filed as Exhibit 3.5 to
the Form 10-Q for the period ending October 31, 2005, as filed with the SEC on December 20,
2005)
|
|
|
|
|
|
|
3.12*
|
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences Series
5-A Convertible Preferred Stock filed January 10, 2008 (filed as Exhibit B to the Form of
Series 5-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.52 herein)
|
|
|
|
|
|
|
3.13*
|
|
|
Certificate of Designation of Rights and Preferences of Series 6-A Convertible Preferred
Stock filed April 2, 2008 (filed as Exhibit 3.1 to the Form 8-K, as filed with the SEC on
April 3, 2008)
|
|
|
|
|
|
|
3.14*
|
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 5-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit 4.2 to the Form
10-Q, as filed with the SEC on May 20, 2008)
|
95
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
3.15
|
*
|
|
Certificate of Amendment to the Certificate of Designation of Rights and Preferences of
Series 6-A Convertible Preferred Stock filed May 15, 2008 (filed as Exhibit B to the Form of
Series 6-A Preferred Stock and Warrant Purchase Agreement, filed as Exhibit 10.54 herein)
|
|
|
|
|
|
|
3.16
|
*
|
|
Amendment to Certificate of Incorporation, dated September 29, 2009 (filed as Exhibit 3.1 to
the Form 8-K, as filed with the SEC on October 1, 2009)
|
|
|
|
|
|
|
4.1
|
*
|
|
Certificate of Decrease of Shares Designated as Series 1-A Convertible Preferred Stock (filed
as Exhibit 4.1 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.2
|
*
|
|
Certificate of Decrease of Shares Designated as Series 2-A Convertible Preferred Stock (filed
as Exhibit 4.2 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.3
|
*
|
|
Certificate of Decrease of Shares Designated as Series 3-A Convertible Preferred Stock (filed
as Exhibit 4.3 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.4
|
*
|
|
Certificate of Decrease of Shares Designated as Series 4-A Convertible Preferred Stock (filed
as Exhibit 4.4 to the Form 8-K, as filed with the SEC on July 13, 2005)
|
|
|
|
|
|
|
4.5
|
*
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of July 7, 2005, by and
among Vsource, Inc. and the investors listed therein (filed as Exhibit 4.1 to the Form 8-K,
as filed with the SEC on July 21, 2005)
|
|
|
|
|
|
|
4.6
|
*
|
|
Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on July 21, 2005)
|
|
|
|
|
|
|
4.7
|
*
|
|
Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on August 23, 2005)
|
|
|
|
|
|
|
4.8
|
*
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated as of September, 18, 2006,
by and among First Physicians Capital Group, Inc. and certain Series 5-A Preferred Stock
Investors (filed as Exhibit 4.1 to the Form 8-K, as filed with the SEC on September 22, 2006)
|
|
|
|
|
|
|
4.9
|
*
|
|
Form of Warrant (filed as Exhibit 4.2 to Form 8-K, filed with the SEC on September 22, 2006)
|
|
|
|
|
|
|
4.10
|
*
|
|
Amended and Restated Articles of Organization of Rural Hospital Acquisition LLC (filed as
Exhibit 4.1 to the Form 8-K, as filed with the SEC on November 5, 2007)
|
|
|
|
|
|
|
4.11
|
*
|
|
Amended and Restated Operating Agreement Rural Hospital Acquisition LLC (filed as Exhibit 4.2
to the Form 8-K, as filed with the SEC on November 5, 2007)
|
|
|
|
|
|
|
4.12
|
*
|
|
Form of Extension of Warrant, dated July 18, 2007 (filed as Exhibit 4.1 to Form 8-K as filed
with the SEC on December 18, 2008)
|
|
|
|
|
|
|
10.1
|
*
|
|
Form of First Group Notes (filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on
November 2, 2007)
|
|
|
|
|
|
|
10.2
|
*
|
|
Form of Second Group Notes (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
November 2, 2007)
|
|
|
|
|
|
|
10.3
|
*
|
|
Form of First Group Warrants (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on
November 2, 2007)
|
|
|
|
|
|
|
10.4
|
*
|
|
Form of Second Group Warrants (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC
on November 2, 2007)
|
96
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.5
|
*
|
|
Form of Limited Guaranty by Tri-Isthmus Group, Inc. (filed as Exhibit 10.1 to the Form 8-K,
as filed with the SEC on November 5, 2007)
|
|
|
|
|
|
|
10.6
|
*
|
|
Employment Agreement of Dennis M. Smith, dated effective as of October 10, 2007 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on December 21, 2007)
|
|
|
|
|
|
|
10.7
|
*
|
|
Option Agreement of Dennis M. Smith, dated effective as of October 10, 2007 (filed as Exhibit
10.2 to the Form 8-K, as filed with the SEC on December 21, 2007)
|
|
|
|
|
|
|
10.8
|
*
|
|
Series 5-A Preferred Stock and Warrant Purchase Agreement, dated January 14, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on January 22, 2008)
|
|
|
|
|
|
|
10.9
|
*
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
January 22, 2008)
|
|
|
|
|
|
|
10.10
|
*
|
|
Form of Warrant issued to SMP Investments I, LLC (filed as Exhibit 10.1 to the Form 8-K, as
filed with the SEC on March 26, 2008)
|
|
|
|
|
|
|
10.11
|
*
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated March 31, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on April 3, 2008)
|
|
|
|
|
|
|
10.12
|
*
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
April 3, 2008)
|
|
|
|
|
|
|
10.13
|
*
|
|
Form of Waveland Warrant (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on
April 3, 2008)
|
|
|
|
|
|
|
10.14
|
*
|
|
Agreement and Plan of Merger, dated April 24, 2008 (filed as Exhibit 10.1 to the Form 8-K, as
filed with the SEC on April 30, 2008)
|
|
|
|
|
|
|
10.15
|
*
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to
the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
|
|
|
|
10.16
|
*
|
|
Form of Warrant issued to each of SMP Investments I, LLC and Ciabattoni Living Trust dated
August 17, 2000 (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
|
|
|
|
10.17
|
*
|
|
Form of Letter Agreement for the issuance of shares of Series 6-A Convertible Preferred Stock
in complete satisfaction of that certain convertible promissory note dated as of October 29,
2007 between Tri-Isthmus Group, Inc., Surgical Center Acquisition Holdings, Inc., Del Mar
Acquisition, Inc., Del Mar GenPar, Inc., Point Loma Acquisition, Inc., and Point Loma GenPar,
Inc. (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on May 7, 2008)
|
|
|
|
|
|
|
10.18
|
*
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated May 29, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on June 4, 2008)
|
|
|
|
|
|
|
10.19
|
*
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
June 4, 2008)
|
|
|
|
|
|
|
10.20
|
*
|
|
Employment Agreement of David Hirschhorn, dated as of July 1, 2008 (filed as Exhibit 10.1 to
the Form 8-K, as filed with the SEC on July 7, 2008)
|
97
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.21
|
*
|
|
Form of Option Grant Agreement of David Hirschhorn, dated as of July 1, 2008 (filed as
Exhibit 10.2 to the Form 8-K, as filed with the SEC on July 7, 2008)
|
|
|
|
|
|
|
10.22
|
*
|
|
Series 6-A Preferred Stock and Warrant Purchase Agreement, dated September 8, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on September 12, 2008)
|
|
|
|
|
|
|
10.23
|
*
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
September 12, 2008)
|
|
|
|
|
|
|
10.24
|
*
|
|
Employment Agreement of Thomas Rice, dated effective as of November 10, 2008 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on November 14, 2008)
|
|
|
|
|
|
|
10.25
|
*
|
|
Option Grant Agreement of Thomas Rice, dated effective as of November 10, 2008 (filed as
Exhibit 10.2 to the Form 8-K, as filed with the SEC on November 14, 2008)
|
|
|
|
|
|
|
10.26
|
*
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Anadarko, LLC, Tri-Isthmus
Group, Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services,
Inc., RHA Stroud, LLC, RHA Tishomingo, LLC, TSG Physicians Group, LLC, and Canadian State
Bank (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.27
|
*
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Stroud, LLC, Tri-Isthmus Group,
Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services, Inc.,
RHA Anadarko, LLC, RHA Tishomingo, LLC, TSG Physicians Group, LLC, and Valliance Bank (filed
as Exhibit 10.3 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.28
|
*
|
|
Form of Loan Agreement, effective November 6, 2008, among RHA Tishomingo, LLC, Tri-Isthmus
Group, Inc., Rural Hospital Acquisition, LLC, First Physicians Community Healthcare Services,
Inc., RHA Stroud, LLC, RHA Anadarko, LLC, TSG Physicians Group, LLC, and Canadian State Bank
(filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.29
|
*
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Anadarko, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on December
17, 2008)
|
|
|
|
|
|
|
10.30
|
*
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Stroud, LLC, in favor of
Valliance Bank (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on December 17,
2008)
|
|
|
|
|
|
|
10.31
|
*
|
|
Form of Promissory Note, effective November 6, 2008, by RHA Tishomingo, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.7 to the Form 8-K, as filed with the SEC on December
17, 2008)
|
|
|
|
|
|
|
10.32
|
*
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Anadarko, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.8 to the Form 8-K, as filed with the SEC on December
17, 2008)
|
|
|
|
|
|
|
10.33
|
*
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Stroud, LLC, in favor of
Valliance Bank (filed as Exhibit 10.9 to the Form 8-K, as filed with the SEC on December 17,
2008)
|
|
|
|
|
|
|
10.34
|
*
|
|
USDA Guaranty Agreement, effective November 6, 2008, by RHA Anadarko, LLC, in favor of
Canadian State Bank (filed as Exhibit 10.10 to the Form 8-K, as filed with the SEC on
December 17, 2008)
|
98
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.35
|
*
|
|
Form of Promissory Note, dated December 11, 2008, by Rural Hospital Acquisition, LLC, in
favor of Carol Schuster (filed as Exhibit 10.11 to the Form 8-K, as filed with the SEC on
December 17, 2008)
|
|
|
|
|
|
|
10.36
|
*
|
|
Form of Guaranty of Tri-Isthmus Group, Inc., dated December 11, 2008, in favor of Carol
Schuster (filed as Exhibit 10.12 to the Form 8-K, as filed with the SEC on December 17, 2008)
|
|
|
|
|
|
|
10.37
|
*
|
|
Form of Convertible Promissory Note Issued in Favor of SMP Investments I, LLC (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on February 13, 2009)
|
|
|
|
|
|
|
10.38
|
*
|
|
Form of Convertible Promissory Note Issued in Favor of Anthony J. Ciabattoni, Trustee of the
Ciabattoni Living Trust dated August 17, 2000 (filed as Exhibit 10.2 to the Form 8-K, as
filed with the SEC on February 13, 2009)
|
|
|
|
|
|
|
10.39
|
*
|
|
Form of Warrant No. 108 (filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.40
|
*
|
|
Form of Warrant No. 109 (filed as Exhibit 10.4 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.41
|
*
|
|
Form of Warrant No. 110 (filed as Exhibit 10.5 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.42
|
*
|
|
Form of Warrant No. 111 (filed as Exhibit 10.6 to the Form 8-K, as filed with the SEC on
February 13, 2009)
|
|
|
|
|
|
|
10.43
|
*
|
|
Form of Convertible Promissory Note (filed as Exhibit 10.1 to the Form 8-K, as filed with the
SEC on March 5, 2009)
|
|
|
|
|
|
|
10.44
|
*
|
|
Form of Warrant (exercisable at $0.50 per share) issued to each of Michael Ciabattoni, Scott
Casey, Jean Heaton, Stephanie Heaton, Jennifer Heaton, Cobea Associates, LLC, William
Wallace, Trustee of the Wallace Family Revocable Trust dated April 23, 2001, Otto J.
Claricurzio, and Phillip J. Ciabattoni (filed as Exhibit 10.2 to the Form 8-K, as filed with
the SEC on March 5, 2009)
|
|
|
|
|
|
|
10.45
|
*
|
|
Form of Warrant (exercisable at $0.75 per share) issued to each of Michael Ciabattoni, Scott
Casey, Jean Heaton, Stephanie Heaton, Jennifer Heaton, Cobea Associates, LLC, William
Wallace, Trustee of the Wallace Family Revocable Trust dated April 23, 2001, Otto J.
Claricurzio, and Phillip J. Ciabattoni (filed as Exhibit 10.3 to the Form 8-K, as filed with
the SEC on March 5, 2009)
|
|
|
|
|
|
|
10.46
|
*
|
|
Form of Convertible Promissory Note issued to each of Frank Darras, Trustee of the Darras
Family Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as
Exhibit 10.1 to the Form 8-K, as filed with the SEC on April 20, 2009)
|
|
|
|
|
|
|
10.47
|
*
|
|
Form of Warrant (exercisable at $0.50 per share) Frank Darras, Trustee of the Darras Family
Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit
10.2 to the Form 8-K, as filed with the SEC on April 20, 2009)
|
|
|
|
|
|
|
10.48
|
*
|
|
Form of Warrant (exercisable at $0.75 per share) Frank Darras, Trustee of the Darras Family
Trust, SFV, Incorporated, NFS LLC/FMTC Rol IRA FBO Neal Katz A/C LMG-001902 (filed as Exhibit
10.3 to the Form 8-K, as filed with the SEC on April 20, 2009)
|
|
|
|
|
|
99
|
|
|
|
|
Exhibit No.
|
|
Description
|
|
|
|
|
|
|
10.49
|
*
|
|
Form of Series 6-A Preferred Stock and Warrant Purchase Agreement (filed as Exhibit 10.1 to
the Form 8-K, as filed with the SEC on June 12, 2009)
|
|
|
|
|
|
|
10.50
|
*
|
|
Form of Investor Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on
June 12, 2009)
|
|
|
|
|
|
|
10.51
|
*
|
|
Form of Medical Advisory Board Warrant (filed as Exhibit 10.3 to the Form 8-K, as filed with
the SEC on June 12, 2009)
|
|
|
|
|
|
|
10.52
|
*
|
|
Form of Series 5-A Preferred Stock and Warrant Purchase Agreement, dated October 19, 2009
(filed as Exhibit 10.1 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.53
|
*
|
|
Form of Warrant issued in connection with 5-A (filed as Exhibit 10.2 to the Form 8-K, as
filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.54
|
*
|
|
Form of Series 6-A Preferred Stock and Warrant Purchase Agreement, dated October 19, 2009
(filed as Exhibit 10.3 to the Form 8-K, as filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.55
|
*
|
|
Form of Warrant issued in connection with 6-A (filed as Exhibit 10.4 to the Form 8-K, as
filed with the SEC on October 23, 2009)
|
|
|
|
|
|
|
10.56
|
*
|
|
Form Subscription Agreement, dated December 3, 2009 (filed as Exhibit 10.1 to the Form 8-K,
as filed with the SEC on December 14, 2009)
|
|
|
|
|
|
|
10.57
|
*
|
|
Form of Warrant (filed as Exhibit 10.2 to the Form 8-K, as filed with the SEC on December 14,
2009)
|
|
|
|
|
|
|
14.1
|
*
|
|
Corporate Code of Business Conduct and Ethics for Directors, Executive Officers, and
Employees, dated effective as of April 22, 2008 (filed as Exhibit 14.1 to the Form 10-K, as
filed with the SEC on January 13, 2009)
|
|
|
|
|
|
|
21.1
|
|
|
Subsidiaries of First Physicians Capital Group, Inc. (f/k/a Tri-Isthmus Group, Inc.)
|
|
|
|
|
|
|
31.1
|
|
|
Certification Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
|
|
|
|
31.2
|
|
|
Certification Pursuant to Rule 13a-14(d) promulgated under the Securities Exchange Act of 1934
|
|
|
|
|
|
|
32.1
|
|
|
Certification Pursuant to 18 U.S.C. 1350
|
|
|
|
|
|
|
32.2
|
|
|
Certification Pursuant to 18 U.S.C. 1350
|
|
|
|
*
|
|
Previously filed with the SEC as indicated, and hereby incorporated herein by reference.
|
|
|
|
Certain portions of these documents have been omitted based on a request for confidential
treatment submitted to the SEC. The non-public information that has been omitted from these
documents has been separately filed with the SEC. Each redacted portion of these documents is
indicated by a [*] and is subject to the request for confidential treatment submitted to
the SEC. The redacted information is confidential information of the Registrant.
|
100
First Physicians Capital (CE) (USOTC:FPCG)
Historical Stock Chart
From Feb 2025 to Mar 2025
First Physicians Capital (CE) (USOTC:FPCG)
Historical Stock Chart
From Mar 2024 to Mar 2025